<SEC-DOCUMENT>0001193125-24-152334.txt : 20240603
<SEC-HEADER>0001193125-24-152334.hdr.sgml : 20240603
<ACCEPTANCE-DATETIME>20240603065134
ACCESSION NUMBER:		0001193125-24-152334
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20240603
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240603
DATE AS OF CHANGE:		20240603

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medtronic plc
		CENTRAL INDEX KEY:			0001613103
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0426

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36820
		FILM NUMBER:		241011948

	BUSINESS ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2
		BUSINESS PHONE:		01135314381700

	MAIL ADDRESS:	
		STREET 1:		20 ON HATCH, LOWER HATCH STREET
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Ltd
		DATE OF NAME CHANGE:	20150112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Medtronic Holdings Ltd
		DATE OF NAME CHANGE:	20140711

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Kalani I Ltd
		DATE OF NAME CHANGE:	20140709
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d811133d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdt="http://www.medtronic.com/20240603" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2024-06-03_to_2024-06-03" name="dei:EntityCentralIndexKey" contextRef="duration_2024-06-03_to_2024-06-03">0001613103</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2024-06-03_to_2024-06-03" name="dei:AmendmentFlag" contextRef="duration_2024-06-03_to_2024-06-03">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mdt-20240603.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-06-03_to_2024-06-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.625PercentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.00PercentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2032Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2034Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20392.250PercentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20391.50PercentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2040Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2049Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001613103</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2050Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-03</xbrli:startDate> <xbrli:endDate>2024-06-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_1">8-K</ix:nonNumeric></span></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-06-03_to_2024-06-03" format="ixt:date-monthname-day-year-en" id="Fact_0">June&#160;3, 2024</ix:nonNumeric></p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_2">Medtronic plc</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="ixv-606">Ireland</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityFileNumber" id="ixv-607">1-36820</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityTaxIdentificationNumber" id="ixv-608">98-1183488</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityAddressAddressLine1" id="ixv-609">20 On Hatch, Lower Hatch Street</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityAddressCityOrTown" id="ixv-610">Dublin</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_3">2</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="ixv-612">Ireland</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices)</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">+<ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:CountryRegion" id="ixv-613">353</ix:nonNumeric> <ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:CityAreaCode" id="ixv-614">1</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_4">438 1700</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Former name or former address, if changed since last report</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:WrittenCommunications" format="ixt:fixed-false" id="ixv-616">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="ixv-617">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="ixv-618">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="ixv-619">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of exchange</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:Security12bTitle" id="ixv-620">Ordinary shares, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:TradingSymbol" id="ixv-621">MDT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-622">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member" name="dei:Security12bTitle" id="ixv-623">0.250% Senior Notes due 2025</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member" name="dei:TradingSymbol" id="ixv-624">MDT/25</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-625">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member" name="dei:Security12bTitle" id="ixv-626">0.000% Senior Notes due 2025</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member" name="dei:TradingSymbol" id="ixv-627">MDT/25A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-628">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member" name="dei:Security12bTitle" id="ixv-629">2.625% Senior Notes due 2025</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member" name="dei:TradingSymbol" id="ixv-630">MDT/25B</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-631">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member" name="dei:Security12bTitle" id="ixv-632">1.125% Senior Notes due 2027</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member" name="dei:TradingSymbol" id="ixv-633">MDT/27</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-634">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member" name="dei:Security12bTitle" id="ixv-635">0.375% Senior Notes due 2028</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member" name="dei:TradingSymbol" id="ixv-636">MDT/28</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-637">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member" name="dei:Security12bTitle" id="ixv-638">3.000% Senior Notes due 2028</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member" name="dei:TradingSymbol" id="ixv-639">MDT/28A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-640">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember" name="dei:Security12bTitle" id="ixv-641">1.625% Senior Notes due 2031</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember" name="dei:TradingSymbol" id="ixv-642">MDT/31</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-643">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember" name="dei:Security12bTitle" id="ixv-644">1.000% Senior Notes due 2031</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember" name="dei:TradingSymbol" id="ixv-645">MDT/31A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-646">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member" name="dei:Security12bTitle" id="ixv-647">3.125% Senior Notes due 2031</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member" name="dei:TradingSymbol" id="ixv-648">MDT/31B</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-649">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member" name="dei:Security12bTitle" id="ixv-650">0.750% Senior Notes due 2032</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member" name="dei:TradingSymbol" id="ixv-651">MDT/32</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-652">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member" name="dei:Security12bTitle" id="ixv-653">3.375% Senior Notes due 2034</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member" name="dei:TradingSymbol" id="ixv-654">MDT/34</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-655">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember" name="dei:Security12bTitle" id="ixv-656">2.250% Senior Notes due 2039</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember" name="dei:TradingSymbol" id="ixv-657">MDT/39A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-658">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember" name="dei:Security12bTitle" id="ixv-659">1.500% Senior Notes due 2039</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember" name="dei:TradingSymbol" id="ixv-660">MDT/39B</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-661">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member" name="dei:Security12bTitle" id="ixv-662">1.375% Senior Notes due 2040</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member" name="dei:TradingSymbol" id="ixv-663">MDT/40A</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-664">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member" name="dei:Security12bTitle" id="ixv-665">1.750% Senior Notes due 2049</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member" name="dei:TradingSymbol" id="ixv-666">MDT/49</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-667">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member" name="dei:Security12bTitle" id="ixv-668">1.625% Senior Notes due 2050</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member" name="dei:TradingSymbol" id="ixv-669">MDT/50</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-670">New York Stock Exchange</ix:nonNumeric></td></tr> </table><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric contextRef="duration_2024-06-03_to_2024-06-03" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="ixv-671">&#9744;</ix:nonNumeric></p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p><p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Notes Offering </span></p><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2024, Medtronic, Inc., an indirect wholly owned subsidiary of Medtronic public limited company (&#8220;Medtronic plc&#8221;), issued &#8364;850,000,000 aggregate principal amount of its 3.650% Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), &#8364;850,000,000 aggregate principal amount of its 3.875% Senior Notes due 2036 (the &#8220;2036 Notes&#8221;), &#8364;600,000,000 aggregate principal amount of its 4.150% Senior Notes due 2043 (the &#8220;2043 Notes&#8221;), and &#8364;700,000,000 aggregate principal amount of its 4.150% Senior Notes due 2053 (the &#8220;2053 Notes&#8221; and together with the 2029 Notes, the 2036 Notes and the 2043 Notes, the &#8220;Notes&#8221;), in an underwritten offering (the &#8220;Offering&#8221;) pursuant to a registration statement on <span style="white-space:nowrap">Form&#160;S-3&#160;(the</span> &#8220;Registration Statement&#8221;) <span style="white-space:nowrap">(File&#160;No.&#160;333-270272)&#160;filed</span> with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;3, 2023, and a preliminary prospectus supplement and prospectus supplement filed with the Commission related to the offering of the Notes. The Notes are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. (&#8220;Medtronic Luxco&#8221;) and Medtronic plc (the &#8220;Guarantees,&#8221; and together with the Notes, the &#8220;Securities&#8221;).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic, Inc. expects to receive net proceeds from the Offering of approximately &#8364;2.97&#160;billion, after deducting the underwriting discount and estimated offering expenses payable by Medtronic, Inc. Medtronic, Inc. expects to use the net proceeds of the Offering for general corporate purposes, which may include repayment of outstanding commercial paper and other indebtedness.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic plc has applied to list each series of Notes on the New York Stock Exchange.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Indenture and Agency Agreement </span></p><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes were issued under an indenture dated as of December&#160;10, 2014 (the &#8220;Base Indenture&#8221;), between Medtronic, Inc. and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#8220;Trustee&#8221;), as supplemented by the Second Supplemental Indenture, dated as of January&#160;26, 2015, between Medtronic plc and the Trustee, the Third Supplemental Indenture, dated as of January&#160;26, 2015, between Medtronic Luxco and the Trustee, the Fourth Supplemental Indenture, dated as of February&#160;22, 2023, between Medtronic, Inc. and the Trustee, and the Fifth Supplemental Indenture (the &#8220;Fifth Supplemental Indenture&#8221;), dated as of June&#160;3, 2024, among Medtronic, Inc., Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent (&#8220;Elavon&#8221;), and shall be subject to the Agency Agreement dated as of June&#160;3, 2024 (the &#8220;Agency Agreement&#8221;) among Medtronic, Inc., U.S. Bank Trust Company, National Association, as transfer agent and registrar, and Elavon.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2029 Notes will mature on October&#160;15, 2029, the 2036 Notes will mature on October&#160;15, 2036, the 2043 Notes will mature on October&#160;15, 2043 and the 2053 Notes will mature on October&#160;15, 2053. The 2029 Notes will bear interest at a rate of 3.650% per annum. The 2036 Notes will bear interest at a rate of 3.875% per annum. The 2043 Notes will bear interest at a rate of 4.150% per annum. The 2053 Notes will bear interest at a rate of 4.150% per annum.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time prior to the applicable Par Call Date (as defined below) Medtronic, Inc. will have the right, at its option, to redeem any series of the Notes, in whole or in part, at any time and from time to time, at a redemption price equal to the greater of 100% of the principal amount of the Notes to be redeemed and a specified make-whole redemption price, in either case plus accrued and unpaid interest to, but not including, the date of redemption. &#8220;Par Call Date&#8221; means September&#160;15, 2029 (one month prior to the maturity date of the 2029 Notes), in the case of the 2029 Notes; July&#160;15, 2036 (three months prior to the maturity date of the 2036 Notes), in the case of the 2036 Notes; April&#160;15, 2043 (six months prior to the maturity date of the 2043 Notes), in the case of the 2043 Notes; and April&#160;15, 2053 (six months prior to the maturity date of the 2053 Notes), in the case of the 2053 Notes.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on and after the applicable Par Call Date, Medtronic, Inc. will have the option to redeem any series of the Notes, in whole at any time or in part from time to time, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes will be general unsecured senior obligations of Medtronic, Inc. and will rank equally in right of payment with all of Medtronic, Inc.&#8217;s other existing and future unsecured senior indebtedness and will rank senior to any subordinated indebtedness that Medtronic, Inc. may incur. The Guarantees will rank equally in right of payment with all of Medtronic plc&#8217;s and Medtronic Luxco&#8217;s other existing and future unsecured senior indebtedness and will rank senior to any subordinated indebtedness from time to time outstanding that Medtronic plc or Medtronic Luxco may incur, and be structurally subordinated to all existing and any future obligations of each of Medtronic plc&#8217;s subsidiaries (other than Medtronic Luxco and Medtronic, Inc.).</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the occurrence of an event of default with respect to the Notes, which includes payment defaults, defaults in the performance of certain covenants, and bankruptcy and insolvency related defaults, Medtronic, Inc.&#8217;s obligations under the Notes may be accelerated, in which case the entire principal amount of the Notes would be immediately due and payable.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic plc and its affiliates maintain ordinary banking relationships and credit facilities with the Trustee. In addition, the Trustee is the trustee for certain of Medtronic plc&#8217;s affiliates&#8217; other debt securities, and from time to time provides services relating to Medtronic plc&#8217;s investment management, stock repurchase and foreign currency hedging programs.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Base Indenture and the Fifth Supplemental Indenture is qualified in its entirety by reference to the Base Indenture and the Fifth Supplemental Indenture. The executed Base Indenture was previously filed as Exhibit 4.1 to the Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;filed</span> by Medtronic, Inc. on December&#160;10, 2014. The executed Fifth Supplemental Indenture is filed as Exhibit 4.1 hereto. Each of the foregoing documents is incorporated herein and into the Registration Statement by reference.</p></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial impact from the Offering and the expected use of proceeds was reflected in Medtronic plc&#8217;s fiscal year 2025 adjusted earnings per share guidance that Medtronic plc announced on May&#160;23, 2024.</p><p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events.</p></td></tr> </table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Underwriting Agreement </span></p><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;29, 2024, Medtronic, Inc., Medtronic plc and Medtronic Luxco entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with the underwriters listed therein, for which Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc acted as representatives, to issue and sell the Notes to the underwriters.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the underwriters party to the Underwriting Agreement and their respective affiliates have in the past performed commercial banking, investment banking and advisory services for Medtronic plc and its affiliates from time to time for which they have received customary fees and reimbursement of expenses and may, from time to time, engage in transactions with and perform services for Medtronic plc in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. Certain of the underwriters or their respective affiliates have been or are lenders under one or more of Medtronic plc&#8217;s, Medtronic, Inc.&#8217;s and Medtronic Luxco&#8217;s credit facilities.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated by reference into the Registration Statement. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Offering, Medtronic plc is filing as Exhibits 5.1, 5.2, 5.3 and 5.4 hereto opinions of counsel addressing the validity of the Notes and the Guarantees and certain related matters. Such opinions are incorporated by reference into the Registration Statement.</p><p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits.</p></td></tr> </table><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex11.htm">Underwriting Agreement, dated as of May&#160;29, 2024, among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., and Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc, as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex41.htm">Fifth Supplemental Indenture, dated as of June&#160;3, 2024, among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, UK Branch, as paying agent (including the forms of the 2029 Notes, the 2036 Notes, the 2043 Notes and the 2053 Notes). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, U.S. counsel to Medtronic plc, Medtronic Global Holdings S.C.A. and Medtronic, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex52.htm">Opinion of A&amp;L Goodbody, Irish counsel to Medtronic plc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex53.htm">Opinion of CM Law,&#160;Luxembourg counsel to Medtronic Global Holdings S.C.A. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex54.htm">Opinion of Thomas L. Osteraas, Legal Director - Corporate and Securities of Medtronic, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex52.htm">Consent of A&amp;L Goodbody (included in Exhibit&#160;5.2). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex53.htm">Consent of CM Law (included in Exhibit&#160;5.3). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d811133dex54.htm">Consent of Thomas L. Osteraas, Legal Director - Corporate&#160;&amp; Securities of Medtronic, Inc. (included in Exhibit&#160;5.4). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded with the Inline XBRL document).</td></tr> </table></div></div><p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%"/> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p><p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:46%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>
<td style="vertical-align:bottom"/>
<td style="width:2%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">MEDTRONIC PUBLIC LIMITED COMPANY</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen L. Parkhill</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;3, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Karen L. Parkhill</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d811133dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>EXECUTION VERSION </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UNDERWRITING AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#128;3,000,000,000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MEDTRONIC,
INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.650% Senior Notes due 2029 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3.875% Senior Notes due 2036 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.150% Senior Notes due 2043 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4.150% Senior Notes due 2053 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Underwriting Agreement </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">May&nbsp;29, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets
Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merrill Lynch
International </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mizuho International plc </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup
Global Markets Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Centre </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canada Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canary Wharf </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London E14 5LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25 Bank Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canary Wharf </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London E14 5JP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Merrill Lynch International </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 King Edward Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London EC1A 1HQ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Mizuho International plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 Old Bailey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London EC4M 7AU </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medtronic, Inc., a
Minnesota corporation (the &#147;Company&#148;), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the &#147;Underwriters&#148;), for whom Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch
International and Mizuho International plc are acting as representatives (the &#147;Representatives&#148;), &#128;850,000,000 principal amount of its 3.650% Senior Notes due 2029 (the &#147;2029 Notes&#148;), &#128;850,000,000 principal amount of
its 3.875% Senior Notes due 2036 (the &#147;2036 Notes&#148;), &#128;600,000,000 principal amount of its 4.150% Senior Notes due 2043 (the &#147;2043 Notes&#148;) and &#128;700,000,000 principal amount of its 4.150% Senior Notes due 2053 (the
&#147;2053 Notes&#148; and together with the 2029 Notes, 2036 Notes and 2043 Notes, the &#147;Securities&#148;). The Securities will be issued pursuant to the Indenture dated as of December&nbsp;10, 2014 between the Company and Computershare Trust
Company, N.A. (as successor to Wells Fargo Bank, National Association), as trustee (the &#147;Trustee&#148;), as supplemented by the second supplemental indenture dated as of January&nbsp;26, 2015 between Medtronic Public Limited Company, a company
incorporated under the laws of Ireland (&#147;Parent&#148;) and the Trustee, as supplemented by the third supplemental indenture dated as of January&nbsp;26, 2015 between Medtronic Global Holdings S.C.A., a corporate partnership limited by shares
(<I>soci&eacute;t&eacute; en commandite par actions</I>), incorporated and existing under the laws of the Grand Duchy of Luxembourg (&#147;Medtronic Global&#148;) and the Trustee, as supplemented by the fourth supplemental indenture dated as of
February&nbsp;22, 2023 between the Company and the Trustee (such indenture as supplemented, the &#147;Base Indenture&#148;), as further supplemented by a supplemental indenture to be dated the Closing Date (as defined below) (the &#147;Fifth
Supplemental Indenture&#148; and, together with the Base Indenture, the &#147;Indenture&#148;) among the Company, Parent, Medtronic Global, the Trustee and Elavon Financial Services DAC, UK Branch (&#147;Elavon&#148;). Each of Parent and Medtronic
Global (together, the &#147;Guarantors&#148;), will fully and unconditionally guarantee the Securities on a senior unsecured basis (the &#147;Guarantees&#148;). In connection with the issuance of the Securities, the Company will enter into an Agency
Agreement (the &#147;Agency Agreement&#148;) with Elavon, to be dated as of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Guarantors hereby
confirm their agreement with the several Underwriters concerning the purchase and sale of the Securities, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration
Statement</U>. The Company and the Guarantors have prepared and filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder
(collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-270272),</FONT> including a prospectus (the &#147;Base
Prospectus&#148;), relating to debt securities to be issued from time to time by the Company. The Company and the Guarantors have also filed, or propose to file, with the Commission pursuant to Rule </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
424 under the Securities Act a prospectus supplement specifically relating to the Securities (the &#147;Prospectus Supplement&#148;). The registration statement, as amended at the time it becomes
effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as
the &#147;Registration Statement&#148;; and as used herein, the term &#147;Prospectus&#148; means the Base Prospectus as supplemented by the Prospectus Supplement specifically relating to the Securities in the form first used (or made available upon
request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities and the term &#147;Preliminary Prospectus&#148; means the preliminary Prospectus Supplement specifically relating to the
Securities together with the Base Prospectus. Any reference in this underwriting agreement (the &#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents
incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus,
as the case may be and any reference to &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents
filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized
terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or
prior to the time when sales of the Securities were first made (the &#147;Time of Sale&#148;), the Company has prepared certain information which information is identified in Annex A of this Agreement (collectively, the &#147;Time of Sale
Information&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of the Securities</U>. (a)&nbsp;The Company agrees to issue and sell the Securities to the
several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase
from the Company the respective principal amount of Securities set forth opposite such Underwriter&#146;s name in Schedule I hereto at a price equal to: (i) 99.641% of the principal amount of 2029 Notes, (ii) 99.455% of the principal amount of 2036
Notes, (iii) 99.173% of the principal amount of 2043 Notes and (iv) 98.667% of the principal amount of 2053 Notes, plus accrued interest, if any, from June&nbsp;3, 2024 to the Closing Date. The Company will not be obligated to deliver any of the
Securities except upon payment for all the Securities to be purchased as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the
Underwriters intend to make a public offering of the Securities as soon after the effectiveness of this Agreement as in the judgment of the Representatives is advisable, and initially to offer the Securities on the terms set forth in the Prospectus.
The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter and that any such affiliate may offer and sell Securities purchased by it to or through any Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for and delivery of the Securities will be made at the offices of Davis
Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M., London time, on June&nbsp;3, 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the
Representatives and the Company may agree upon in writing. The time and date of such payment and delivery is referred to herein as the &#147;Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Payment for the Securities shall be made by wire transfer in immediately available funds to the account(s) specified by the Company to the
Representatives against delivery of the Securities in book-entry form through a common depositary for Clearstream Banking, S.A. (&#147;Clearstream&#148;) and Euroclear Bank S.A./N.V. (&#147;Euroclear&#148;), for the account of the Underwriters, of
one or more global notes representing the Securities (collectively, the &#147;Global Note&#148;), with any transfer taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Note will be made available for
inspection by the Representatives not later than 1:00 P.M., London time, on the business day prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company
and the Guarantors acknowledge and agree that the Underwriters are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company and the Guarantors with respect to the offering of Securities contemplated hereby
(including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company, the Guarantors or any other person. Additionally, neither the Representatives nor any other
Underwriter is advising the Company, the Guarantors or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company and the Guarantors shall consult with their own advisors concerning such
matters and shall be responsible for making their own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company or the Guarantors with respect
thereto. Any review by the Underwriters of the Company, the Guarantors, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of
the Company or the Guarantors or any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Merrill Lynch International acknowledges that the Notes represented by the Global
Notes will initially be credited to an account (the &#147;Commissionaire Account&#148;) for the benefit of Merrill Lynch International the terms of which include a third-party beneficiary clause (&#145;stipulation pour autrui&#146;) with the Company
as the third-party beneficiary and provide that such Notes are to be delivered to others only against payment of the net subscription monies for the Notes into the Commissionaire Account on a delivery against payment basis. Merrill Lynch
International acknowledges that (i)&nbsp;the Notes represented by the Global Notes shall be held to the order of the Company as set out above and (ii)&nbsp;the net subscription monies for the Notes received in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commissionaire Account will be held on behalf of the Company until such time as they are transferred to the Company&#146;s order. Merrill Lynch International undertakes that the net subscription
monies for the Notes will be transferred to the Company&#146;s order promptly following receipt of such monies in the Commissionaire Account. The Company acknowledges and accepts the benefit of the third-party beneficiary clause (&#145;stipulation
pour autrui&#146;) pursuant to the Civil Code of Belgium and Luxembourg, as applicable, in respect of the Commissionaire Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Representations and Warranties of the Company and the Guarantors</U>. The Company and each of the Guarantors, jointly and severally, represent and warrant to each Underwriter that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission,
and each Preliminary Prospectus, at the time of filing thereof, complied in all material respects with the Securities Act and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and each of the Guarantors makes no representation or warranty with respect to any
statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Guarantors in writing by such Underwriter through the Representatives expressly for use in any Preliminary
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Time of Sale Information</I>. The Time of Sale Information, at the Time of Sale did not, and at the Closing Date will
not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that none of the
Company nor any Guarantor makes any representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Guarantors in writing by
such Underwriter through the Representatives expressly for use in such Time of Sale Information. No statement of material fact included in the Prospectus has been omitted from the Time of Sale Information and no statement of material fact included
in the Time of Sale Information that is required to be included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer</I> <I>Free
Writing Prospectus. </I>The Company and the Guarantors (including their agents and representatives, other than the Underwriters in their capacity as such) have not prepared, made, used, authorized, approved or referred to and will not prepare, make,
use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company,
the Guarantors or their agents and representatives (other than a communication referred to in clauses (i), (ii), (iii) and (iv)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus
pursuant to Section </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act, (ii)&nbsp;the Registration Statement, (iii)&nbsp;the Preliminary Prospectus, (iv)&nbsp;the Prospectus, (v)&nbsp;the
documents listed on Annex A hereto as constituting the Time of Sale Information and (vi)&nbsp;any electronic road show or any other written communications, in each case approved in writing in advance by the Representatives. Each such Issuer Free
Writing Prospectus complied in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and, when taken together
with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, at the Time of Sale, did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and the Guarantors make no representation or warranty with respect to
any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Guarantors in writing by such Underwriter through the
Representatives expressly for use in any Issuer Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Registration Statement and Prospectus.</I> The
Registration Statement is an &#147;automatic shelf registration statement&#148; as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection
of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company or any Guarantor. No order suspending the effectiveness of the
Registration Statement has been issued by the Commission and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or any Guarantor or related to the offering has been initiated or threatened by the
Commission; as of the applicable effective date of the Registration Statement and any amendment thereto, the Registration Statement complied and will comply in all material respects with the Securities Act and the Trust Indenture Act of 1939, as
amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Trust Indenture Act&#148;), and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company and the
Guarantors make no representation or warranty with respect to (i)&nbsp;that part of the Registration Statement that constitutes the Statement of Eligibility and Qualification (Form <FONT STYLE="white-space:nowrap">T-1)</FONT> of the Trustee under
the Trust Indenture Act or (ii)&nbsp;any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company and the Guarantors in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Incorporated Documents.</I> The documents incorporated by reference in the
Registration Statement, the Prospectus and the Time of Sale Information, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Exchange Act, and none of such
documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
and during the Prospectus Delivery Period (as defined in Section&nbsp;4(b)) any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Time of Sale Information, when such documents become
effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and will not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Financial Statements.</I> The consolidated historical financial statements and schedules of Parent and its consolidated subsidiaries
included or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus present fairly in all material respects the financial condition, results of operations and cash flows of Parent as of the dates and
for the periods indicated, comply as to form with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> and have been prepared in conformity with generally accepted accounting principles applied on a
consistent basis throughout the periods involved (except as otherwise noted therein). The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information
called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of Parent included or incorporated by reference
in the Registration Statement, the Time of Sale Information and the Prospectus, (i)&nbsp;except for regular quarterly dividends payable on the ordinary shares, par value $0.0001 per share, of Parent in amounts per share that are consistent with past
practice, there has not been any material change in the capital stock or long-term debt of Parent or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by Parent on any class of capital
stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position or results of operations of Parent and its
subsidiaries taken as a whole; (ii)&nbsp;neither Parent nor any of its subsidiaries has entered into any transaction or agreement that is material to Parent and its subsidiaries taken as a whole or incurred any liability or obligation, direct or
contingent, that is material to Parent and its subsidiaries taken as a whole; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) Parent and its subsidiaries, taken as a whole, have not sustained any material loss or interference with their business from fire, explosion, flood or other calamity, whether or not covered
by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except as otherwise disclosed in the Registration Statement, the Time of Sale Information and
the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Organization and Good Standing.</I> Parent, the Company and Medtronic Global have each been duly organized and are
validly existing as entities in good standing under the laws of Ireland, Minnesota and Luxembourg, respectively, with corporate power and authority to own their properties and conduct their business as described in the Registration Statement, the
Time of Sale Information and the Prospectus, and have been duly qualified as a foreign corporation for the transaction of business and are in good standing under the laws of each other jurisdiction in which they own or lease properties or conduct
any business so as to require such qualification, except where the failure to be so qualified in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties,
management, financial position or results of operations of Parent and its subsidiaries, taken as a whole (a &#147;Material Adverse Effect&#148;); and each of Parent&#146;s subsidiaries that constitutes a &#147;significant subsidiary&#148; (as such
term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (collectively, the &#147;Significant Subsidiaries&#148;) has been duly organized and is validly existing in good standing
under the laws of its jurisdiction of organization except where the failure to be so organized, qualified or in good standing would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Capitalization.</I> All the outstanding shares of capital stock of each Significant Subsidiary have been duly authorized and validly
issued and are fully paid and nonassessable, and, except as otherwise set forth in the Registration Statement, the Time of Sale Information and the Prospectus, all outstanding shares of capital stock of each Significant Subsidiary are owned by
Parent either directly or through wholly-owned subsidiaries free and clear of any security interest, claim, lien or encumbrance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
<I>Underwriting Agreement.</I> This Agreement has been duly authorized, executed and delivered by the Company and each of the Guarantors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>The Indenture. </I>The Base Indenture has been duly authorized, executed and delivered by the Company and each of the Guarantors party
thereto. The Fifth Supplemental Indenture has been duly authorized by the Company and each of the Guarantors. On the Closing Date, the Fifth Supplemental Indenture will be duly executed and delivered by the Company and each of the Guarantors and,
when duly executed and delivered in accordance with its terms by each of the other parties thereto, will constitute valid and legally binding agreements of the Company and each of the Guarantors enforceable against the Company and each of the
Guarantors in accordance with their terms, except as enforceability may be limited by applicable mandatory law provisions or bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws relating to or affecting the
enforcement of creditors&#146; rights generally or by equitable principles relating to enforceability (collectively, the &#147;Enforceability Exceptions&#148;); and on the Closing Date, the Indenture will conform in all material respects to the
requirements of the Trust Indenture Act and the rules and regulations of the Commission applicable to an indenture that is qualified thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>The Agency Agreement. </I>The Agency Agreement has been duly authorized by the
Company. On the Closing Date, the Agency Agreement will be duly executed and delivered by the Company and, when duly executed and delivered in accordance with its terms by each of the other parties thereto, will constitute a valid and legally
binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by the Enforceability Exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>The Securities and the Guarantees</I>. The Securities have been duly authorized by the Company and, when duly executed, authenticated,
issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance
with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture; and the Guarantees have been duly authorized by each of the Guarantors and, when the Securities have been duly executed,
authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will constitute valid and legally binding obligations of each of the Guarantors, enforceable against each of the Guarantors in accordance with their
terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Descriptions of the
Transaction Documents</I>. Each of this Agreement, the Securities, the Indenture (including each Guarantee set forth therein) and the Agency Agreement (collectively, the &#147;Transaction Documents&#148;) conforms in all material respects to the
description thereof contained in the Registration Statement, the Time of Sale Information and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>No Violation or
Default.</I> None of Parent, the Company or any of the Significant Subsidiaries is in violation or default of (i)&nbsp;any provision of its certificate of incorporation, articles of association, articles of incorporation, bylaws or similar governing
or organizational documents (the &#147;Governing Documents&#148;); (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which
it is a party or bound or to which its property is subject; or (iii)&nbsp;any statute, law, rule, regulation, judgment, order or decree applicable to Parent, the Company or any of the Significant Subsidiaries of any court, regulatory body,
administrative agency, governmental body, arbitrator or other authority having jurisdiction over Parent, the Company or such Significant Subsidiary or any of its properties, as applicable, except, in the case of clauses (ii)&nbsp;and (iii), where
such violation or default would not, individually or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Conflicts. </I>None of the execution and delivery of any of the Transaction
Documents by the Company and each of the Guarantors, the issuance and sale of the Securities or the Guarantees or the consummation by the Company and the Guarantors of any other transaction contemplated by the Transaction Documents will result in a
breach or violation of or imposition of any lien, charge or encumbrance upon any property or assets of Parent, the Company or any of the Significant Subsidiaries pursuant to (i)&nbsp;the Governing Documents of Parent, the Company or any of the
Significant Subsidiaries; (ii)&nbsp;the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which Parent or any of its subsidiaries is
a party or bound or to which its or their property is subject; or (iii)&nbsp;any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having
jurisdiction over Parent or any of its subsidiaries or any of its or their properties; except, in the case of clauses (ii)&nbsp;and (iii), where such violation, breach, conflict or lien would not, individually or in the aggregate, have a Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Consents Required</I>. No consent, approval, authorization, order, registration or qualification of or with any
court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company and each of the Guarantors of each of the Transaction Documents, the issuance and sale of the Securities (and the
Guarantees) and compliance by the Company and each of the Guarantors with the terms thereof and the consummation of the transactions contemplated by the Transaction Documents, except for (i)&nbsp;the registration of the Securities under the
Securities Act, (ii)&nbsp;the qualification of the Indenture under the Trust Indenture Act or (iii)&nbsp;such consents, approvals, authorizations, orders and registrations or qualifications as may be required under applicable state securities laws
in connection with the purchase and distribution of the Securities by the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>Legal Proceedings.</I> Except as disclosed
in the Registration Statement, the Time of Sale Information and the Prospectus, no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving Parent, the Company or any of the Significant
Subsidiaries or its or their property is pending or, to the best knowledge of Parent, threatened that (i)&nbsp;could reasonably be expected to have a material adverse effect on the performance of any of the Transaction Documents, or the consummation
of any of the transactions contemplated hereby or thereby or (ii)&nbsp;could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Independent Accountants.</I> PricewaterhouseCoopers LLP, who have audited certain financial statements of Parent and its subsidiaries,
are, to the knowledge of Parent, an independent registered public accounting firm with respect to Parent and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board
(United States) and as required by the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Title to Intellectual Property.</I> Except as would not, individually or in the
aggregate, have a Material Adverse Effect, Parent, the Company and the Significant Subsidiaries own, possess, license or have other rights to use on reasonable terms, all patents, trademarks and service marks, trade names, copyrights, domain names
(in each case including all registrations and applications to register same), inventions, trade secrets, technology, <FONT STYLE="white-space:nowrap">know-how,</FONT> and other intellectual property (collectively, the &#147;Intellectual
Property&#148;) necessary for the conduct of Parent&#146;s, the Company&#146;s and the Significant Subsidiaries&#146; respective businesses as now conducted. Except as set forth in the Registration Statement, the Time of Sale Information and the
Prospectus and except as would not, individually or in the aggregate, have a Material Adverse Effect, (i)&nbsp;Parent, the Company and the Significant Subsidiaries own, or have rights to use under license, all such Intellectual Property free and
clear of all adverse claims, liens or other encumbrances; (ii)&nbsp;to the knowledge of Parent, there is no infringement, misappropriation or other violation by any third parties of any such Intellectual Property; (iii)&nbsp;there is no pending or,
to the knowledge of Parent, threatened action, suit, proceeding or claim by any third party challenging Parent&#146;s, the Company&#146;s or the Significant Subsidiaries&#146; rights in or to any such Intellectual Property, and the Company and the
Guarantors are unaware of any facts which would form a reasonable basis for any such claim, action, suit or proceeding; (iv)&nbsp;there is no pending or, to the knowledge of Parent, threatened action, suit, proceeding or claim by any third party
challenging the validity, scope or enforceability of any such Intellectual Property, and the Company is unaware of any facts that would form a reasonable basis for any such claim, action, suit or proceeding; (v)&nbsp;there is no pending or, to the
knowledge of Parent, threatened action, suit, proceeding or claim by any third party that Parent, the Company or any Significant Subsidiary infringes, misappropriates or otherwise violates any Intellectual Property rights of any third party, and
Parent is unaware of any other fact which would form a reasonable basis for any such claim, action, suit or proceeding; and (vi)&nbsp;to the knowledge of Parent, there is no valid and subsisting patent or published patent application that would
preclude Parent, the Company and the Significant Subsidiaries from practicing any Intellectual Property necessary for the conduct of Parent&#146;s, the Company&#146;s and the Significant Subsidiaries&#146; respective businesses as now conducted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Investment Company Act.</I> Neither the Company nor any Guarantor is, and immediately after giving effect to the offering and sale
of the Securities and the application of the proceeds thereof as described in the Registration Statement, the Time of Sale Information and the Prospectus will be, an &#147;investment company&#148; within the meaning of the Investment Company Act of
1940, as amended, and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Taxes.</I> Parent, the Company and the Significant
Subsidiaries have filed all <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> U.S. federal, state and local tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not
have a Material Adverse Effect and except as set forth in or contemplated in the Registration Statement, the Time of Sale Information and the Prospectus) and have paid all taxes required to be paid by it and any other assessment, fine or penalty
levied against it, to the extent that any of the foregoing is due and payable, except for any such tax, assessment, fine or penalty that is currently being contested in good faith or which would not, individually or in the aggregate, have a Material
Adverse Effect and except as set forth in or contemplated in the Registration Statement, the Time of Sale Information and the Prospectus (exclusive of any amendment or supplement thereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Compliance with Environmental Laws.</I> Parent, the Company and the Significant
Subsidiaries are (i)&nbsp;in compliance with any and all applicable <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> U.S. federal, state and local laws and regulations relating to the protection of human health and safety, the environment or
hazardous or toxic substances or wastes, pollutants or contaminants (&#147;Environmental Laws&#148;); (ii) have received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to
conduct their respective businesses; and (iii)&nbsp;have not received notice of any actual or potential liability known to management of Parent under any Environmental Law, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with Environmental Laws, failure to receive required permits, licenses or other approvals, or liability would not, individually or in the aggregate, have a Material Adverse Effect, or except as set forth in or contemplated in the Registration
Statement, the Time of Sale Information and the Prospectus (exclusive of any amendment or supplement thereto). Except as set forth in the Registration Statement, the Time of Sale Information and the Prospectus, neither Parent, the Company nor any of
the Significant Subsidiaries has been named as a &#147;potentially responsible party&#148; under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Accounting Controls.</I> Parent, the Company and each of the Significant Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)
<I>Compliance with Money Laundering Laws</I>. The operations of Parent and its subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any governmental agency (collectively, the &#147;Money Laundering Laws&#148;); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving Parent or any of its
subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of Parent, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Insurance</I>. Parent, the Company and the Significant Subsidiaries self-insure
against losses relating to their properties, operations, personnel and businesses, and have insurance covering their respective directors and officers which, in the Company&#146;s and the Guarantors&#146; reasonable belief, is in an amount and
insures against such losses and risks as are adequate to protect such directors and officers and the Parent, the Company and the Significant Subsidiaries, and such policy is in full force and effect in all material respects, except where failure to
maintain such policy would not reasonably be expected to result in a Material Adverse Effect and except as set forth in or contemplated in the Registration Statement, the Time of Sale Information and the Prospectus (exclusive of any amendment or
supplement thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Compliance with OFAC. </I>None of Parent, the Company or any of its Significant Subsidiaries or, to the
knowledge of Parent, any director, officer, employee or affiliate of Parent, the Company or the Significant Subsidiaries is currently the target of any U.S. sanctions administered or enforced by the Office of Foreign Assets Control of the U.S.
Department of the Treasury (&#147;OFAC&#148;), the U.S. Department of State, the United Nations Security Council (&#147;UNSC&#148;), the European Union or the United Kingdom (collectively, &#147;Sanctions&#148;), nor is the Parent, Company or any of
its Significant Subsidiaries located, organized or resident in a country or territory that is currently the subject of comprehensive Sanctions (currently, Crimea, the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the
Zaporizhzhia and Kherson Regions of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of
Ukraine as may be identified by the Secretary of the Treasury, in consultation with the Secretary of State, pursuant to Executive Order 14065, Cuba, Iran, North Korea and Syria). The Company and the Guarantors will not directly or, to the knowledge
of Parent, indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently the target of Sanctions or in any other manner that would result in a violation of Sanctions by any person participating in this Agreement. The representations in this Section&nbsp;3(aa) shall not apply to, nor are
they sought by or made to any person if and to the extent that it is or would be unenforceable by or in respect of that person by reason of breach of (i)&nbsp;any provision of Council Regulation (EC) No 2271/96 of 22&nbsp;November 1996, as amended
(the &#147;Blocking Regulation&#148;) (or any law or regulation implementing such Blocking Regulation in any member state of the European Union) or (ii)&nbsp;to the extent that it does not result in a violation of the Blocking Regulation as it forms
part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (or any law or regulation implementing such regulation in the United Kingdom). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>No Unlawful Payments.</I> Each of Parent and its subsidiaries and, to the knowledge of Parent, all directors, officers or employees of
Parent or any of its subsidiaries (i)&nbsp;complies and has complied in all material respects with the Bribery Act 2010 of the United Kingdom, the OECD Convention on Bribery of Foreign Public Officials in International Business Transactions, the
Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder and (ii)&nbsp;with respect to Parent and its subsidiaries, have instituted and maintain and will continue to maintain policies and procedures designed to
promote and ensure continued compliance with all applicable anti-bribery and anti-corruption laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>No Registration Rights</I>. Except as disclosed in the Registration Statement, the
Time of Sale Information and the Prospectus, no person has the right to require Parent or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission
or the issuance and sale of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>No Stabilization.</I> Neither the Company nor any of the Guarantors has taken,
directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result, under the Exchange Act or otherwise, in stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of Parent or any of Parent&#146;s directors or officers, in their
capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302
and 906 related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Status under the Securities Act</I>. Neither the Company nor any Guarantor is an ineligible
issuer, and the Company and the Guarantors are well-known seasoned issuers, in each case as defined under the Securities Act, in each case at the times specified in the Securities Act in connection with the offering of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Certain Statements</I>. The statements in the Registration Statement, the Time of Sale Information and Prospectus under &#147;Certain
Tax Considerations&#148; and, except for the Underwriter Information (as defined below), &#147;Underwriting&#148; fairly summarize the matters therein described in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Stamp Taxes</I>. There are no stamp or other issuance or transfer taxes or duties or other similar fees or charges required to be paid
by or on behalf of the Underwriters in the United States, Luxembourg or Ireland or any political subdivision or taxing authority thereof in connection with the execution and delivery of the Transaction Documents or the offer or sale of the
Securities, except in the case of voluntary registration of the Transaction Documents in Luxembourg and/or the registration of the Transaction Documents in Luxembourg, which will be required where such documents are physically attached
(<I>annex&eacute;(s)</I>) to a public deed or to any other document subject to mandatory registration, in which case either a nominal registration duty or an ad valorem duty (of, for instance, 0.24 (zero point twenty four) percent of the amount of
the payment obligation mentioned in the document so registered) will be payable depending on the nature of the document to be registered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>No Withholding Tax</I>. All payments to be made by the Company or the Guarantors to
the Underwriters on or by virtue of the execution delivery, performance or enforcement of the Transaction Documents and, except as disclosed in each of the Time of Sale Information and the Prospectus, all interest, principal, premium, if any,
additional amounts, if any, and other payments under the Transaction Documents, under the current laws and regulations of the United States of America, Luxembourg or Ireland, any political subdivision thereof or any applicable taxing jurisdiction
(each, a &#147;Taxing Jurisdiction&#148;), will not be subject to withholding, duties, levies, deductions, charges or other taxes under the current laws and regulations of the Taxing Jurisdiction and are otherwise payable free and clear of any other
withholding, duty, levy, deduction, charge or other tax in the Taxing Jurisdiction and without the necessity of obtaining any governmental authorization in the Taxing Jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Immunity</I>. Neither Parent nor any of its subsidiaries nor any of its or their properties or assets has any immunity from the
jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) under the laws of Luxembourg or Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Cybersecurity; Data Protection</I>. Except as would not, individually or in the aggregate, have a Material Adverse Effect,
(i)&nbsp;the Parent&#146;s, the Company&#146;s and the Significant Subsidiaries&#146; information technology, computers, systems, networks, hardware, software and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Parent, the Company and the Significant Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses,
time bombs, malware and other corruptants; (ii)&nbsp;the Parent, the Company and the Significant Subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their
material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#147;Data&#148;)) used in
connection with their businesses; (iii)&nbsp;to the knowledge of the Parent, there has been no breach, unauthorized use or access or compromise of any IT Systems; and (iv)&nbsp;the Parent, the Company and the Significant Subsidiaries are presently
in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations applicable, in each case,
to the Parent, the Company and the Significant Subsidiaries relating to the security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Privacy</I>. Except as would not, individually or in the aggregate, have a Material Adverse Effect, (i)&nbsp;the Parent, the Company
and the Significant Subsidiaries have complied, and are presently in compliance, in all material respects, with all applicable state, federal and international data privacy and security laws and regulations, including without limitation, to the
extent applicable, the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) and the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679) (collectively, the &#147;Data Security
Obligations&#148;); (ii) neither the Parent, the Company nor the Significant Subsidiaries has received any notification of or complaint regarding, and are aware of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other facts that, individually or in the aggregate, would reasonably indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> by the Parent, the Company and the Significant
Subsidiaries with any Data Security Obligation; (iii)&nbsp;there is no pending, or to the knowledge of the Parent, threatened, action, suit or proceeding by or before any applicable court or governmental agency, authority or body alleging <FONT
STYLE="white-space:nowrap">non-compliance</FONT> by the Parent, the Company and the Significant Subsidiaries with any Data Security Obligation; (iv)&nbsp;to ensure compliance with the Data Security Obligations, the Parent, the Company and the
Significant Subsidiaries have taken steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the use, collection, storage, disclosure or other processing of
Data that is subject to the Data Security Obligations (the &#147;Policies&#148;) to protect such Data against loss and unauthorized access, use, modification, disclosure or other misuse; and (v)&nbsp;the Parent, the Company and the Significant
Subsidiaries have made all disclosures of their then-current Policies to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the
Parent, been inaccurate or in violation of any applicable laws and regulatory rules or requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Submission to
Jurisdiction</I>. The Company and each of the Guarantors have the power to submit, and pursuant to Section&nbsp;15(e) of this Agreement and Section&nbsp;1.12 of the Indenture have legally, validly, effectively and irrevocably submitted, to the
exclusive jurisdiction of the courts specified therein; and have the power to designate, appoint and empower, and pursuant to Section&nbsp;15(e) of this Agreement and Section&nbsp;1.12 of the Indenture, have legally, validly and effectively
designated, appointed and empowered an agent for service of process in any suit or proceeding based on or arising under this Agreement or the Indenture, as applicable, in any court specified therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company and the Guarantors</U>. The Company and each of the Guarantors, jointly and severally, covenant and
agree with each Underwriter that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company and the Guarantors will file the final Prospectus with the
Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus (including the term sheet in the form of Annex B hereto) to the extent required by Rule
433 under the Securities Act; and will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act
subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing
Prospectus (to the extent not previously delivered) to the Underwriters in New York City as soon as available on the business day next succeeding the date of this Agreement, in such quantities as the Representatives may reasonably request. The
Company will pay the registration fees for this offering within the time period required by Rule 456(b)(1)(i) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, to each
Underwriter, including to each of the Representatives, (i)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and (ii)&nbsp;during the
Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein) and each Issuer Free Writing Prospectus as the Representatives may
reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to
the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Securities by any Underwriter or dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements; Issuer Free Writing Prospectuses.</I> Before making, preparing, using, authorizing, approving, referring to
or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the Prospectus, whether before or after the time that the Registration Statement becomes effective, the Company will furnish
to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing
Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the
Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing, (i)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (ii)&nbsp;when any supplement to the
Prospectus or any amendment to the Prospectus or any Issuer Free Writing Prospectus has been filed; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the
receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information; (iv)&nbsp;of the issuance by the Commission of any order suspending the effectiveness of the
Registration Statement or preventing or suspending the use of any Preliminary Prospectus or the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (v)&nbsp;of the
occurrence of any event within the Prospectus Delivery Period as a result of which the Prospectus, the Time of Sale Information or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Time of Sale Information or any such Issuer Free Writing
Prospectus is delivered to a purchaser, not misleading; (vi)&nbsp;of the receipt by the Company or any Guarantor of any notice of objection of the Commission to the use of the Registration Statement or any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act; and (vii)&nbsp;of the receipt by the Company or any Guarantor of any notice with respect to any suspension of
the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company and the Guarantors will use their reasonable best efforts to prevent the issuance of any
such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus or the Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will
obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Time of Sale Information.</I> If at any time prior to the Closing Date
(i)&nbsp;any event shall occur or condition shall exist as a result of which the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company will immediately notify the
Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or
supplements to the Time of Sale Information as may be necessary so that the statements in the Time of Sale Information as so amended or supplemented will not, in the light of the circumstances, be misleading or so that the Time of Sale Information
will comply with law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Ongoing Compliance</I>. If during the Prospectus Delivery Period (i)&nbsp;any event shall occur or condition
shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will immediately notify the
Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Prospectus
as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with
law.<I> </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Blue Sky Compliance.</I> The Company will qualify the Securities for offer and sale under the securities or Blue Sky
laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for the distribution of the Securities; <U>provided</U> that neither the Company nor any of the Guarantors
shall be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in
any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Earning Statement. </I>Parent will make generally available to its security holders
and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning
with the first fiscal quarter of Parent occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Clear Market.</I> During the period from the date hereof through and including the Closing Date, the Company and each of the Guarantors
will not, without the prior written consent of the Representatives, offer, sell, contract to sell or otherwise dispose of any debt securities issued or guaranteed by the Company or any of the Guarantors and having a tenor of more than one year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Securities as described in the Registration
Statement, the Time of Sale Information and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>No Stabilization.</I>
None of the Company or any of the Guarantors will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free
Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Tax Indemnity</I>.
The Company and each of the Guarantors, jointly and severally, further agree to indemnify and hold harmless the Underwriters against any documentary, stamp, registration, sales, transaction or similar issuance tax, including any interest and
penalties, on the creation, issue and sale of the Securities, and on the execution, delivery, performance and enforcement of the Transaction Documents. The Company and each of the Guarantors agree with each of the Underwriters that all payments made
to the Underwriters under the Transaction Documents shall be without withholding or deduction for or on account of any present or future taxes, duties or governmental charges whatsoever imposed by any Taxing Jurisdiction, unless the Company or any
such Guarantor, as the case may be, is compelled by law to deduct or withhold such taxes, duties or charges. In that event, the Company or such Guarantor, as the case may be, shall pay such additional amounts as may be necessary in order that the
net amounts received by each Underwriter after such withholding or deduction will equal the amounts that would have been received if no withholding or deduction has been made, except to the extent that such taxes, duties or charges (a)&nbsp;were
imposed due to some connection of an Underwriter with the Taxing Jurisdiction other than the mere entering into of this Agreement or receipt of payments hereunder or (b)&nbsp;would not have been imposed but for the failure of such Underwriter to
comply with any reasonable certification, identification or other reporting requirements concerning the nationality, residence, identity or connection with the Taxing Jurisdiction of the Underwriter if such compliance is required or imposed by law
as a precondition to an exemption from, or reduction in, such taxes, duties or other charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby represents and
agrees that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not used and will not use, authorize use of, refer to, or participate in the planning for use of, any &#147;free
writing prospectus,&#148; as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company or any Guarantor and not incorporated by reference into the Registration
Statement and any press release issued by the Company or any Guarantor) other than (i)&nbsp;a free writing prospectus that, solely as a result of use by such underwriter, would not trigger an obligation to file such free writing prospectus with the
Commission pursuant to Rule 433, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared
by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;). Notwithstanding the foregoing, the Underwriters
may use a term sheet or term sheets substantially in the forms attached as Annex B hereto without the consent of the Company or any Guarantor; <U>provided</U> that any Underwriter using such term sheets shall notify the Company and provide a copy of
any such term sheet or term sheets to the Company prior to the first use of such term sheet or term sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It is not subject to any
pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It will abide by the offering restrictions as set forth on Schedule II hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase Securities on the Closing Date as
provided herein is subject to the performance by the Company and each of the Guarantors of their respective covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect, and
no proceeding for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely
filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission
for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Representations and Warranties.</I> The representations and warranties of the Company
and each of the Guarantors contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company, the Guarantors and their respective officers made in any certificates delivered pursuant
to this Agreement shall be true and correct on and as of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Downgrade.</I> Subsequent to the earlier of
(A)&nbsp;the Time of Sale and (B)&nbsp;the execution and delivery of this Agreement, (i)&nbsp;no downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock of or guaranteed by Parent or any
of its subsidiaries by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined by the Commission in Section&nbsp;3(a)(62) of the Exchange Act and (ii)&nbsp;no such organization shall have publicly announced
that it has under surveillance or review for possible downgrade to its rating of the Securities or of any other debt securities or preferred stock of or guaranteed by Parent or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(g) hereof shall have occurred or shall
exist, which event or condition is not described in the Time of Sale Information (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the
Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Officer&#146;s Certificate.</I> The Representatives shall have received on and as of the Closing Date a certificate of an executive
officer of Parent who has specific knowledge of Parent&#146;s financial matters and is satisfactory to the Representatives (i)&nbsp;confirming that such officer has carefully reviewed the Registration Statement, the Time of Sale Information and the
Prospectus and, to the knowledge of such officer, the representations set forth in Sections 3(b) or 3(d) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company and each of the Guarantors in
this Agreement are true and correct and that the Company and each of the Guarantors has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date and
(iii)&nbsp;confirming the matters set forth in paragraphs (a), (c) and (d)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Comfort Letters.</I> On the date of this
Agreement and on the Closing Date, PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of Parent, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance
reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial
information contained or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus; <U>provided</U> that the letter delivered on the Closing Date shall use a
<FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinions and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for
the Company and the Guarantors.</I> (i)&nbsp;Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company and the Guarantors, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT
STYLE="white-space:nowrap">10b-5</FONT> Statement and (ii)&nbsp;Thomas L. Osteraas, <FONT STYLE="white-space:nowrap">in-house</FONT> counsel for the Company and the Guarantors, (iii)&nbsp;A&amp;L Goodbody, special Irish counsel for Parent and
(iv)&nbsp;CM Law, special Luxembourg counsel for the Company, shall each have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date and addressed to the Underwriters, each in form and
substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of
Counsel for the Underwriters.</I> The Representatives shall have received on and as of the Closing Date a written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Davis Polk&nbsp;&amp; Wardwell LLP, counsel for the
Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>CFO Certificate.</I> The Representatives shall have received on and as of the date of this Agreement and on and as of the Closing Date
a certificate of the chief financial officer of the Parent, in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
<I>No Legal Impediment to Issuance.</I> No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the
Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale
of the Securities or the Guarantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date
satisfactory evidence of the good standing of the Company and the Guarantors, in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in
writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Clearance
and Settlement</I>. The Securities shall be eligible for clearance and settlement through the facilities of Clearstream and Euroclear. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Supplemental Indenture. </I>The Company shall have executed and delivered the
Supplemental Indenture and the Underwriters shall have received executed copies thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Listing and Trading.</I> Application
shall have been made to list the Securities on the New York Stock Exchange for trading on the New York Stock Exchange and, in connection therewith, the Company shall have caused to be prepared and submitted to the New York Stock Exchange a listing
application with respect to the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Additional Documents.</I> On or prior to the Closing Date, the Company and the
Guarantors shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company and each of the Guarantors, jointly and severally,
agree to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act,
from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are
incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a
material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Prospectus, the
Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale Information, or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue
statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company and the Guarantors.</I> Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, the Guarantors, each of their respective directors, officers who signed the Registration Statement and each person, if any, who controls the Company or any of the Guarantors
within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that
arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale Information, it being understood and agreed that
the only such information consists of the following: the second, third and fourth sentences of the third paragraph in the text under the caption &#147;Underwriting&#148; in the Preliminary Prospectus and the Prospectus concerning the terms of the
offering, including the concession and reallowance to certain dealers, by the Underwriters and the seventh, eighth and ninth paragraphs, and only with respect to the underwriters, of text under the caption &#147;Underwriting&#148; in the Preliminary
Prospectus and the Prospectus relating to over-allotment and stabilization by the Underwriters (such information collectively the &#147;Underwriter Information&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b) above, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person against whom such
indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under this Section&nbsp;7 except to the
extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it from any liability
that it may have to an Indemnified Person otherwise than under paragraphs (a)&nbsp;or (b) of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person
thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any
others entitled to indemnification pursuant to Section&nbsp;7 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses of such proceeding and shall pay the fees and expenses of counsel related to such
proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying
Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified
Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any
impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them. It is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than
one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and
any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, the Guarantors, each of their respective directors, officers who signed the Registration Statement and any
control persons of the Company and the Guarantors shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent
or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any
time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any
proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified
Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any
Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance
reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on
behalf of any Indemnified Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;and (b) above is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall
contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company and the Guarantors
on the one hand and the Underwriters on the other from the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company and the Guarantors on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in such losses, claims,
damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Guarantors on the one hand and the Underwriters on the other shall be deemed to be in the same respective
proportions as the net proceeds (before deducting expenses) received by the Company from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the
Prospectus, bear to the aggregate offering price of the Securities. The relative fault of the Company and the Guarantors on the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or any Guarantor or by the Underwriters and the parties&#146; relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company, the
Guarantors and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose)
or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities
referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the
provisions of this Section&nbsp;7, in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of
the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within
the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;7 are
several in proportion to their respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or
in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the
parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to
the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on the New York Stock Exchange or the Nasdaq Stock Market; (ii)&nbsp;trading
of any securities issued or guaranteed by the Company or any of the Guarantors shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a
general moratorium on commercial banking activities shall have been declared by federal or New York State authorities or European Union authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any calamity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or crisis, involving the United States, Ireland or Luxembourg, or any change in the United States or international financial markets, that, in the judgment of the Representatives, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. (a)&nbsp;If, on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities
that it has agreed to purchase hereunder, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained
in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the Company shall be entitled to a
further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Securities on such terms. If other persons become obligated or agree to
purchase the Securities of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in
the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement, the Time of Sale Information and the Prospectus or in any other document or arrangement, and the Company agrees to promptly
prepare any amendment or supplement to the Registration Statement, the Time of Sale Information and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this
Agreement unless the context otherwise requires, any person not listed in Schedule I hereto that, pursuant to this Section&nbsp;10, purchases Securities that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate principal amount of such Securities that remains unpurchased does not exceed
<FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate principal amount of all the Securities, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the
principal amount of Securities that such Underwriter agreed to purchase hereunder plus such Underwriter&#146;s <U>pro</U> <U>rata</U> share (based on the principal amount of Securities that such Underwriter agreed to purchase hereunder) of the
Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to
any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate
principal amount of such Securities that remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate principal amount of all the Securities, or if the Company shall not exercise the right described in paragraph
(b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section 10 shall be without liability on
the part of the Company or the Guarantors, except that the Company and the Guarantors will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not
terminate and shall remain in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company, the Guarantors or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, for purposes of this Section&nbsp;10, each series of Securities issued pursuant to the Indenture shall be
treated as a separate series, and this Section&nbsp;10 shall apply to each series as if this Underwriting Agreement applied solely to such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I> (a)&nbsp;Whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, the Company and each of the Guarantors, jointly and severally, agree to pay or cause to be paid all costs and expenses incident to the performance of their respective obligations hereunder, including without limitation,
(i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of
the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Time of Sale Information and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the
costs of reproducing and distributing each of the Transaction Documents; (iv)&nbsp;the fees and expenses of the Company&#146;s and the Guarantors&#146; counsel and independent accountants; (v)&nbsp;the fees and expenses incurred in connection with
the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum
(including the reasonable related fees and expenses of counsel for the Underwriters); (vi) any fees charged by rating agencies for rating the Securities; (vii)&nbsp;the fees and expenses of the Trustee and any paying agent (including related fees
and expenses of any counsel to such parties and all fees and expenses incurred by the Company or the Guarantors in connection with the approval of the Securities for &#147;book-entry&#148; transfer by Clearstream and Euroclear); (viii) all expenses
and application fees incurred in connection with any filing with, and clearance of the offering by, the Financial Industry Regulatory Authority, Inc.; (ix) all fees and expenses related to the listing of the Securities on the New York Stock
Exchange; and (x)&nbsp;all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors. Except as provided in this Section&nbsp;11 and in Section&nbsp;7, the Underwriters shall be responsible for
paying their own expenses, on a pro rata basis in accordance with the amount of Securities purchased by such Underwriter as set forth on Schedule I, including the fees and disbursements of their counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company
for any reason fails to tender the Securities for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this Agreement, the Company and each of the Guarantors, jointly and
severally, agree to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the
Underwriters in connection with this Agreement and the offering contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Underwriter agrees severally to pay the
portion of the aggregate expenses of the Underwriters represented by such Underwriter&#146;s pro rata share (based on the proportion that the principal amount of Securities set forth opposite each Underwriter&#146;s name in Schedule I bears to the
aggregate principal amount of Securities set forth opposite the names of all Underwriters) of the Securities (with respect to each Underwriter, the &#147;Pro Rata Expenses&#148;). Notwithstanding anything contained in the International Capital
Markets Association Primary Market Handbook, each Underwriter hereby agrees that the Settlement Lead Manager (as defined in Section&nbsp;15 (l)) may allocate the Pro Rata Expenses to the account of such Underwriter for settlement of accounts
(including payment of such Underwriter&#146;s fees by the Settlement Lead Manager) as soon as practicable but in any case no later than 90 days following the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and
their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to
give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Underwriter shall be deemed to be a successor merely by reason of such
purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution, representations, warranties and agreements of the
Company, the Guarantors and the Underwriters contained in this Agreement or made by or on behalf of the Company, the Guarantors or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of
and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company, the Guarantors or the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term
&#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term
&#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant subsidiary&#148; has the meaning set forth in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act, as applied at the end of the Company&#146;s most recently completed fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. (a)<I>&nbsp;Authority of the Representatives.</I> Any action by
the Underwriters hereunder may be taken by the Representatives on behalf of the Underwriters, and any such action taken by the Representatives shall be binding upon the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L.
<FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company and the Guarantors, which
information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to Citigroup Global Markets Limited, Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, United Kingdom (fax: +44 20 7986
1927), Attention: Syndicate Desk, J.P. Morgan Securities plc, 25 Bank Street, Canary Wharf, London E14 5JP, United Kingdom (email: <U>emea_syndicate@jpmorgan.com</U>), Attention: Head of International Syndicate, Merrill Lynch International, 2 King
Edward Street, London EC1A 1HQ, United Kingdom, (telephone +44 (0)20 7995 3966) (email: dcm_london@bofa.com), Attention: Syndicate Desk and Mizuho International plc, 30 Old Bailey, London EC4M 7AU, United Kingdom (telephone: +44 (0)20 7248 3920),
Attention: Primary Debt Syndicate Desk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices to the Company and the Guarantors shall be given to Medtronic, Inc. at 710 Medtronic Parkway NE LC150,
Minneapolis, Minnesota 55432-5604, Attention: Benjamin Wood, Sr. Treasury Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Governing Law.</I> This Agreement shall be
governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Consent to Jurisdiction</I>. Any legal suit,
action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby (&#147;Related Proceedings&#148;) shall be instituted in the federal courts of the United States of America located in the City and County of
New York or the courts of the State of New York in each case located in the City and County of New York (collectively, the &#147;Specified Courts&#148;), and each of the Company, the Guarantors and the other parties hereto irrevocably submits to the
exclusive jurisdiction (except for suits, actions, or proceedings instituted in regard to the enforcement of a judgment of any Specified Court in a Related Proceeding, as to which such jurisdiction is
<FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of the Specified Courts in any Related Proceeding. Each of the Company and the Guarantors irrevocably appoints Corporation Service Company, with offices at 80 State Street, Albany, New York
12207-2543, United States, as its agent for service of process or other legal summons for purposes of any Related Proceeding. Service of any process, summons, notice or document by mail to such party&#146;s address set forth in paragraph
(c)&nbsp;above shall be effective service of process for any Related Proceeding brought in any Specified Court. The Company, the Guarantors and the other parties hereto irrevocably and unconditionally waive any objection to the laying of venue of
any Specified Proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim in any Specified Court that any Related Proceeding brought in any Specified Court has been brought in an inconvenient forum.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Waiver of Immunity</I>. To the extent that the Company or any Guarantor has or
hereafter may acquire any immunity (sovereign or otherwise) from jurisdiction of any court of (i)&nbsp;Luxembourg or Ireland or any political subdivision thereof, (ii)&nbsp;the United States, the State of Minnesota or the State of New York,
(iii)&nbsp;any jurisdiction in which they own or lease property or assets or from any legal process (whether through service of notice, attachment prior to judgment, attachment in aid of execution, execution,
<FONT STYLE="white-space:nowrap">set-off</FONT> or otherwise) with respect to themselves or their respective property and assets or this Agreement, the Company and each Guarantor hereby irrevocably waive such immunity in respect of their obligations
under this Agreement to the fullest extent permitted by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Judgment Currency</I>. If for the purposes of obtaining
judgment in any court it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties to this Agreement agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at
which in accordance with normal banking procedures the purchasers could purchase United States dollars with such other currency in New York City on the business day preceding that on which final judgment is given. The obligation of the Company and
the Guarantors with respect to any sum due from it to any Underwriter or controlling person of such Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day
following receipt by such Underwriter or controlling person of such Underwriter of any sum in such other currency, and only to the extent that such Underwriter or controlling person of such Underwriter may in accordance with normal banking
procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Underwriter or controlling person of such Underwriter hereunder, the Company and the
Guarantors, jointly and severally, agree, as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter or controlling person of such Underwriter against such loss. If the United States dollars so purchased are
greater than the sum originally due to such Underwriter or controlling person of such Underwriter hereunder, such Underwriter or controlling person of such Underwriter agrees to pay to the Company or a Guarantor, as applicable, an amount equal to
the excess of the dollars so purchased over the sum originally due to such Underwriter or controlling person of such Underwriter hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Waiver of Jury Trial</I>. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of
or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Counterparts.</I> This Agreement may be signed in counterparts, each of which shall be an original
and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement,
nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Agreement Among Underwriters</I>. The execution of this Agreement by each
Underwriter constitutes the acceptance of each Underwriter of the International Capital Markets Association Agreement Among Managers Version 1/New York Law Schedule (the &#147;Agreement Among Managers&#148;) as amended in the manner set out below.
For purposes of the Agreement Among Managers, &#147;Managers&#148; means the Underwriters, &#147;Lead Manager&#148; means the Representatives, &#147;Settlement Lead Manager&#148; means Merrill Lynch International, &#147;Stabilizing Manager&#148;
means Merrill Lynch International and &#147;Subscription Agreement&#148; means this Agreement. Clause 3 of the Agreement Among Managers shall be deleted in its entirety and replaced with Section&nbsp;10 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Stabilization</I>. The Company hereby authorizes Merrill Lynch International in its role as stabilizing manager (the &#147;Stabilizing
Manager&#148;) to make any such public disclosure as is required under applicable laws in connection with any stabilization activity undertaken by the Stabilizing Manager or any person acting on its behalf. The Stabilizing Manager (or any person
acting on behalf of the Stabilizing Manager) for its own account may, to the extent permitted by applicable laws, over-allot and effect transactions with a view to supporting the market price of the Securities at a level higher than that which might
otherwise prevail, but in doing so the Stabilizing Manager shall act as principal and not as agent of the Company and any loss resulting from overallotment and stabilization shall be borne, and any profit arising therefrom shall be beneficially
retained, by the Stabilizing Manager. However, there is no assurance that the Stabilizing Manager (or persons acting on behalf of the Stabilizing Manager) will undertake any stabilization action. Nothing contained in this paragraph shall be
construed so as to require the Company to issue in excess of the aggregate principal amount of Securities specified in Schedule I hereto. Such stabilization, if commenced, may be discontinued at any time and shall be conducted by the Stabilizing
Manager in accordance with all applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) (1) <I>Contractual Recognition of European Union
<FONT STYLE="white-space:nowrap">Bail-In</FONT></I>. Notwithstanding and to the exclusion of any other term of this Agreement or any other agreements, arrangements or understandings between the Underwriters and the Company, the Company acknowledges
and accepts that a BRRD Liability (as defined below) arising under this Agreement may be subject to the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers (as defined below) by the Relevant Resolution Authority (as defined below) and
acknowledges, accepts, and agrees to be bound by: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the effect of the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by
the Relevant Resolution Authority in relation to any BRRD Liability of each Covered Underwriter (as defined below) to the Company under this Agreement, that (without limitation) may include and result in any of the following, or some combination
thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) the reduction of all, or a portion, of the BRRD Liability or outstanding amounts due thereon; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) the conversion of all, or a portion, of the BRRD Liability into shares, other securities or other obligations of the relevant Covered
Underwriter or another person, and the issue to or conferral on the Company of such shares, securities or obligations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) the
cancellation of the BRRD Liability; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) the amendment or alteration of any interest, if applicable, thereon, the maturity or the
dates on which any payments are due, including by suspending payment for a temporary period; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the variation of the terms of this
Agreement, as deemed necessary by the Relevant Resolution Authority, to give effect to the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant Resolution Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15(n)(1), <FONT STYLE="white-space:nowrap">&#147;Bail-in</FONT> Legislation&#148; means in relation to a member
state of the European Economic Area which has implemented, or which at any time implements, the BRRD (as defined below), the relevant implementing law, regulation, rule or requirement as described in the EU
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation Schedule from time to time; <FONT STYLE="white-space:nowrap">&#147;Bail-in</FONT> Powers&#148; means any Write-down and Conversion Powers as defined in the EU
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation Schedule, in relation to the relevant <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation; &#147;BRRD&#148; means Directive 2014/59/EU establishing a framework for the recovery and
resolution of credit institutions and investment firms, as amended or replaced from time to time; &#147;BRRD Liability&#148; means a liability in respect of which the relevant Write-Down and Conversion Powers in the applicable <FONT
STYLE="white-space:nowrap">Bail-in</FONT> Legislation may be exercised; &#147;Covered Underwriter&#148; means any Underwriter subject to <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers; &#147;EU <FONT STYLE="white-space:nowrap">Bail-in</FONT>
Legislation Schedule&#148; means the document described as such, then in effect, and published by the Loan Market Association (or any successor person) from time to time at http://www.lma.eu.com/pages.aspx?p=499; and &#147;Relevant Resolution
Authority&#148; means the resolution authority with the ability to exercise any <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers in relation to the relevant Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) <I>Contractual Recognition of UK <FONT STYLE="white-space:nowrap">Bail-In.</FONT></I>
Notwithstanding and to the exclusion of any other term of this Agreement or any other agreements, arrangements, or understandings between the Underwriters and the Company, the Company acknowledges and accepts that a UK
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability (as defined below) arising under this Agreement may be subject to the exercise of UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers (as defined below) by the relevant UK resolution
authority, and acknowledges, accepts, and agrees to be bound by: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the effect of the exercise of UK
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the relevant UK resolution authority in relation to any UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability of each Covered Underwriter (as defined below) to the Company under this
Agreement, that (without limitation) may include and result in any of the following, or some combination thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) the reduction of
all, or a portion, of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability or outstanding amounts due thereon; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) the
conversion of all, or a portion, of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability into shares, other securities or other obligations of the relevant Covered Underwriter or another person, and the issue to or conferral on the
Company of such shares, securities or obligations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C) the cancellation of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT>
Liability; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D) the amendment or alteration of any interest, if applicable, thereon, the maturity or the dates on which any payments
are due, including by suspending payment for a temporary period; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the variation of the terms of this Agreement, as deemed
necessary by the relevant UK resolution authority, to give effect to the exercise of UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the relevant UK resolution authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15(n)(2), &#147;Covered Underwriter&#148; means any Underwriter subject to UK
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers; &#147;UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation&#148; means Part I of the UK Banking Act 2009 and any other law or regulation applicable in the United Kingdom relating to
the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration or other insolvency proceedings); &#147;UK
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability&#148; means a liability in respect of which the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers may be exercised; and &#147;UK <FONT STYLE="white-space:nowrap">Bail-in</FONT>
Powers&#148; means the powers under the UK <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation to cancel, transfer or dilute shares issued by a person that is a bank or investment firm or affiliate of a bank or investment firm, to cancel,
reduce, modify or change the form of a liability of such a person or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to
provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>UK MiFIR Product Governance Rules</I>. Solely for the purposes of the requirements of 3.2.7R of the FCA Handbook Product Intervention
and Product Governance Sourcebook (the &#147;UK MiFIR Product Governance Rules&#148;) regarding the mutual responsibilities of manufacturers under the UK MiFIR Product Governance Rules: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) each of Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch
International and Mizuho International plc (each a &#147;UK Manufacturer&#148; and together the &#147;UK Manufacturers&#148;) acknowledges to each other UK Manufacturer that it understands the responsibilities conferred upon it under the UK MiFIR
Product Governance Rules relating to each of the product approval process, the target market and the proposed distribution channels as applying to the Notes and the related information set out in the Prospectus in connection with the Notes; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the Company and the Underwriters (other than the UK Manufacturers) note the application of the UK MiFIR Product Governance Rules and
acknowledge the target market and the proposed distribution channels as applying to the Securities and the related information set out in the Prospectus in connection with the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special
Resolution Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined below) of such Underwriter becomes subject
to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be
exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;15(p), &#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); &#147;Covered Entity&#148; means any of the following (A)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (B) a
&#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (C)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b);
&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and &#147;U.S. Special Resolution Regime&#148; means each of (x)&nbsp;the
Federal Deposit Insurance Act and the regulations promulgated thereunder and (y)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sheila Quintus</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sheila Quintus</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President&nbsp;&amp; Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sheila Quintus</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sheila Quintus</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President&nbsp;&amp; Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., Luxembourg corporate partnership limited by shares (soci&eacute;t&eacute; en commandite par actions) represented by Medtronic Global Holdings GP S.&agrave; r.l., in its capacity as
General Partner itself acting by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Salvador Sens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Salvador Sens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accepted: May&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Citigroup Global Markets Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">J.P. Morgan Securities plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merrill Lynch International</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mizuho International plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Barclays Bank PLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Deutsche Bank AG, London Branch</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Goldman Sachs&nbsp;&amp; Co. LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HSBC Bank plc</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drexel Hamilton, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Guzman&nbsp;&amp; Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Independence Point Securities LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Siebert Williams Shank&nbsp;&amp; Co., LLC</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CITIGROUP GLOBAL MARKETS LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philip Magowan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Philip Magowan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Delegated Signatory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Chambers</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Robert Chambers</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Executive Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MERRILL LYNCH INTERNATIONAL</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Angus Reynolds</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Angus Reynolds</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MIZUHO INTERNATIONAL PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Manabu Shibuya</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Manabu Shibuya</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Authorised Signatory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BARCLAYS BANK PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lynda Fleming</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Lynda Fleming</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Authorised Signatory</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEUTSCHE BANK AG, LONDON BRANCH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Prior</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Kevin Prior</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <FONT STYLE="white-space:nowrap">Ben-Zion</FONT> Smilchensky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: <FONT STYLE="white-space:nowrap">Ben-Zion</FONT> Smilchensky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GOLDMAN SACHS&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam T. Greene</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Adam T. Greene</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HSBC BANK PLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ana Kraemer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ana Kraemer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Senior Legal Counsel</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DREXEL HAMILTON, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Melissa Fay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Melissa Fay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Partner</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GUZMAN&nbsp;&amp; COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ruslan Magdeev</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ruslan Magdeev</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INDEPENDENCE POINT SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Isaac Taylor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Isaac Taylor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Partner</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SIEBERT WILLIAMS SHANK&nbsp;&amp; CO., LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ahmad Ismail</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ahmad Ismail</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: &#8194;Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule I </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Principal&nbsp;Amount&nbsp;of&nbsp;Securities&nbsp;to&nbsp;be</B><br><B>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2029 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2036 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2043 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2053 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merrill Lynch International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho International plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Bank PLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deutsche Bank AG, London Branch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drexel Hamilton, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guzman&nbsp;&amp; Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independence Point Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Siebert Williams Shank&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">850,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">850,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule II </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Offering Restrictions </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European
Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The notes may not be offered, sold or otherwise made available to and should not be offered, sold or otherwise made
available to any retail investor in the EEA. For the purposes of this provision: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the expression &#147;retail investor&#148; means a person who is one (or
more) of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client as defined in point (11)&nbsp;of Article 4(1) of MiFID II; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of Directive 2016/97/EU (as amended or superseded, &#147;IMD&#148;), where that
customer would not qualify as a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The notes may not offered, sold or otherwise made available and should not be offered, sold or otherwise made available to any
retail investor in the United Kingdom. For the purposes of this provision, the expression &#147;retail investor&#148; means a person who is one (or more) of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client, as defined in point (8)&nbsp;of Article 2 of Regulation (EU) No 2017/565 as it forms part of
domestic law by virtue of the EUWA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to
implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in
connection with the issue or sale of the notes may only be communicated or caused to be communicated in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to Medtronic, Inc., Medtronic plc or Medtronic Luxco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the notes in, from or
otherwise involving the United Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The notes may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if the prospectus supplement and the accompanying prospectus (including any amendment thereto) contain a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser
within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for
particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT>
regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The notes may not be offered or sold in Hong Kong by means of any document other than (a)&nbsp;to &#147;professional investors&#148; as defined
in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (the &#147;SFO&#148;) and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the
Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance, and no advertisement, invitation or document relating to the notes may be
issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to the notes which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any
rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The notes have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) (the Financial Instruments and Exchange Law) and will not be sold or offered, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each underwriter has acknowledged that the prospectus supplement has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, each underwriter has represented, warranted and agreed (1)&nbsp;that it has not offered or sold any notes (2)&nbsp;or caused the notes to be made the subject of an invitation for subscription or purchase and will not offer or
sell any notes or cause the notes to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, the prospectus supplement or any other document or material in
connection with the offer or sale, or invitation for subscription or purchase, of the notes, whether directly or indirectly, to any person in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities
and Futures Act 2001 of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA or (ii)&nbsp;to an accredited investor (as defined in Section&nbsp;4A of the SFA) pursuant to and in
accordance with the conditions specified in Section&nbsp;275 of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification&#151;Solely for the
purposes of its obligations pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A of the SFA), that the notes are &#147;prescribed capital markets
products&#148; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment
Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ireland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any issuance or placement of the notes must be in conformity with: (a)&nbsp;the European Union (Markets in Financial Instruments) Regulations
2017 (S.I. 375 of 2017) and Regulation (EU) No.&nbsp;600 of 2014, and any codes of conduct used in connection therewith and the provisions of the Investor Compensation Act 1998 (to the extent applicable); (b) the provisions of the Companies Act 2014
(as amended), the Irish Central Bank Acts 1942 to 2018 (as amended) and any codes of conduct rules made under Section&nbsp;117(1) of the Central Bank Act 1989; (c) the provisions of the European Union (Prospectus) Regulations 2019 (S.I. 380 of 2019)
(as amended) and any rules issued under Section&nbsp;1363 of the Companies Act 2014 (as amended) by the Central Bank of Ireland; and (d)&nbsp;the provisions of the Market Abuse Regulation (EU 596/2014), the European Union (Market Abuse) Regulations
2016 (S.I. 349 of 2016) and any rules issued under Section&nbsp;1370 of the Companies Act 2014 (as amended) by the Central Bank of Ireland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time of Sale Information </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Prospectus Supplement dated May&nbsp;29, 2024 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pricing Term Sheet dated May&nbsp;29, 2024 in the form set forth on Annex B </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Medtronic, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pricing Term
Sheet </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;29, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuer:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Medtronic, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Guarantors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Medtronic plc and Medtronic Global Holdings S.C.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trade Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">May&nbsp;29, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement Date*:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">T+3; June&nbsp;3, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Denominations:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">&#128;100,000 x &#128;1,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Listing:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Issuer intends to apply to list the Notes on the New York Stock Exchange</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joint Bookrunners:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior <FONT STYLE="white-space:nowrap">Co-Managers:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Barclays Bank PLC, Deutsche Bank AG, London Branch, Goldman Sachs&nbsp;&amp; Co. LLC and HSBC Bank plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Managers:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7">Drexel Hamilton, LLC, Guzman&nbsp;&amp; Company, Independence Point Securities LLC and Siebert Williams Shank&nbsp;&amp; Co., LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Amount:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;850,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;850,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;600,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;700,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.650% Senior Notes due 2029</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.875% Senior Notes due 2036</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.150% Senior Notes due 2043</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.150% Senior Notes due 2053</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Security Type/Format:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Notes/SEC Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Notes/SEC Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Notes/SEC Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Notes/SEC Registered</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Maturity Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">October&nbsp;15, 2029</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">October&nbsp;15, 2036</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">October&nbsp;15, 2043</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">October&nbsp;15, 2053</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Coupon:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.650%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.875%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.150%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.150%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Price to Public:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.991%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.930%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.823%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.417%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yield to Maturity:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.655%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.884%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.165%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.186%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reference to <FONT STYLE="white-space:nowrap">Mid-swaps</FONT> Rate:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.005%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.934%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.865%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.636%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spread to <FONT STYLE="white-space:nowrap">Mid-swaps:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">65 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">95 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">130 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">155 bps</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spread to Benchmark Bund:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">99.5 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">110.9 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">128.0 bps</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">136.1 bps</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benchmark Bund:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DBR 0.000% due August&nbsp;15, 2029</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DBR 0.000% due May&nbsp;15, 2036</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DBR 3.250% due July&nbsp;4, 2042</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DBR 1.800% due August&nbsp;15, 2053</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benchmark Bund Price and Yield:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;87.22 / 2.660%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;72.09 / 2.775%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;105.08 / 2.885%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;79.80 / 2.825%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Payment Dates:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annually on October&nbsp;15 of each year, beginning on October&nbsp;15, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annually on October&nbsp;15 of each year, beginning on October&nbsp;15, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annually on October&nbsp;15 of each year, beginning on October&nbsp;15, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annually on October&nbsp;15 of each year, beginning on October&nbsp;15, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Day Count Convention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Actual/Actual (ICMA)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Actual/Actual (ICMA)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Actual/Actual (ICMA)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Actual/Actual (ICMA)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Optional Redemption:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The issuer may redeem the 2029 Notes in whole or in part, at any time prior to September&nbsp;15, 2029 (one month prior to their maturity date) at a redemption price equal to the greater of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The issuer may redeem the 2036 Notes in whole or in part, at any time prior to July&nbsp;15, 2036 (three months prior to their maturity date) at a redemption price equal to the greater of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The issuer may redeem the 2043 Notes in whole or in part, at any time prior to April&nbsp;15, 2043 (six months prior to their maturity date) at a redemption price equal to the greater of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The issuer may redeem the 2053 Notes in whole or in part, at any time prior to April&nbsp;15, 2053 (six months prior to their maturity date) at a redemption price equal to the greater of:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the 2029 Notes being redeemed; and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) the sum of the present values of the remaining scheduled payments of principal and
interest on the 2029 Notes to be redeemed (excluding any portion of such payments of interest accrued and paid as of the date of redemption and assuming that the 2029 Notes matured on September&nbsp;15, 2029), discounted to the redemption date on an
annual basis at the Comparable Bond Rate, as described in the preliminary prospectus supplement, plus 15 basis points, plus, in each case, accrued and unpaid interest to, but not including, the date of redemption.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, at any time on or after September&nbsp;15, 2029 (one month prior to their
maturity date), the issuer may at its option redeem the 2029 Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the 2029 Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including,
the date of redemption.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the 2036 Notes being redeemed; and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) the sum of the present values of the remaining scheduled payments of principal and
interest on the 2036 Notes to be redeemed (excluding any portion of such payments of interest accrued and paid as of the date of redemption and assuming that the 2036 Notes matured on July&nbsp;15, 2036), discounted to the redemption date on an
annual basis at the Comparable Bond Rate, as described in the preliminary prospectus supplement, plus 20 basis points, plus, in each case, accrued and unpaid interest to, but not including, the date of redemption.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, at any time on or after July&nbsp;15, 2036 (three months prior to their
maturity date), the issuer may at its option redeem the 2036 Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the 2036 Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including,
the date of redemption.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the 2043 Notes being redeemed; and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) the sum of the present values of the remaining scheduled payments of principal and
interest on the 2043 Notes to be redeemed (excluding any portion of such payments of interest accrued and paid as of the date of redemption and assuming that the 2043 Notes matured on April&nbsp;15, 2043), discounted to the redemption date on an
annual basis at the Comparable Bond Rate, as described in the preliminary prospectus supplement, plus 20 basis points, plus, in each case, accrued and unpaid interest to, but not including, the date of redemption.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, at any time on or after April&nbsp;15, 2043 (six months prior to their
maturity date), the issuer may at its option redeem the 2043 Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the 2043 Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including,
the date of redemption.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the 2053 Notes being redeemed; and</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) the sum of the present values of the remaining scheduled payments of principal and
interest on the 2053 Notes to be redeemed (excluding any portion of such payments of interest accrued and paid as of the date of redemption and assuming that the 2053 Notes matured on April&nbsp;15, 2053), discounted to the redemption date on an
annual basis at the Comparable Bond Rate, as described in the preliminary prospectus supplement, plus 25 basis points, plus, in each case, accrued and unpaid interest to, but not including, the date of redemption.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, at any time on or after April&nbsp;15, 2053 (six months prior to their
maturity date), the issuer may at its option redeem the 2053 Notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the 2053 Notes being redeemed, plus accrued and unpaid interest, if any, to, but not including,
the date of redemption.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ISIN:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2834367646</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2834367729</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2834367992</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2834368453</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Code:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">283436764</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">283436772</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">283436799</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">283436845</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>We expect to deliver the Notes against payment for the Notes on June&nbsp;3, 2024, the third business day
following the date of this pricing term sheet (&#147;T+3&#148;). Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties
to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes prior to the first business day preceding the settlement date will be required, by virtue of the fact that the Notes initially settle in T+3, to specify an
alternate settlement arrangement at the time of any such trade to prevent a failed settlement. </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The issuer has filed a
registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer and the guarantors
have filed with the SEC for more complete information about the issuer and the guarantors and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any guarantor, any
underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting Citigroup Global Markets Limited at +1 800 831 9146, J.P. Morgan Securities plc at +44 20 7134 2468 <FONT
STYLE="white-space:nowrap">(non-U.S.</FONT> investors) or J.P. Morgan Securities LLC collect at +1 212 834 4533 (U.S. investors), Merrill Lynch International at +1 800 294 1322 and Mizuho International plc at +44 20 7248 3920. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This pricing term sheet supplements the preliminary form of prospectus supplement filed by Medtronic, Inc. on May&nbsp;29, 2024 relating to its prospectus
dated March&nbsp;3, 2023. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturer target market (UK MiFIR product governance) is eligible counterparties and professional clients only (all
distribution channels). No PRIIPs/UK PRIIPs key information document has been prepared as the notes are not available to retail investors in the EEA and the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is being distributed to, and is directed only at, persons in the United Kingdom in circumstances where section 21(1) of the Financial
Services and Markets Act 2000 does not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization.</B>&nbsp;Relevant stabilization regulations including FCA/ICMA apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d811133dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as
Issuer, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC PUBLIC LIMITED COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and MEDTRONIC GLOBAL HOLDINGS S.C.A. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Guarantors, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPUTERSHARE TRUST COMPANY, N.A. as successor to </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WELLS FARGO BANK, NATIONAL ASSOCIATION, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Trustee, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELAVON FINANCIAL SERVICES DAC, UK BRANCH, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Paying Agent </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIFTH
SUPPLEMENTAL INDENTURE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Dated as of June&nbsp;3, 2024 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE INDENTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Dated as of December&nbsp;10, 2014 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Relating to </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;850,000,000
3.650% Senior Notes due 2029 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;850,000,000 3.875% Senior Notes due 2036 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;600,000,000 4.150% Senior Notes due 2043 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;700,000,000 4.150% Senior Notes due 2053 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIFTH SUPPLEMENTAL INDENTURE, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental
Indenture</B>&#148;), to the Indenture dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the &#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor
to Wells Fargo Bank, National Association, as trustee (the &#147;<B>Trustee</B>&#148;), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc, a public limited company incorporated under the
laws of Ireland (&#147;<B>Parent</B>&#148;), and the Trustee (the &#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Global Holdings S.C.A., a Luxembourg
corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;), and the Trustee (the &#147;<B>Third Supplemental
Indenture</B>&#148;), and the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), among the Company, Parent, Medtronic Luxco, the Trustee and
Elavon Financial Services DAC, UK Branch, as paying agent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Guarantors, as applicable, executed and delivered to the Trustee the Base Indenture, the Second Supplemental
Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, providing for the issuance from time to time of the Company&#146;s debentures, notes or other evidences of indebtedness (herein and therein called the
&#147;<B>Securities</B>&#148;), to be issued in one or more series as provided in the Base Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Section&nbsp;9.01 of the
Base Indenture permits the Company and the Trustee to enter into an indenture supplemental to the Base Indenture to establish the form and terms of any series of Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Section&nbsp;2.01 of the Base Indenture permits the form of Securities of any series to be established in an indenture supplemental
to the Base Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Section&nbsp;3.01 of the Base Indenture permits certain terms of any series of Securities to be
established pursuant to an indenture supplemental to the Base Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Sections 2.01 and 3.01 of the Base
Indenture, the Company desires to provide for the establishment of four new series of its Securities to be known as its 3.650% Senior Notes due 2029 (the &#147;<B>2029 Notes</B>&#148;), 3.875% Senior Notes due 2036 (the &#147;<B>2036
Notes</B>&#148;), 4.150% Senior Notes due 2043 (the &#147;<B>2043 Notes</B>&#148;) and 4.150% Senior Notes due 2053 (the &#147;<B>2053 Notes</B>&#148; and, together with the 2029 Notes, the 2036 Notes and the 2043 Notes, the
&#147;<B>Notes</B>&#148;), to be fully and unconditionally guaranteed by the Guarantors (the &#147;<B>Guarantees</B>&#148;), the form and substance of such Notes and the terms, provisions and conditions thereof to be set forth as provided in the
Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture, the Fourth Supplemental Indenture and this Fifth Supplemental Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company has requested that the Trustee and the Paying Agent execute and deliver this Fifth Supplemental Indenture, and all
requirements necessary to make this Fifth Supplemental Indenture a valid instrument in accordance with its terms, to make the Notes, when executed by the Company and authenticated by and delivered to the Trustee, the valid and legally
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
binding obligations of the Company, to make the Guarantees, when executed by the Guarantors, the valid and legally binding obligations of the Guarantors, and all acts and things necessary have
been done and performed to make this Fifth Supplemental Indenture enforceable in accordance with its terms, and the execution and delivery of this Fifth Supplemental Indenture have been duly authorized in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, THIS FIFTH SUPPLEMENTAL INDENTURE WITNESSETH: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For and in consideration of the premises contained herein, each party agrees for the benefit of each other party and for the equal and ratable
benefit of the Holders of the Notes, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01 <I>Relation to Base Indenture</I>. This Fifth Supplemental Indenture constitutes a part of the Base Indenture in respect of
the Notes but shall not modify, amend or otherwise affect the Base Indenture insofar as it relates to any other series of Securities or modify, amend or otherwise affect in any manner the terms and conditions of the Securities of any other series.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02 <I>Definitions</I>. For all purposes of this Fifth Supplemental Indenture, the capitalized terms used herein
(i)&nbsp;which are defined in this Section&nbsp;1.02 have the respective meanings assigned hereto in this Section&nbsp;1.02 and (ii)&nbsp;which are defined in the Base Indenture (and which are not defined in this Section&nbsp;1.02) have the
respective meanings assigned thereto in the Base Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For all purposes of this Fifth Supplemental Indenture: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Unless the context otherwise requires, any reference to an Article or Section refers to an Article or Section, as the case
may be, of this Fifth Supplemental Indenture; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The words &#147;herein,&#148; &#147;hereof&#148; and
&#147;hereunder&#148; and words of similar import refer to this Fifth Supplemental Indenture as a whole and not to any particular Article, Section or other subdivision; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The terms defined in this Section&nbsp;1.02(a)(iii) have the meanings assigned to them in this Section and include the
plural as well as the singular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2029 Notes</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2036 Notes</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2043 Notes</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>2053 Notes</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional Amounts</B>&#148; has the meaning set forth in Section&nbsp;3.03. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Base Indenture</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day, other than a Saturday or Sunday, (1)&nbsp;which is not a day on which banking institutions in
The City of New York or London are authorized or required by law, regulation or executive order to close and (2)&nbsp;on which the Trans-European Automated Real-Time Gross Settlement Express Transfer system, or any successor or replacement thereto,
is open. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CBOI</B>&#148; has the meaning set forth in Section&nbsp;4.12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Clearstream</B>&#148; means Clearstream Banking, <I>soci&eacute;t&eacute; anonyme</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; has the meaning set forth in Section&nbsp;3.03(a)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Depositary</B>&#148; has the meaning set forth in Section&nbsp;2.01(b)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Euro</B>&#148; and &#147;<B>&#128;</B>&#148; means the single currency introduced at the third stage of the European Economic and
Monetary Union pursuant to the Treaty establishing the European Community, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Euroclear</B>&#148; means Euroclear Bank
SA/NV, as operator of the Euroclear System. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FCA</B>&#148; has the meaning set forth in Section&nbsp;4.12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fifth Supplemental Indenture</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fourth Supplemental Indenture</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Guarantor</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interest Payment Date</B>&#148; has the meaning set forth in Section&nbsp;2.01(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Medtronic Luxco</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Notes</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Paying Agent</B>&#148; has the meaning set forth in Section&nbsp;2.01(b)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PRA</B>&#148; has the meaning set forth in Section&nbsp;4.12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Supplemental Indenture</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities</B>&#148; has the meaning provided in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Taxes</B>&#148; has the meaning set forth in Section&nbsp;3.03. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Taxing Jurisdiction</B>&#148; has the meaning set forth in Section&nbsp;3.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Supplemental Indenture</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trustee</B>&#148; has the meaning provided in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Dollar</B>&#148; means the lawful currency of the United States of America. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GENERAL TERMS AND
CONDITIONS OF THE NOTES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01 <I>Terms of Notes</I>. Pursuant to Sections 2.01 and 3.01 of the Base Indenture, there is
hereby established four series of Securities, the terms of which shall be as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Designation and Principal Amount. </I>The
2029 Notes, the 2036 Notes, the 2043 Notes and the 2053 Notes are hereby authorized, each unlimited in aggregate principal amount. The 2029 Notes, the 2036 Notes, the 2043 Notes and the 2053 Notes issued on the date hereof pursuant to the terms of
this Indenture shall be in an aggregate principal amount of &#128;850,000,000, &#128;850,000,000, &#128;600,000,000 and &#128;700,000,000, respectively, which amounts shall be set forth in the written order of the Company for the authentication and
delivery of the Notes pursuant to Section&nbsp;3.03 of the Base Indenture. In addition, the Company may, from time to time, without notice to or the consent of the Holders of the Notes, create and issue additional Notes of any series ranking equally
and ratably with the Notes of such series issued on the date hereof in all respects (or in all respects except for the payment of interest accruing prior to the issue date of such additional Notes or except for the first payment of interest
following the issue date of such additional Notes), so that such additional Notes shall be consolidated and form a single series with such series of Notes issued on the date hereof and shall have the same terms as to status, redemption or otherwise
as such series of Notes issued on the date hereof; provided, that if any such additional Notes are not fungible with the Notes of such series initially issued hereunder for U.S. federal income tax purposes, such additional Notes shall have a
separate CUSIP/ISIN number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Form and Payment</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Notes shall be issued as global notes, only in fully registered book-entry form, without coupons, in minimum
denominations of &#128;100,000 and integral multiples of &#128;1,000 in excess thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Payments of principal,
premium, if any, and/or interest, if any, on the global notes representing the Notes shall be made to the Paying Agent which in turn shall make payment to Euroclear and Clearstream as the Depositary with respect to the Notes of such series or its
nominee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The global notes representing the Notes shall be deposited with, or on behalf of, Elavon Financial Services
DAC, as the common depositary for Euroclear and Clearstream (the &#147;<B>Common Depositary</B>&#148;), and shall be registered, at the request of the Common Depositary, in the name of the nominee of the Common Depositary, for Euroclear and
Clearstream. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Company initially appoints U.S. Bank Trust Company National
Association as Security Registrar with respect to the Notes pursuant to Section&nbsp;3.05 of the Base Indenture until such time as the Security Registrar has resigned or a successor has been appointed. Elavon Financial Services DAC, UK Branch shall
initially act as paying agent (the &#147;<B>Paying Agent</B>&#148;) for the Notes. The Company may appoint and change the Paying Agent without prior notice to the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Maturity Date</I>. The principal amount of the 2029 Notes shall be payable on October&nbsp;15, 2029, the principal amount of the 2036
Notes shall be payable on October&nbsp;15, 2036, the principal amount of the 2043 Notes shall be payable on October&nbsp;15, 2043 and the principal amount of the 2053 Notes shall be payable on October&nbsp;15, 2053. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Interest</I>. Interest on the Notes shall accrue at the rate of 3.650% per annum for the 2029 Notes, 3.875% per annum for the 2036
Notes, 4.150% per annum for the 2043 Notes and 4.150% per annum for the 2053 Notes. Interest on the Notes shall be payable annually in arrears on October&nbsp;15, commencing on October&nbsp;15, 2024 (each such date, an &#147;<B>Interest Payment
Date</B>&#148;), to the Holders in whose names the respective Notes are registered at the close of business on the Business Day (which shall for purposes of this Section&nbsp;2.01(d) include only days on which Clearstream and Euroclear are open for
business) immediately preceding the applicable Interest Payment Date. Interest on the Notes shall be computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and
including the last date on which interest was paid on the notes (or June&nbsp;3, 2024, if no interest has been paid on the applicable series of Notes), to, but excluding, the next scheduled Interest Payment Date (ACTUAL/ACTUAL (ICMA). If any
Interest Payment Date (other than a maturity date or redemption date) would otherwise be a day that is not a Business Day, such Interest Payment Date will be postponed to the next date that is a Business Day and no interest will accrue on the
amounts payable from and after such Interest Payment Date to the next Business Day. If the maturity date or redemption date of any series of Notes would fall on a day that is not a Business Day, then the related payment of principal, premium, if
any, and interest, if any, shall be made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and no interest shall accrue on the amounts so payable for the period from and after such date
to the next Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Issuance in Euro.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Principal, including any payments made upon any redemption or repurchase of the Notes, premium, if any, and interest
payments, if any, in respect of the Notes will be payable in Euros. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Distributions of principal, premium, if any, and
interest, if any, with respect to any Global Security will be credited in euros to the extent received by Euroclear or Clearstream from the Paying Agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant
system&#146;s rules and procedures. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If on or after the date hereof, the Euro is unavailable to the Company
or, in the case of the Guarantees, Parent or Medtronic Luxco, due to the imposition of exchange controls or other circumstances beyond the Company&#146;s, Parent&#146;s or Medtronic Luxco&#146;s control or if the Euro is no longer being used by the
then member states of the European Economic and Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect
of the Notes will be made in U.S. Dollars until the Euro is again available to the Company or, in the case of the Guarantees, Parent or Medtronic Luxco, or so used. In such circumstances, the amount payable on any date in Euro will be converted by
the Company into U.S. Dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant Interest Payment Date or, in the event the U.S. Federal Reserve Board has not mandated
a rate of conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date. Any payment in respect of the Notes so made in U.S.
Dollars will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with this Section&nbsp;2.01(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Other Terms</I>. The Notes shall be unsecured senior indebtedness of the Company and shall rank equally and ratably in right of payment
with all of the Company&#146;s other unsecured and unsubordinated indebtedness outstanding from time to time. The Notes shall not be convertible into, or exchangeable for, any other securities of the Company, except that the Notes shall be
exchangeable for other Notes to the extent provided for in the Base Indenture. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REDEMPTION OF THE NOTES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01 <I>Optional Redemption</I>. (a)&nbsp;The Company may redeem any series of the 2029 Notes, the 2036 Notes, the 2043 Notes and
the 2053 Notes, at any time prior to the applicable Par Call Date, at a Redemption Price equal to the greater of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 100%
of the principal amount of the Notes to be redeemed, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the sum, as determined by a Quotation Agent, of the present
values of the Remaining Scheduled Payments of principal and interest on the Notes of such series to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Notes matured on the
applicable Par Call Date), discounted to the Redemption Date on an annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 15 basis points, in the case of the 2029 Notes, 20 basis points, in the case of the 2036 Notes, 20 basis points,
in the case of the 2043 Notes and 25 basis points, in the case of the 2053 Notes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">plus, in each case, accrued and unpaid interest, if
any, to, but not including, the Redemption Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At any time on and after the applicable Par Call Date, the Company may redeem each
series of the 2029 Notes, the 2036 Notes, the 2043 Notes and the 2053 Notes at the Company&#146;s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest,
if any, to, but not including, the applicable Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in the Base Indenture, the
Second Supplemental Indenture, the Third Supplemental Indenture or the Fourth Supplemental Indenture, in the case of any redemption at the election of the Company, the Company shall, at least 10 days prior to the date on which the Company mails the
notice of redemption to each holder (unless a shorter notice shall be satisfactory to the Trustee), notify the Trustee and the Paying Agent of the applicable Redemption Date, of the principal amount of Notes of such series to be redeemed and, if
applicable, of the tenor of the Notes to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in the Base Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, (i)&nbsp;notice of redemption shall be delivered not less than 10 nor more than 60 days prior to the applicable Redemption Date, to each Holder of Notes
to be redeemed, at such Holder&#146;s address appearing in the Security Register and (ii)&nbsp;an Officers&#146; Certificate specifying the actual redemption price shall be sent to the Trustee no later than two Business Days prior to the Redemption
Date. A notice of redemption may, at the discretion of the Company, be subject to one or more conditions precedent, including, but not limited to, completion of an equity offering, a financing, or other corporate transaction, provided that if such
redemption or notice is subject to satisfaction of one or more conditions precedent, such notice shall state that, in the Company&#146;s discretion, the redemption date may be postponed until up to 60 days following the notice of redemption, and
such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the redemption date (including as it may be postponed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notes may be redeemed in part in the minimum authorized denomination or in any integral multiple of such amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) For purposes of this Section&nbsp;3.01, the following definitions are applicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Comparable Bond Rate</B>&#148; means, for any Redemption Date, the rate per annum equal to the annual equivalent yield to maturity or
interpolated yield to maturity (on a day count basis), computed as of the third Business Day immediately preceding that Redemption Date, of the Comparable Government Issue, assuming a price for the Comparable Government Issue (expressed as a
percentage of its principal amount) equal to the Comparable Price for such Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Comparable Government
Issue</B>&#148; means the euro-denominated security issued by the German federal government selected by a Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the Notes to be redeemed (assuming that such
Notes matured on the applicable Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of
the Notes to be redeemed. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Comparable Price</B>&#148; means, with respect to any Redemption Date, (i)&nbsp;the
average of the Reference Dealer Quotations for such Redemption Date, after excluding the highest and lowest of the Reference Dealer Quotations, (ii)&nbsp;if the Company obtains fewer than four Reference Dealer Quotations, the arithmetic average of
all those Reference Dealer Quotations or (iii)&nbsp;if the Company obtains only one Reference Dealer Quotation, such Reference Dealer Quotation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Par Call Date</B>&#148; means in the case of the 2029 Notes, September&nbsp;15, 2029; in the case of the 2036 Notes, July&nbsp;15,
2036; in the case of the 2043 Notes, April&nbsp;15, 2043; and in the case of the 2053 Notes, April&nbsp;15, 2053. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Quotation
Agent</B>&#148; means the Reference Dealer appointed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Dealer</B>&#148; means (i)&nbsp;each of Citigroup
Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc and their respective successors; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and/or a market
maker in, German government bonds (a &#147;<B>Primary Bond Dealer</B>&#148;), the Company shall substitute another Primary Bond Dealer and (ii)&nbsp;any other Primary Bond Dealers selected by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Dealer Quotations</B>&#148; means, with respect to each Reference Dealer and any Redemption Date, the average, as
determined by the Quotation Agent, of the bid and asked prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Quotation Agent by such Reference Dealer at 11:00 a.m.,
London time, on the third Business Day preceding such Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Remaining Scheduled Payments</B>&#148; means, with
respect to each of the Notes to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon that would be due after the related redemption date but for such redemption (assuming that the Notes to be redeemed matured
on the applicable Par Call Date); provided, however, that if such Redemption Date is not an Interest Payment Date with respect to such Note, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of
interest accrued thereon to such Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02 <I>Redemption upon Changes in Withholding Taxes</I>. Unless otherwise
provided pursuant to Section&nbsp;3.01 of the Base Indenture, the Notes may be redeemed, as a whole but not in part, at the option of the Company, upon not less than 30 nor more than 60 days&#146; notice (which notice shall be irrevocable), at a
redemption price equal to 100% of the principal amount thereof, together with accrued and unpaid interest, if any, to the redemption date and Additional Amounts, if any, if as a result of any amendment to, or change in, the laws, regulations,
rulings or treaties of the United States, Ireland, Luxembourg or other jurisdiction in which the Company or any Guarantor or, in each case, any successor thereof (including a continuing Person formed by a consolidation with the Company or any
Guarantor, into which the Company or such Guarantor is merged, or that acquires or leases all or substantially all of the property and assets of the Company or such Guarantor) may be organized, as applicable, or any political subdivision thereof or
therein having the power to tax (a &#147;<B>Taxing Jurisdiction</B>&#148;), or any change in the application or official interpretation of such laws, regulations, rulings or treaties, including any action taken by, or change in the published
administrative practice of, a taxing </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authority or a holding by a court of competent jurisdiction (regardless of whether such action, change or holding is with respect to the Company or a Guarantor), which amendment or change is
announced or becomes effective on or after the date the Notes are issued, the Company or such Guarantor has become, or there is a material probability that it will become, obligated to pay Additional Amounts on the next date on which any amount
would be payable with respect to such Notes, and such obligation cannot be avoided by the use of commercially reasonable measures available to the Company or such Guarantor, as the case may be, not including substitution of the obligor on the Notes;
provided, however, that no such notice of redemption may be given earlier than 60 days prior to the earliest date on which the Company or any Guarantor, as the case may be, would be obligated, or there is a material probability the Company or
Guarantor would otherwise be obligated, to pay such Additional Amount. Prior to the publication or, where relevant, mailing (and/or to the extent permitted by applicable procedures or regulations, electronic delivery) of any notice of redemption
described in this Section&nbsp;3.02, the Company shall deliver to the Trustee (i)(A) an Officer&#146;s Certificate of the Company stating that the obligation to pay Additional Amounts cannot be avoided by the Company taking commercially reasonable
measures available to it or (B)&nbsp;an Officer&#146;s Certificate of the applicable Guarantor stating that the obligation to pay Additional Amounts cannot be avoided by such Guarantor taking commercially reasonable measures available to it, as the
case may be, as described above, and (ii)&nbsp;a written opinion of independent tax counsel to the Company or the applicable Guarantor, as the case may be, of recognized standing to the effect that the Company or the applicable Guarantor, as the
case may be, has or there is a material probability that it will become obligated to pay Additional Amounts as a result of a change, amendment, official interpretation or application described above and that the Company or the applicable Guarantor,
as the case may be, cannot avoid the payment of such Additional Amounts by taking commercially reasonable measures available to it as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03 <I>Payment of Additional Amounts</I>. All payments made by the Company or any Guarantor under or with respect to the Notes
and the Guarantees will be made free and clear of and without withholding or deduction for or on account of any present or future taxes, duties, levies, imposts, assessments or governmental charges of whatever nature imposed or levied by or on
behalf of any Taxing Jurisdiction (&#147;<B>Taxes</B>&#148;), unless the Company or any Guarantor, as the case may be, is required to withhold or deduct Taxes by law or by the interpretation or administration thereof. In the event that the Company
or any Guarantor is required to so withhold or deduct any amount for or on account of any Taxes from any payment made under or with respect to the Notes or the Guarantees, as the case may be, the Company or the applicable Guarantor, as the case may
be, will pay such additional amounts (&#147;<B>Additional Amounts</B>&#148;) as may be necessary so that the net amount received by each holder of the Notes (including Additional Amounts) after such withholding or deduction will equal the amount
that such Holder would have received if such Taxes had not been required to be withheld or deducted; provided that no Additional Amounts will be payable with respect to a payment to a holder of Securities or a holder of beneficial interests in
Global Securities where such holder is subject to taxation on such payment by a relevant Taxing Jurisdiction for any reason other than such holder&#146;s mere ownership of the Securities or for or on account of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) any Taxes that are imposed or withheld solely because such holder (or the beneficial owner for whose benefit such holder holds such
Securities) or a fiduciary, settlor, beneficiary, member, shareholder or other equity owner of, or possessor of a power over, such holder (or beneficial owner) if such holder (or beneficial owner) is an estate, trust, partnership, limited liability
company, corporation or other entity that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) is or was present or engaged in, or is or was treated as present or engaged
in, a trade or business in the Taxing Jurisdiction or has or had a permanent establishment in the Taxing Jurisdiction (in each case, other than the mere fact of ownership of such Securities, without another presence or business in such Taxing
Jurisdiction); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) has or had any present or former connection (other than the mere fact
of ownership of such Securities) with the Taxing Jurisdiction imposing such Taxes, including being or having been a national citizen or resident thereof, being treated as being or having been a resident thereof or being or having been physically
present therein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) with respect to any withholding Taxes imposed by the United States, is or was with respect to the
United States a personal holding company, a passive foreign investment company, a controlled foreign corporation, a foreign private foundation or other foreign tax exempt organization or corporation that has accumulated earnings to avoid United
States federal income tax; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) actually or constructively owns or owned 10% or more of the total combined voting power of
all classes of stock of the Company or the applicable Guarantor within the meaning of Section&nbsp;871(h)(3) of the United States Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) is or was a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the
ordinary course of its trade or business within the meaning of Section&nbsp;881(c)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any estate, inheritance, gift,
sales, transfer, excise, personal property or similar Taxes imposed with respect to the Notes, except as otherwise provided herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
any Taxes imposed solely as a result of the presentation of the Notes (where presentation is required) for payment on a date more than 15 days after the date on which such payment became due and payable or the date on which payment thereof is duly
provided for, whichever is later, except to the extent that the beneficiary or holder thereof would have been entitled to the payment of Additional Amounts had the Securities been presented for payment on any date during such <FONT
STYLE="white-space:nowrap">15-day</FONT> period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any Taxes imposed or withheld solely as a result of the failure of such holder or
any other person to comply with applicable certification, information, documentation or other reporting requirements concerning the nationality, residence, identity or connection with the Taxing Jurisdiction of such holder, if such compliance is
required by statute, regulation, ruling or administrative practice of the relevant Taxing Jurisdiction or by any applicable tax treaty to which the relevant Taxing Jurisdiction is a party as a precondition to relief or exemption from such Taxes;
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) with respect to withholding Taxes imposed by the United States, any such Taxes imposed
by reason of the failure of such holder to fulfill the statement requirements of sections 871(h) or 881(c) of the Code; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any Taxes
that are payable by any method other than withholding or deduction by the Company or a Guarantor or any paying agent from payments in respect of such Notes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) any Taxes required to be withheld by any paying agent from any payment in respect of any Notes if such payment can be made without such
withholding by at least one other paying agent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any withholding or deduction for Taxes which would not have been imposed if the
relevant Notes had been presented to another paying agent in a country that is a member of the European Union as of the date of this Fifth Supplemental Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any withholding or deduction required pursuant to sections 1471 through 1474 of the Code, any regulations or agreements thereunder,
official interpretations thereof, any intergovernmental agreement, or any law, rule, guidance or administrative practice implementing an intergovernmental agreement entered into in connection with such sections of the Code; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) any combination of Section&nbsp;3.03(a), (b), (c), (d), (e), (f), (g), (h) or (i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional Amounts also will not be payable to any Holder or the holder of a beneficial interest in a Global Security that is a fiduciary, partnership,
limited liability company or other fiscally transparent entity, or to such holder that is not the sole Holder or holder of such beneficial interests of such Security, as the case may be. This exception, however, will apply only to the extent that a
beneficiary or settlor with respect to the fiduciary, or a beneficial owner or member of the partnership, limited liability company or other fiscally transparent entity, would not have been entitled to the payment of an Additional Amount had the
beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company or the applicable
Guarantor, as the case may be, will also (i)&nbsp;make such withholding or deduction of Taxes and (ii)&nbsp;remit the full amount of Taxes so deducted or withheld to the relevant Taxing Jurisdiction in accordance with all applicable laws. The
Company or the applicable Guarantor, as the case may be, will use its commercially reasonable efforts to obtain certified copies of tax receipts evidencing the payment of any Taxes so deducted or withheld from each Taxing Authority imposing such
Taxes. The Company or the applicable Guarantor, as the case may be, will, upon request, make available to the holders of the Notes, within 90 days after the date the payment of any Taxes so deducted or withheld is due pursuant to applicable law,
certified copies of tax receipts evidencing such payment by the Company or the applicable Guarantor or if, notwithstanding the Company&#146;s or the applicable Guarantor&#146;s efforts to obtain such receipts, the same are not obtainable, other
evidence of such payments by the Company or the applicable Guarantor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At least 30 days prior to each date on which any payment under or with respect to
the Notes or the Guarantees is due and payable, if the Company or a Guarantor will be obligated to pay Additional Amounts with respect to such payment, the Company or the applicable Guarantor will deliver to the Trustee an Officers&#146; Certificate
stating the fact that such Additional Amounts will </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be payable and the amounts so payable and will set forth such other information as is necessary to enable such Trustee to pay such Additional Amounts to holders of Securities on the payment date.
The Trustee shall not at any time be under any duty or responsibility to any Holder to determine the Additional Amounts, or with respect to the nature, extent, or calculation of the amount of Additional Amounts owed, or with respect to the method
employed in such calculation of the Additional Amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company will pay any stamp, issue, registration, documentary or other similar
taxes and duties, including interest, penalties and Additional Amounts with respect thereto, payable in Luxembourg or the United States or any political subdivision or taxing authority of or in the foregoing in respect of the creation, issue,
offering, enforcement, redemption or retirement of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of Sections 3.02 and 3.03 shall survive any termination of the discharge of
this Fifth Supplemental Indenture and shall apply mutatis mutandis to any jurisdiction in which the Company or a Guarantor or any successor Person to the Company or a Guarantor, as the case may be, is organized or is engaged in business for tax
purposes or any political subdivisions or taxing authority or agency thereof or therein; provided, however, the date on which the Company or the applicable Guarantor changes its jurisdiction in which it is organized or such Person becomes a
successor to the Company or the applicable Guarantor, as the case may be, shall be substituted for the date on which the series of Notes was issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever in this Fifth Supplemental Indenture, the Notes or the Guarantees there is mentioned, in any context, the payment of principal and premium, if any,
redemption price, interest or any other amount payable under or with respect to any Notes, such mention shall be deemed to include mention of the payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were or
would be payable in respect thereof. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01
<I>Covenant Defeasance</I>. Article 13 of the Base Indenture shall be applicable to the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02 <I>Form of Notes</I>.
(a)&nbsp;The Notes and the Trustee&#146;s certificates of authentication to be endorsed thereon are to be substantially in the forms of Exhibits A through D attached hereto, which forms are hereby incorporated in and made a part of this Fifth
Supplemental Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The terms and provisions contained in the Notes shall constitute, and are hereby expressly made, a part of
this Fifth Supplemental Indenture, and the Company, the Trustee and the Paying Agent, by their execution and delivery of this Fifth Supplemental Indenture, expressly agree to such terms and provisions and to be bound thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03 <I>Ratification of Base Indenture</I>. The Base Indenture, as supplemented by the Second Supplemental Indenture, the Third
Supplemental Indenture, the Fourth Supplemental Indenture and this Fifth Supplemental Indenture, is in all respects ratified and confirmed, and this Fifth Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the
extent herein and therein provided. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04 <I>Trust Indenture Act Controls</I>. If any provision hereof limits,
qualifies or conflicts with the duties imposed by Section&nbsp;310 through Section&nbsp;317 of the Trust Indenture Act of 1939, the imposed duties shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05 <I>Listing</I>. Upon listing of the Notes of a series on the New York Stock Exchange, the Company will use commercially
reasonable efforts to maintain such listing and satisfy the requirements for such continued listing as long as the Notes of such series are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06 <I>Conflict with Indenture</I>. To the extent not expressly amended or modified by this Fifth Supplemental Indenture, the
Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture shall remain in full force and effect. If any provision of this Fifth Supplemental Indenture relating to the Notes is
inconsistent with any provision of the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture or the Fourth Supplemental Indenture, the provision of this Fifth Supplemental Indenture shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07 <I>Governing Law</I>. THIS SUPPLEMENTAL INDENTURE AND THE NOTES SHALL BE DEEMED TO BE A CONTRACT UNDER THE LAWS OF THE STATE
OF NEW YORK, AND FOR ALL PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF SUCH STATE, EXCEPT AS MAY OTHERWISE BE REQUIRED BY MANDATORY PROVISIONS OF LAW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08 <I>Service of Process. </I>The Company and each Guarantor appoints Corporation Service Company, with offices at 80 State
Street, Albany, New York 12207-2543, United States, as its agent to receive service of process or other legal summons for purposes of any suit, action or proceeding based on or arising out of or relating to this Supplemental Indenture or any Notes
or Guarantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09 <I>Successors. </I>All agreements of the Company and the Guarantor in the Base Indenture, this
Supplemental Indenture and the Notes shall bind their respective successors. All agreements of the Trustee in the Base Indenture and this Supplemental Indenture shall bind its successors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <I>Counterparts</I>. This instrument may be executed in any number of counterparts, each of which so executed shall be
deemed to be an original, but all such counterparts shall together constitute but one and the same instrument. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. This
Supplemental Indenture shall be valid, binding, and enforceable against a party only when executed and delivered by an authorized individual on behalf of the party by means of (i)&nbsp;any electronic signature permitted by the federal Electronic
Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, and/or any other relevant electronic signatures law, including relevant provisions of the Uniform Commercial Code/UCC (collectively,
&#147;Signature Law&#148;); (ii) an original manual signature; or (iii)&nbsp;a faxed, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scanned, or photocopied manual signature. Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect, and
admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic
signature, of any party and shall have no duty to investigate, confirm or otherwise verify the validity or authenticity thereof. For avoidance of doubt, original manual signatures shall be used for execution or indorsement of writings when required
under the UCC or other Signature Law due to the character or intended character of the writings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11 <I>Trustee
Disclaimer</I>. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture other than as to the validity of its execution and delivery by the Trustee. The recitals and statements herein are deemed to be
those of the Company and the Guarantors and not the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12 <U>Contractual Recognition of <FONT
STYLE="white-space:nowrap">Bail-In.</FONT></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Paying Agent is authorized and regulated by the Central Bank of Ireland
(&#147;<B>CBOI</B>&#148;). It is additionally authorized by the UK Prudential Regulation Authority (&#147;<B>PRA</B>&#148;) and its activities in the UK are subject to limited regulation by the UK Financial Conduct Authority (&#147;<B>FCA</B>&#148;)
and the PRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the worldwide effort against the funding of terrorism and money laundering activities, the Paying
Agent may be required under various national laws and regulations to which they are subject to obtain, verify and record information that identifies each person who opens an account with it. For a
<FONT STYLE="white-space:nowrap">non-individual</FONT> person such as a business entity, a charity, a trust or other legal entity, the Paying Agent shall be entitled to ask for documentation to verify such entity&#146;s formation and legal existence
as well as financial statements, licenses, identification and authorization documents from individuals claiming authority to represent the entity or other relevant documentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties to this Indenture acknowledge and agree that the obligations of the Paying Agent under this Indenture are limited by and
subject to compliance by them with EU and U.S. Federal anti-money laundering statutes and regulations. If the Paying Agent or any of their directors know or suspect that a payment is the proceeds of criminal conduct, such person is required to
report such information pursuant to the applicable authorities and such report shall not be treated as a breach by such person of any confidentiality covenant or other restriction imposed on such person under this Indenture, by law or otherwise on
the disclosure of information. The Paying Agent shall be indemnified and held harmless by the Issuer from and against all losses suffered by them that may arise as a result of the Paying Agent being prevented from fulfilling their obligations
hereunder due to the extent doing so would not be consistent with applicable statutory anti-money laundering requirements. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in this Indenture or in any other agreement,
arrangement or understanding among any such parties, each party hereto acknowledges that any liability of the Paying Agent arising under this Indenture or any such other document, to the extent such liability is unsecured or not otherwise exempted,
may be subject to the write-down and conversion powers of a Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the application of any Write-Down and Conversion Powers by a Resolution Authority to any such liabilities arising hereunder
which may be payable to it by any party hereto; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the effects of any
<FONT STYLE="white-space:nowrap">Bail-in</FONT> Action on any such liability, including, if applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) a reduction
in full or in part or cancellation of any such liability; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) a conversion of all, or a portion of, such liability into
shares or other instruments of ownership in such party, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of
any rights with respect to any such liability under this Indenture or any other agreement; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) the variation of the
terms of such liability in connection with the exercise of the write-down and conversion powers of any Resolution Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For the
purposes of this Section&nbsp;4.12 the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Bail-In</FONT>
Action</B>&#148; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation</B>&#148; means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law
for such EEA Member Country from time to time which is described in the EU <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule and in relation to any other state, any analogous law or regulation from time to time which requires
contractual recognition of any Write-down and Conversion Powers contained in that law or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EEA Member Country</B>&#148; means any of
the member states of the European Union, Iceland, Liechtenstein, and Norway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>EU <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation
Schedule</B>&#148; means the EU <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Resolution Authority</B>&#148; means any public administrative authority or any person entrusted with public administrative authority to exercise any
Write-down and Conversion Powers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Write-Down and Conversion Powers</B>&#148; means, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in relation to any <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation described in the EU <FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation Schedule from time to time, the powers described as such in relation to that <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation in the EU <FONT STYLE="white-space:nowrap">Bail-In</FONT>
Legislation Schedule; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any powers under the <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation to cancel,
transfer or dilute shares issued by a person that is a bank or investment firm or other financial institution or affiliate of a bank, investment firm or other financial institution, to cancel, reduce, modify or change the form of a liability of such
a person or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have
effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation that are related to or ancillary to any of those
powers; and any similar or analogous powers under that <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page
Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Fifth Supplemental Indenture to be
duly executed as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen L. Parkhill</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Karen L. Parkhill</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Executive Vice President and<BR>Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Attest:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sheila Quintus</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sheila Quintus</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President&nbsp;&amp; Treasurer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Medtronic, Inc. Fifth Supplemental Indenture</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sheila Quintus</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sheila Quintus</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President&nbsp;&amp; Treasurer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) represented by Medtronic Global Holdings GP S.&agrave; r.l., in its capacity
as General Partner itself acting by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Salvador Sens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Salvador Sens</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPUTERSHARE TRUST COMPANY, N.A., Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Corey J. Dahlstrand</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Corey J. Dahlstrand</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Vice President</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ELAVON FINANCIAL SERVICES DAC, UK BRANCH, as Paying Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Leong</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Michael Leong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Authorised Signatory</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (&#147;EUROCLEAR&#148;) AND CLEARSTREAM BANKING,
S.A. (&#147;CLEARSTREAM&#148; AND, TOGETHER WITH EUROCLEAR, &#147;EUROCLEAR/CLEARSTREAM&#148;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR&#146;S NOMINEE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.650% Senior Notes due 2029 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No._____</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">CUSIP NO. 585055 BV7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ISIN NO. XS2834367646</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">COMMON CODE: 283436764</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#128;_____</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medtronic, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota
(herein called the &#147;<B>Company</B>,&#148; which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to USB Nominees (UK) Limited, or registered assigns, the principal
sum of &#8195;&#8195;&#8195;Euros on October&nbsp;15, 2029 and to pay interest thereon from June&nbsp;3, 2024 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October&nbsp;15
in each year, commencing October&nbsp;15, 2024, at the rate of 3.650% per annum, until the principal hereof is paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without
regard to any applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for
such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may
either be paid to the Person in whose name this Security is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of
this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon
such notice as may be required by such exchange, all as more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the principal of (and premium,
if any) and any such interest on this Security will be made at the office or agency of the Paying Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that
at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of
exchange controls or other circumstances beyond its control or the Euro is no longer used by the then member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public
institutions of or within the international banking community, then all payments in respect of the 2029 Notes will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any
date in Euro will be converted by the Company into U.S. Dollars at the rate mandated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate
of conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published
such exchange rate, the rate will be determined in the Company&#146;s sole discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2029 Notes so made in
U.S. Dollars will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the
Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: &#8195;&#8195;&#8195;, 20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Medtronic, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attest:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTATION OF GUARANTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received, the undersigned (the &#147;<B>Guarantor</B>&#148;), to the extent set forth in and subject to the terms of the Indenture
dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the &#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National
Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic
plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the &#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015,
between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;),
and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as
supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the
Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, hereby fully and unconditionally guarantees, on a joint
and several basis, to each Holder and to the Trustee and its successors and assigns, that the principal of and premium, if any, and interest on the 2029 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration,
redemption or otherwise, and interest on the overdue principal of and interest on the 2029 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or
performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture
are expressly set forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2029 Notes to which this Notation of Guarantee is endorsed,
by accepting such 2029 Notes, agrees to and shall be bound by such provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Notation of Guarantee which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated: &#8195;&#8195;&#8195;, 20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) represented by Medtronic Global Holdings GP S.&agrave;.r.l. its General
Partner, in turn acting by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is one of the Securities of the series designated therein referred to in the within-mentioned
Indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;&#8195; , 20 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COMPUTERSHARE TRUST</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">COMPANY, N.A.,
as Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signature</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Reverse of Note] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.650%
Senior Notes Due 2029 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Security is one of a duly authorized issue of securities of the Company (herein called the
&#147;<B>Securities</B>&#148;), issued and to be issued in one or more series under an Indenture dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the
&#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined
below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the
&#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en
commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;), and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of
February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental
Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic
Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount
to &#128;850,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred
and is continuing with respect to the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series may be redeemed at any time prior to the applicable Par
Call Date, as a whole or in part, at the option of the Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal
to the greater of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the Securities being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 15 basis points; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at any time on and after the applicable Par Call Date, the Securities are
redeemable at the Company&#146;s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed
portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to
Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the
time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the
right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect
of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal
amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing
shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the
Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by
a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder&#146;s attorney duly authorized in writing, and thereupon one or more new Securities of this series and
of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series are issuable only in registered form without coupons in
denominations of &#128;100,000 or an integral multiple of &#128;1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To assign this Note, fill in the form below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(I) or (we) assign and transfer this Note to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Insert assignee&#146;s legal
name)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Insert assignee&#146;s soc. sec. or tax I.D. no.)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Print or type assignee&#146;s name, address and zip code)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and irrevocably appoint</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">to transfer this Note on the books of the Company. The agent may substitute another to
act for him.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: _______</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your&nbsp;Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Sign exactly as your name appears on the face of this Note)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature Guarantee*:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (&#147;EUROCLEAR&#148;) AND CLEARSTREAM BANKING,
S.A. (&#147;CLEARSTREAM&#148; AND, TOGETHER WITH EUROCLEAR, &#147;EUROCLEAR/CLEARSTREAM&#148;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR&#146;S NOMINEE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.875% Senior Notes due 2036 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No._____</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">CUSIP NO. 585055 BW5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ISIN NO. XS2834367729</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">COMMON CODE: 283436772</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#128;_____</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medtronic, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota
(herein called the &#147;<B>Company</B>,&#148; which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to USB Nominees (UK) Limited, or registered assigns, the principal
sum of &#8195;&#8195;&#8195;Euros on October&nbsp;15, 2036 and to pay interest thereon from June&nbsp;3, 2024 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October&nbsp;15
in each year, commencing October&nbsp;15, 2024, at the rate of 3.875% per annum, until the principal hereof is paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without
regard to any applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for
such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may
either be paid to the Person in whose name this Security is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of
this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon
such notice as may be required by such exchange, all as more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the principal of (and premium,
if any) and any such interest on this Security will be made at the office or agency of the Paying Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that
at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of
exchange controls or other circumstances beyond its control or the Euro is no longer used by the then member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public
institutions of or within the international banking community, then all payments in respect of the 2036 Notes will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any
date in Euro will be converted by the Company into U.S. Dollars at the rate mandated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate
of conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published
such exchange rate, the rate will be determined in the Company&#146;s sole discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2036 Notes so made in
U.S. Dollars will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the
Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&#8195;&#8195;&#8195; , 20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Medtronic, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attest:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTATION OF GUARANTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received, the undersigned (the &#147;<B>Guarantor</B>&#148;), to the extent set forth in and subject to the terms of the Indenture
dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the &#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National
Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic
plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the &#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015,
between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;),
and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as
supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the
Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, hereby fully and unconditionally guarantees, on a joint
and several basis, to each Holder and to the Trustee and its successors and assigns, that the principal of and premium, if any, and interest on the 2036 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration,
redemption or otherwise, and interest on the overdue principal of and interest on the 2036 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or
performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture
are expressly set forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2036 Notes to which this Notation of Guarantee is endorsed,
by accepting such 2036 Notes, agrees to and shall be bound by such provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Notation of Guarantee which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;&#8195;, 20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) represented by Medtronic Global Holdings GP S.&agrave;.r.l. its General
Partner, in turn acting by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is one of the Securities of the series designated therein referred to in the within-mentioned
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;&#8195;, 20 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPUTERSHARE TRUST COMPANY, N.A., as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signature</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Reverse of Note] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.875%
Senior Notes Due 2036 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Security is one of a duly authorized issue of securities of the Company (herein called the
&#147;<B>Securities</B>&#148;), issued and to be issued in one or more series under an Indenture dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the
&#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined
below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the
&#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en
commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;), and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of
February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental
Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic
Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount
to &#128;850,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred
and is continuing with respect to the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series may be redeemed at any time prior to the applicable Par
Call Date, as a whole or in part, at the option of the Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal
to the greater of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the Securities being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 20 basis points; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at any time on and after the applicable Par Call Date, the Securities are
redeemable at the Company&#146;s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed
portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to
Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the
time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the
right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect
of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal
amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing
shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the
Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by
a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder&#146;s attorney duly authorized in writing, and thereupon one or more new Securities of this series and
of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series are issuable only in registered form without coupons in
denominations of &#128;100,000 or an integral multiple of &#128;1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To assign this Note, fill in the form below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(I) or (we) assign and transfer this Note to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Insert assignee&#146;s legal
name)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Insert assignee&#146;s soc. sec. or tax I.D. no.)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Print or type assignee&#146;s name, address and zip code)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and irrevocably appoint</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">to transfer this Note on the books of the Company. The agent may substitute another to
act for him.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: _______</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your&nbsp;Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Sign exactly as your name appears on the face of this Note)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature Guarantee*:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (&#147;EUROCLEAR&#148;) AND CLEARSTREAM BANKING,
S.A. (&#147;CLEARSTREAM&#148; AND, TOGETHER WITH EUROCLEAR, &#147;EUROCLEAR/CLEARSTREAM&#148;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR&#146;S NOMINEE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.150% Senior Notes due 2043 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No._____</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">CUSIP NO. 585055 BX3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ISIN NO. XS2834367992</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">COMMON CODE: 283436799</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#128;_____</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medtronic, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota
(herein called the &#147;<B>Company</B>,&#148; which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to USB Nominees (UK) Limited, or registered assigns, the principal
sum of Euros on October&nbsp;15, 2043 and to pay interest thereon from June&nbsp;3, 2024 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October&nbsp;15 in each year,
commencing October&nbsp;15, 2024, at the rate of 4.150% per annum, until the principal hereof is paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any
applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interest so payable,
and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which
shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the
Person in whose name this Security is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less
than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the principal of (and premium, if any) and any such
interest on this Security will be made at the office or agency of the Paying Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the
Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or
other circumstances beyond its control or the Euro is no longer used by the then member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the
international banking community, then all payments in respect of the 2043 Notes will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted
by the Company into U.S. Dollars at the rate mandated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate
of conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published
such exchange rate, the rate will be determined in the Company&#146;s sole discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2043 Notes so made in
U.S. Dollars will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the
Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&#8195;&#8195;, 20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Medtronic, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attest:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTATION OF GUARANTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received, the undersigned (the &#147;<B>Guarantor</B>&#148;), to the extent set forth in and subject to the terms of the Indenture
dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the &#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National
Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic
plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the &#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015,
between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;),
and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as
supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the
Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, hereby fully and unconditionally guarantees, on a joint
and several basis, to each Holder and to the Trustee and its successors and assigns, that the principal of and premium, if any, and interest on the 2043 Notes shall be promptly paid in full when due, whether at Stated Maturity, by acceleration,
redemption or otherwise, and interest on the overdue principal of and interest on the 2043 Notes, if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or
performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture
are expressly set forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2043 Notes to which this Notation of Guarantee is endorsed,
by accepting such 2043 Notes, agrees to and shall be bound by such provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Notation of Guarantee which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;, 20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) represented by Medtronic Global Holdings GP S.&agrave;.r.l. its General
Partner, in turn acting by</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is one of the Securities of the series designated therein referred to in the within-mentioned
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;, 20 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">COMPUTERSHARE TRUST COMPANY, N.A., as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signature</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Reverse of Note] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.150%
Senior Notes Due 2043 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Security is one of a duly authorized issue of securities of the Company (herein called the
&#147;<B>Securities</B>&#148;), issued and to be issued in one or more series under an Indenture dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the
&#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined
below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the
&#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en
commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;), and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of
February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental
Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic
Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount
to &#128;600,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred
and is continuing with respect to the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series may be redeemed at any time prior to the applicable Par
Call Date, as a whole or in part, at the option of the Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal
to the greater of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the Securities being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 20 basis points; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at any time on and after the applicable Par Call Date, the Securities are
redeemable at the Company&#146;s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed
portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to
Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the
time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the
right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect
of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal
amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing
shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the
Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by
a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder&#146;s attorney duly authorized in writing, and thereupon one or more new Securities of this series and
of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series are issuable only in registered form without coupons in
denominations of &#128;100,000 or an integral multiple of &#128;1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To assign this Note, fill in the form below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(I) or (we) assign and transfer this Note to:&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Insert assignee&#146;s legal name)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Insert assignee&#146;s soc. sec. or tax I.D. no.)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Print or type assignee&#146;s name, address and zip code)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and irrevocably appoint</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">to transfer this Note on the books of the Company. The agent may substitute another to
act for him.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: _______</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your&nbsp;Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Sign exactly as your name appears on the face of this Note)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature Guarantee*:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF NOTE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS
SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR BANK SA/NV (&#147;EUROCLEAR&#148;) AND CLEARSTREAM BANKING,
S.A. (&#147;CLEARSTREAM&#148; AND, TOGETHER WITH EUROCLEAR, &#147;EUROCLEAR/CLEARSTREAM&#148;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF USB NOMINEES (UK)
LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF EUROCLEAR/CLEARSTREAM (AND ANY PAYMENT IS MADE TO USB NOMINEES (UK) LIMITED OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
EUROCLEAR/CLEARSTREAM), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, ELAVON FINANCIAL SERVICES DAC, HAS AN INTEREST HEREIN. TRANSFERS OF THIS GLOBAL SECURITY
SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF USB NOMINEES (UK) LIMITED OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR&#146;S NOMINEE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.150% Senior Notes due 2053 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No._____</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">CUSIP NO. 585055 BY1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ISIN NO. XS2834368453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">COMMON CODE: 283436845</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#128;_____</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medtronic, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota
(herein called the &#147;<B>Company</B>,&#148; which term includes any successor corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to USB Nominees (UK) Limited, or registered assigns, the principal
sum of Euros on October&nbsp;15, 2053 and to pay interest thereon from June&nbsp;3, 2024 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, annually in arrears on October&nbsp;15 in each year,
commencing October&nbsp;15, 2024, at the rate of 4.150% per annum, until the principal hereof is paid or made available for payment. The Company shall pay interest on overdue principal, and on overdue installments of interest (without regard to any
applicable grace periods) to the extent lawful, from time to time on demand at the rate borne by this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interest so payable,
and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security is registered at the close of business on the Regular Record Date for such interest, which
shall be the Business Day immediately preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the
Person in whose name this Security is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less
than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the principal of (and premium, if any) and any such
interest on this Security will be made at the office or agency of the Paying Agent maintained for that purpose in London, Dublin or any financial center in a European Economic Area jurisdiction in Euro; provided, however, that at the option of the
Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. If the Euro is unavailable to the Company due to the imposition of exchange controls or
other circumstances beyond its control or the Euro is no longer used by the then member states of the European Monetary Union that have adopted the Euro as their currency or for the settlement of transactions by public institutions of or within the
international banking community, then all payments in respect of the 2053 Notes will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstances, the amount payable on any date in Euro will be converted
by the Company into U.S. Dollars at the rate mandated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate
of conversion, on the basis of the most recent U.S. Dollar/Euro exchange rate published in The Wall Street Journal on or prior to the second Business Day prior to the relevant payment date or, in the event The Wall Street Journal has not published
such exchange rate, the rate will be determined in the Company&#146;s sole discretion on the basis of the most recently available market exchange rate for the Euro. For the avoidance of doubt, any such payment in respect of the 2053 Notes so made in
U.S. Dollars will not constitute an Event of Default. Neither the Trustee nor the Paying Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the
Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&#8195;&#8195;, 20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Medtronic, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attest:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTATION OF GUARANTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For value received, the undersigned (the &#147;<B>Guarantor</B>&#148;), to the extent set forth in and subject to the terms of the Indenture
dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the &#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National
Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic
plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the &#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015,
between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;),
and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as
supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the
Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, hereby fully and unconditionally guarantees, on a joint
and several basis, to each Holder and to the Trustee and its successors and assigns, that the principal of and premium, if any, and interest on the 2053 Notes shall be promptly paid in full when due, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">whether at Stated Maturity, by acceleration, redemption or otherwise, and interest on the overdue principal of and interest on the 2053 Notes,
if any, if lawful, and all other obligations of the Company to the Holders or the Trustee hereunder or thereunder shall be promptly paid in full or performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Guarantor to the Holders and to the Trustee pursuant to this Notation of Guarantee and the Indenture are expressly set
forth in Article 14 of the Indenture, and reference is hereby made to the Indenture for the precise terms and limitations of this Notation of Guarantee. Each Holder of the 2053 Notes to which this Notation of Guarantee is endorsed, by accepting such
2053 Notes, agrees to and shall be bound by such provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Notation of Guarantee which are defined in the
Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Guarantor has caused this Notation of Guarantee to be signed by a
duly authorized officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;&#8195;, 20 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC PUBLIC LIMITED COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDTRONIC GLOBAL HOLDINGS S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en commandite par actions</I>) represented by Medtronic Global Holdings GP S.&agrave;.r.l. its General
Partner, in turn acting by</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is one of the Securities of the series designated therein referred to in the within-mentioned
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&#8195;&#8195;&#8195;, 20 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">COMPUTERSHARE TRUST COMPANY, N.A., as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signature</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Reverse of Note] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDTRONIC, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.150%
Senior Notes Due 2053 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Security is one of a duly authorized issue of securities of the Company (herein called the
&#147;<B>Securities</B>&#148;), issued and to be issued in one or more series under an Indenture dated as of December&nbsp;10, 2014 (the &#147;<B>Base Indenture</B>&#148;), between Medtronic, Inc., a Minnesota corporation (the
&#147;<B>Company</B>&#148;), and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#147;<B>Trustee</B>&#148;, which term includes any successor trustee under the Indenture (as defined
below)), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc, a public limited company incorporated under the laws of Ireland (the &#147;<B>Medtronic plc</B>&#148;), and the Trustee (the
&#147;<B>Second Supplemental Indenture</B>&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Global Holdings S.C.A., a Luxembourg corporate partnership limited by shares (<I>soci&eacute;t&eacute; en
commandite par actions</I>) (&#147;<B>Medtronic Luxco</B>&#148; and together with Parent, the &#147;<B>Guarantors</B>&#148;), and the Trustee (the &#147;<B>Third Supplemental Indenture</B>&#148;), the Fourth Supplemental Indenture, dated as of
February&nbsp;22, 2023, between the Company and the Trustee (the &#147;<B>Fourth Supplemental Indenture</B>&#148;), and as supplemented by the Fifth Supplemental Indenture, dated as of June&nbsp;3, 2024 (the &#147;<B>Fifth Supplemental
Indenture</B>&#148; and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the &#147;<B>Indenture</B>&#148;), among the Company, Medtronic plc, Medtronic
Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as paying agent, and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount
to &#128;700,000,000. The Company may at any time issue additional Securities under the Indenture in unlimited amounts having the same terms as the Securities; provided that no additional Securities may be issued if an Event of Default has occurred
and is continuing with respect to the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series may be redeemed at any time prior to the applicable Par
Call Date, as a whole or in part, at the option of the Company, upon mailing notice of such redemption not less than 10 and not more than 60 days prior to the applicable Redemption Date to the Holders of such Securities, at a Redemption Price equal
to the greater of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 100% of the principal amount of the Securities being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the sum, as determined by a Quotation Agent, of the present values of the Remaining Scheduled Payments of principal and
interest on the Securities to be redeemed (excluding any portion of such payments of interest accrued as of the Redemption Date and assuming that such Securities matured on the applicable Par Call Date), discounted to the Redemption Date on an
annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Bond Rate, plus 25 basis points; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">plus, in each case, accrued and unpaid interest to, but not
including, the Redemption Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at any time on and after the applicable Par Call Date, the Securities are
redeemable at the Company&#146;s option, in whole or in part, at a Redemption Price equal to 100% of the principal amount of the Securities to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed
portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to
Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the
time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be
conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is
made upon this Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the
right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of
Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect
of such Event of Default as Trustee and offered the Trustee indemnity against the costs, expenses and liabilities to be incurred in compliance with such request, and the Trustee shall not have received from the Holders of a majority in principal
amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing
shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the
Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by
a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or the Holder&#146;s attorney duly authorized in writing, and thereupon one or more new Securities of this series and
of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of this series are issuable only in registered form without coupons in
denominations of &#128;100,000 or an integral multiple of &#128;1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal
amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Security for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the Indenture. Such further
provisions shall for all purposes have the same effect as though fully set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To assign this Note, fill in the form below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(I) or (we) assign and transfer this Note to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Insert assignee&#146;s legal
name)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Insert assignee&#146;s soc. sec. or tax I.D. no.)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Print or type assignee&#146;s name, address and zip code)</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and irrevocably appoint</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">to transfer this Note on the books of the Company. The agent may substitute another to
act for him.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: _______</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your&nbsp;Signature:&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Sign exactly as your name appears on the face of this Note)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature Guarantee*:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-11 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d811133dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g811133dsp58.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">June&nbsp;3, 2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 202 663 6000(t)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 202 663 6363 (f)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">710 Medtronic
Parkway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, MN 55432 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Medtronic, Inc. Senior
Notes </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as special
U.S. counsel for Medtronic, Inc., a Minnesota corporation (the &#147;Company&#148;), and the Guarantors (as defined below) in connection with the offer and sale by the Company of &#128;850,000,000 in aggregate principal amount of its 3.650% Senior
Notes due 2029 (the &#147;2029 Notes&#148;), &#128;850,000,000 in aggregate principal amount of its 3.875% Senior Notes due 2036 (the &#147;2036 Notes&#148;), &#128;600,000,000 in aggregate principal amount of its 4.150% Senior Notes due 2043 (the
&#147;2043 Notes&#148;), and &#128;700,000,000 in aggregate principal amount of its 4.150% Senior Notes due 2053 (the &#147;2053 Notes&#148; and together with the 2029 Notes, the 2036 Notes and the 2043 Notes, the &#147;Notes&#148;), pursuant to an
underwriting agreement dated May&nbsp;29, 2024, among the Company, the Guarantors (as defined below) and Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc, as representatives of
the several underwriters (the &#147;Underwriting Agreement&#148;). The Notes will be fully and unconditionally guaranteed on an unsecured unsubordinated basis (the &#147;Guarantees&#148;) by Medtronic Global Securities S.C.A., an entity organized
under the laws of Luxembourg (&#147;Medtronic Luxco&#148;) and Medtronic Public Limited Company, a company organized under the laws of Ireland (&#147;Medtronic plc,&#148; and together with Medtronic Luxco, the &#147;Guarantors&#148;). The Notes will
be issued pursuant to an Indenture dated as of December&nbsp;10, 2014 (the &#147;Base Indenture&#148;), between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the
&#147;Trustee&#148;), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc and the Trustee (the &#147;Second Supplemental Indenture&#148;), the Third Supplemental Indenture, dated as of
January&nbsp;26, 2015, between Medtronic Luxco and the Trustee (the &#147;Third Supplemental Indenture&#148;), the Fourth Supplemental Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;Fourth Supplemental
Indenture&#148;), and the Fifth Supplemental Indenture dated as of June&nbsp;3, 2024 (together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the
&#147;Indenture&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, UK Branch, as the paying agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and the Guarantors filed with the Securities and Exchange Commission (the &#147;Commission&#148;) a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;(File</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-270272</FONT> ) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), on March&nbsp;3, 2023 (the &#147;Registration
Statement&#148;), including the prospectus dated March&nbsp;3, 2023 (the &#147;Base Prospectus&#148;), as supplemented by a preliminary prospectus supplement dated May&nbsp;29, 2024 (the &#147;Preliminary Prospectus Supplement&#148;) relating to the
Notes, and a final prospectus supplement dated May&nbsp;29, 2024 (the &#147;Prospectus Supplement&#148;) relating to the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined and
relied upon signed copies of the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement, the Prospectus Supplement, the Underwriting Agreement, the Indenture, the Notes and the Guarantees (the &#147;Transaction
Documents&#148;). For purposes of this opinion, we have also examined and relied without investigation upon the accuracy of (i)&nbsp;the opinion letter of A&amp;L Goodbody, Irish counsel for Medtronic plc, dated the date hereof and filed as Exhibit
5.2 to Medtronic plc&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;to</FONT> be filed on the date hereof (the <FONT STYLE="white-space:nowrap">&#147;Form&nbsp;8-K&#148;);&nbsp;(ii)</FONT> the opinion letter of CM Law,
special Luxembourg counsel for the Company dated the date hereof and filed as Exhibit 5.3 to the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K;&nbsp;and</FONT> (iii)&nbsp;the opinion letter of Thomas L. Osteraas, Legal Director &#150; Corporate and
Securities of Medtronic, Inc., dated the date hereof and filed as Exhibit 5.4 to the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.&nbsp;We</FONT> have relied as to certain matters on information obtained from public officials and officers of the
Company, Medtronic plc and Medtronic Luxco. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g811133dsp58a.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 3, 2024</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"> Page
 2
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g811133dsp58.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our examination of the documents referred to above, we have assumed the genuineness of all signatures, the
legal capacity of all individual signatories, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, and the authenticity of such original documents. Insofar
as the opinions relate to factual matters, we have assumed, without independent investigation, that representations of officers and directors of the Company and the Guarantors and documents furnished to us by the Company and Guarantors are true and
correct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have assumed that (i)&nbsp;the Trustee has the power, corporate or other, to enter into and
perform its obligations under the Indenture; (ii)&nbsp;the Indenture, the Notes and the Guarantees have been duly authorized, executed and delivered by all parties thereto (including, without limitation, the Company and the Guarantors); and
(iii)&nbsp;the Indenture is a valid and binding obligation of the Trustee. We have also assumed that the Board of Directors (or comparable body) of the Company and the Board of Directors (or comparable body) of each Guarantor (or any person acting
pursuant to authority properly delegated to such person by the Board of Directors (or comparable body) of the Company or the Board of Directors (or comparable body) of each Guarantor) have not taken any action to rescind or otherwise reduce their
prior authorization of the issuance of the Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions below are qualified to the extent that they may be subject to or affected by
(i)&nbsp;applicable bankruptcy, insolvency, reorganization, moratorium, usury, fraudulent conveyance or similar laws relating to or affecting the rights or remedies of creditors generally; (ii)&nbsp;statutory or decisional law concerning recourse by
creditors to security in the absence of notice or hearing, (iii)&nbsp;duties and standards imposed on creditors and parties to contracts, including, without limitation, requirements of materiality, good faith, reasonableness and fair dealing; and
(iv)&nbsp;general equitable principles. Furthermore, we express no opinion as to the availability of any equitable or specific remedy upon any breach of the Indenture, the Notes, or the Guarantees, or to the successful assertion of any equitable
defenses, inasmuch as the availability of such remedies or the success of any equitable defenses may be subject to the discretion of a court. We express no opinion herein as to the laws of any jurisdiction other than the state laws of the State of
New York. We have not acted as counsel for the Company with respect to matters of Minnesota law, Irish law, Luxembourg law or other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of our opinions rendered below, and without limiting any other comments and qualifications set forth herein, insofar as they relate to the enforceability against any Guarantor, we have assumed that such Guarantor has received reasonably
equivalent value and fair consideration in exchange for its obligations or undertakings in connection with the transactions contemplated by the Transaction Documents, and that prior to and after consummation of the transactions contemplated by the
Transaction Documents, such Guarantor is not insolvent, rendered insolvent, left with unreasonably small capital or intends to or believes it will incur debts beyond its ability to pay as they mature within the meaning of 11 U.S.C. &#167; 548 and
the New York Debtor and Creditor Law statute &#167;&#167; 270 et seq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of, and subject to, the foregoing, we are of the opinion that
(i)&nbsp;when the Notes have been duly executed by the Company and duly authenticated by the Trustee in accordance with the terms of the Indenture, and delivered to the purchasers thereof against payment of the consideration therefor in accordance
with the terms of the Underwriting Agreement, the Notes will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms; and (ii)&nbsp;when the Guarantees have been duly executed by each
Guarantor in accordance with the terms of the Indenture and the Notes, the Guarantees will constitute valid and binding obligations of each Guarantor, enforceable against each Guarantor in accordance with their terms. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 3, 2024</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"> Page
 3
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g811133dsp58.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be
inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions and is rendered as of the date hereof, and we disclaim any obligation to advise you of any change in any of the
foregoing sources of law or subsequent developments in law or changes in facts or circumstances that might affect any matters or opinions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion with the Commission as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to
be filed by Medtronic plc in connection with the issuance and sale of the Notes in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act and to the use of our name
therein and in the Prospectus Supplement under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the
rules and regulations of the Commission. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Wilmer Cutler Pickering Hale and Dorr LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WILMER CUTLER PICKERING</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HALE AND DORR LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>d811133dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>A&amp;L Goodbody LLP</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Dublin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">3 Dublin Landings</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Belfast</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">North Wall Quay, Dublin 1</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">London</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">D01 C4E0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">T: +353 1 649 2000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">San&nbsp;Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">DX: 29 Dublin | www.algoodbody.com</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Palo Alto</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3&nbsp;June 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:2pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:2pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Our ref</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">01446113</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:2pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Your ref</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Medtronic plc </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20
Lower Hatch Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dublin 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ireland </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Addressee </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Irish solicitors to Medtronic
plc (formerly known as Medtronic Limited) (CRO number 545333) (the<B> Company</B>) in connection with the offer and sale by Medtronic, Inc., (the <B>Issuer</B>) of &#128;850,000,000 aggregate principal amount of 3.650% Senior Notes due 2029 (the
<B>2029 Notes</B>), of &#128;850,000,000 aggregate principal amount of 3.875% Senior Notes due 2036 (the <B>2036 Notes</B>), of &#128;600,000,000 aggregate principal amount of 4.150% Senior Notes due 2043 (the <B>2043 Notes</B>), of
&#128;700,000,000 aggregate principal amount of 4.150% Senior Notes due 2053 (the <B>2053 Notes</B> and together with the 2029 Notes, the 2036 Notes and the 2043 Notes, the <B>Notes</B>) pursuant to an underwriting agreement dated as of 29&nbsp;May
2024 (the <B>Underwriting Agreement</B>) among the Issuer, the Company, Medtronic Global Holdings S.C.A., a corporate partnership limited by shares (soci&eacute;t&eacute; en commandite par actions), incorporated and existing under the laws of the
Grand Duchy of Luxembourg (<B>Medtronic Global</B>), Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc as representatives of the several underwriters named in the Underwriting
Agreement. The Notes will be issued pursuant to the indenture dated as of 10&nbsp;December 2014 (the <B>Base Indenture</B>), between the Issuer and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as
trustee (the <B>Trustee</B>), as supplemented by the second supplemental indenture, dated as of 26&nbsp;January 2015, between the Company and the Trustee (the <B>Second Supplemental Indenture</B>), as supplemented by the third supplemental
indenture, dated as of 26&nbsp;January 2015, between Medtronic Global and the Trustee (the <B>Third Supplemental Indenture</B>), as supplemented by the fourth supplemental indenture, dated as of 22&nbsp;February 2023 (the <B>Fourth Supplemental
Indenture</B>) and as supplemented by the fifth supplemental indenture, dated as of 3&nbsp;June 2024 among the Issuer, the Company, Medtronic Global, the Trustee and Elavon Financial Services DAC, UK Branch, as the paying agent (the <B>Fifth
Supplemental Indenture</B> and, together with the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the <B>Indentures</B>). The Company will fully and unconditionally guarantee
the Notes pursuant to the terms of the Indentures (the <B>Guarantee</B>) and separately, Medtronic Global will also fully and unconditionally guarantee the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer and sale of the Notes is being made pursuant to the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the <B>Registration
Statement</B>), filed with the Securities and Exchange Commission (the <B>SEC</B>) on 3&nbsp;March 2023 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-270272-01)</FONT> by the Company, the Issuer and Medtronic Global, which Registration
Statement includes a prospectus dated 3&nbsp;March 2023 (the <B>Base Prospectus</B>), as supplemented by the preliminary prospectus dated as of 29&nbsp;May 2024 (the <B>Preliminary Prospectus Supplement</B>) and the prospectus supplement dated as of
29&nbsp;May 2024 relating to the issuance by the Issuer of the Notes (the <B>Prospectus Supplement</B>). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have examined PDF executed copies of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each of the Transaction Documents set out in Schedule 1 hereto; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">CE Gill &#149; JG Grennan &#149; PD White &#149; VJ Power &#149; SM Doggett &#149; M Sherlock &#149; KP Allen &#149; C Rogers &#149; G O&#146;Toole &#149; JN
Kelly &#149; N O&#146;Sullivan &#149; MJ Ward &#149; D Widger &#149; C Christle &#149; S &Oacute; Cr&oacute;inin DR Baxter &#149; A McCarthy &#149; JF Whelan &#149; JB Somerville &#149; MF Barr &#149; AM Curran &#149; A Roberts &#149; RM Moore
&#149; D Main &#149; J Cahir &#149; M Traynor &#149; PM Murray &#149; P Walker &#149; K Furlong PT Fahy &#149; D Inverarity &#149; M Coghlan &#149; DR Francis &#149; A Casey &#149; B Hosty &#149; M O&#146;Brien &#149; L Mulleady &#149; K Ryan &#149;
E Hurley &#149; D Dagostino &#149; R Grey &#149; R Lyons &#149; J Sheehy &#149; C Carroll &#149; SE Carson P Diggin &#149; J Williams &#149; A O&#146;Beirne &#149; J Dallas &#149; SM Lynch &#149; M McElhinney &#149; C Owens &#149; AD Ion &#149; K
O&#146;Connor &#149; JH Milne &#149; T Casey &#149; M Doyle &#149; CJ Comerford &#149; R Marron &#149; K O&#146;Shaughnessy S O&#146;Connor &#149; SE Murphy &#149; D Nangle &#149; C &Oacute; Conluain &#149; N McMahon &#149; HP Brandt &#149; A
Sheridan &#149; N Cole &#149; M Devane &#149; D Fitzgerald &#149; G McDonald &#149; N Meehan &#149; R O&#146;Driscoll &#149; B O&#146;Malley C Bollard &#149; M Daly &#149; D Geraghty &#149; LC Kennedy &#149; E Mulhern &#149; E O&#146;Keeffe &#149;
MJ Ellis &#149; D Griffin &#149; D McElroy &#149; C Culleton &#149; B Nic Suibhne &#149; S Quinlivan &#149; J Rattigan &#149; K Mulhern A Muldowney&#8195;&#149; L Dunne&#8195;&#149; A Burke&#8195;&#149; C Bergin&#8195;&#149; P Fogarty </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Consultants: Professor JCW Wylie &#149; MA Greene &#149; AV Fanagan &#149; PM Law &#149; SW Haughey &#149; PV Maher </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">corporate certificate (the <B>Corporate</B> <B>Certificate</B>) of the Company dated the date hereof<B>
</B>attaching: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">true, complete and up to date copies of the certificate of incorporation, the certificate on change of name<B>
</B>and memorandum and articles of association of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the extract of minutes of a meeting of the board of directors of the Company dated 7&nbsp;March 2024;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the extract of minutes of a meeting of the board of directors of the Company dated 8&nbsp;December
2022; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and such other documents as we have considered necessary or desirable to examine in order that we may give this
opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms defined in the Transaction Documents have the same meaning in this opinion letter. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of giving this opinion we have assumed: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the authenticity of all documents submitted to us as originals and the completeness and conformity to the
originals of all copies of documents of any kind furnished to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the copies produced to us of minutes of meetings and/or of resolutions are true copies and correctly
record the proceedings of such meetings and/or the subject-matter which they purport to record and that any meetings referred to in such copies were duly convened and held and that all resolutions set out in such minutes were duly passed and are in
full force and effect and have not been revoked, rescinded or varied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all the signatures (electronic or otherwise), stamps and seals on all original and copy
documents which we have examined, and that any signatures (electronic or otherwise) are the signatures of the persons who they purport to be, that each witness to a signature (electronic or otherwise) actually physically witnessed that signature,
and that each original was executed in the manner appearing on the copy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the memorandum and articles of association of the Company attached to the Corporate Certificate are
correct and up to date and they have not been amended or varied since the date of the Base Indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accuracy and completeness as to factual matters of the representations and warranties of the Company
contained in the Transaction Documents<B> </B>and the accuracy of all certificates, including the Corporate Certificate, provided to us by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that there are no agreements or arrangements in existence which in any way amend or vary the terms of the
Guarantee and Transaction as disclosed by the Transaction Documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">without having made any investigation, that the terms of the Transaction Documents are lawful and fully
enforceable under the laws of the State of New York and any other applicable laws other than the laws of Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accuracy and completeness of all information appearing on public records, including information available
on the Companies Registrations Office (<B>CRO</B>) website; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Company has entered into the Transaction and Transaction Documents in good faith, for its legitimate
business purposes, for good consideration, and that it derives commercial benefit from the Transaction and Transaction Documents commensurate with the risks undertaken by it in the Transaction and Transaction Documents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Notes issued in connection with the Guarantee and Transaction will not be sold or offered for sale to
any persons resident in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Company will not, by the entry into the Transaction Documents and the performance of the transactions
contemplated thereby, be giving financial assistance for the purposes of Section&nbsp;82 of the Companies Act 2014 of Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Base Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture and the Fourth
Supplemental Indenture remain in full force and effect and have not been revoked, rescinded or terminated or amended or varied save as pursuant to the Transaction Documents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We express no opinion as to any matters falling to be determined other than under the laws of Ireland and,
without reference to provisions of other laws imported by Irish private international law, in Ireland as of the date of this letter. Subject to that qualification and to the other qualifications set out herein, we are of the opinion that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is a company duly incorporated as a public limited liability company under the laws of Ireland and
is a separate legal entity, subject to suit in its own name. Based only on searches carried out in the CRO and the Central Office of the High Court on 31&nbsp;May 2024, the Company is validly existing under the laws of Ireland and no steps have been
taken or are being taken to appoint a receiver, examiner or liquidator over it or its assets or to wind it up; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has the necessary power and authority, and all necessary corporate and other action required by it
have been taken, to enable it to execute, deliver and perform the obligations undertaken by it under the Guarantee and the other Transaction Documents to which it is party, and the implementation by it of the foregoing will not cause:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any limit on it or on its directors (whether imposed by the documents constituting it or by statute or
regulation) to be exceeded; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any violation of the memorandum and articles of association of the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any law or order to be contravened; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Guarantee and the other Transaction Documents to which the Company is a party have been duly executed on
its behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no authorisations, approvals, licences, exemptions or consents of governmental or regulatory authorities with
respect to the Guarantee and the other Transaction Documents are required to be obtained in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is not necessary or advisable under the laws of Ireland in order to ensure the validity, enforceability or
priority of the obligations or rights of any party to the Transaction Documents that any of the Transaction Documents be filed, registered, recorded, or notarised in any public office or elsewhere or that any other instrument relating thereto be
signed, delivered, filed, registered or recorded; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is not entitled to claim any immunity from suit, execution, attachment or other legal process in
Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any proceedings taken in Ireland for the enforcement of the Transaction Documents, the choice of the laws of
the State of New York<B> </B>as the governing law of the Transaction Documents would be upheld by the Irish courts in accordance with the provisions of the Rome I Regulation EC No.&nbsp;593/2008 on the Law Applicable to Contractual Obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the submission on the part of the Company under the Transaction Documents to the jurisdiction of the courts of
the State of New York is valid and binding on the Company and will be upheld by the Irish courts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any proceedings taken in Ireland for the enforcement of a judgment obtained against the Company in the
courts of the State of New York<B> </B>(a <B>Foreign Judgment</B>) the Foreign Judgment should be recognised and enforced by the courts of Ireland save that to enforce such a Foreign Judgment in Ireland it would be necessary to obtain an order of
the Irish courts. Such order should be granted on proper proof of the Foreign Judgment without any <FONT STYLE="white-space:nowrap">re-trial</FONT> or examination of the merits of the case subject to the following qualifications:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the foreign court had jurisdiction, according to the laws of Ireland; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Foreign Judgment was not obtained by fraud; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Foreign Judgment is not contrary to public policy or natural justice as understood in Irish law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Foreign Judgment is final and conclusive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Foreign Judgment is for a definite sum of money; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the procedural rules of the court giving the Foreign Judgment have been observed; and
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">any such order of the Irish courts may be expressed in a currency other than euro in respect of the amount due and
payable by the Company but such order may be issued out of the Central Office of the Irish High Court expressed in euro by reference to the official rate of exchange prevailing on the date of issue of such order. However, in the event of a winding
up of the Company, amounts claimed by or against the Company in a currency other than the euro (the <B>Foreign Currency</B>) would, to the extent properly payable in the winding up, be paid if not in the Foreign Currency in the euro equivalent of
the amount due in the Foreign Currency converted at the rate of exchange pertaining on the date of the commencement of such winding up; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The opinions set forth in this opinion letter are given subject to the following qualifications:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an order of specific performance or any other equitable remedy is a discretionary remedy and is not available
when damages are considered to be an adequate remedy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this opinion is given subject to general provisions of Irish law relating to insolvency, bankruptcy,
liquidation, reorganisation, receivership, moratoria, court scheme of arrangement, administration and examination, and the unfair preference of creditors and other Irish law generally affecting the rights of creditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this opinion is subject to the general laws relating to the limitation of actions in Ireland;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a determination, description, calculation, opinion or certificate of any person as to any matter provided for
in the Transaction Documents might be held by the Irish courts not to be final, conclusive or binding if it could be shown to have an unreasonable, incorrect, or arbitrary basis or not to have been made in good faith; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">additional interest imposed by any clause of any Transaction Documents might be held to constitute a penalty
and the provisions of that clause imposing additional interest would thus be held to be void. The fact that such provisions are held to be void would not in itself prejudice the legality and enforceability of any other provisions of the relevant
Transaction Documents but could restrict the amount recoverable by way of interest under such Transaction Documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">claims may be or become subject to defences of <FONT STYLE="white-space:nowrap">set-off</FONT> or
counter-claim; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Irish court has power to stay an action where it is shown that there is some other forum having competent
jurisdiction which is more appropriate for the trial of the action, in which the case can be tried more suitably for the interests of all the parties and the ends of justice, and where staying the action is not inconsistent with the provisions of
Regulation (EU) No.&nbsp;1215/2012 (recast) on jurisdiction and the recognition and the enforcement of judgments in civil and commercial matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the enforceability of severance clauses is at the discretion of the court and may not be enforceable in all
circumstances; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a waiver of all defences to any proceedings may not be enforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provisions in any of the Transaction Documents providing for indemnification resulting from loss suffered on
conversion of the amount of a claim made in a foreign currency into euro in a liquidation may not be enforceable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Irish court may refuse to give effect to undertakings contained in any of the Transaction Documents that the
Company will pay legal expenses and costs in respect of any action before the Irish courts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this opinion is subject to the effects of any United Nations, European Union or Irish financial restrictions,
sanctions or other similar measures implemented or effective in Ireland; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we express no opinion on any taxation matters or on the contractual terms of the relevant documents other than
by reference to the legal character thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is given on the basis that it will be construed in accordance with,
and governed in all respects by, the laws of Ireland which shall apply between us and all persons interested. We hereby consent to the filing of this opinion with the SEC as an exhibit to the Issuer&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to be filed on the date hereof, which Form <FONT STYLE="white-space:nowrap">8-K</FONT> will be incorporated by reference into the Registration Statement and to the reference to our firm contained under the
heading &#147;Legal Matters&#148; in the Base Prospectus, Preliminary Prospectus Supplement and Prospectus Supplement included therein. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required
under Section&nbsp;7 of the Securities Act of 1933 as amended, or the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter speaks only as of the date
hereof and we disclaim any obligation to advise you or any other person of changes of law or fact that occur after the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ A&amp;L Goodbody LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A&amp;L Goodbody LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133dsp61.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Transaction Documents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Underwriting Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notations of guarantee dated as of 3&nbsp;June 2024 by the Company attached to the Notes; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Indentures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.3
<SEQUENCE>6
<FILENAME>d811133dex53.htm
<DESCRIPTION>EX-5.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g811133g0601030541937.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To:</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Medtronic Global Holdings S.C.A.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>40, avenue Monterey, <FONT
STYLE="white-space:nowrap">L-2163</FONT> Luxembourg</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(the
&#147;<B>Addressee</B>&#148;)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By <FONT STYLE="white-space:nowrap">e-mail</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Luxembourg, 3&nbsp;June 2024</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic Global Holdings GP S.&agrave;
r.l. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs, </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Introduction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been appointed as legal counsel in the Grand Duchy of Luxembourg (&#147;<B>Luxembourg</B>&#148;) in order to provide you with this legal opinion with
respect to the execution of the Transaction Documents (as defined in Schedule 1) under the laws of Luxembourg by <B>Medtronic Global Holdings S.C.A.</B>, a corporate partnership limited by shares (&#147;<I>soci&eacute;t&eacute; en commandite par
actions</I>&#148;), having its registered office located at 40, avenue Monterey, <FONT STYLE="white-space:nowrap">L-2163</FONT> Luxembourg and registered with the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des
Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) under number R.C.S. Luxembourg B 191.129 (the &#147;<B>Company</B>&#148;), acting through its managing general partner Medtronic Global Holdings GP S.&agrave; r.l., a private limited liability company
(&#147;<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e</I>&#148;), having its registered office located at 40, avenue Monterey, <FONT STYLE="white-space:nowrap">L-2163</FONT> Luxembourg and registered with the Luxembourg Trade
and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) under number R.C.S. Luxembourg B 191.031 (the &#147;<B>General Partner</B>&#148;), in connection with the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This legal opinion is issued by CM Law, a private limited liability company (&#147;<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute;
limit&eacute;e</I>&#148;) incorporated and existing under the laws of Luxembourg, registered with the Luxembourg Bar as lawyers, having its registered office located at 68, rue Marie-Ad&eacute;la&iuml;de,
<FONT STYLE="white-space:nowrap">L-2128</FONT> Luxembourg, registered with the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) under number R.C.S. Luxembourg B
198.369, whose purpose is the exercise of the profession of lawyer in Luxembourg. Individuals that are involved in the services provided by or on behalf of CM Law cannot be held liable in any manner whatsoever. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This legal opinion addresses certain matters relating to the Transaction Documents and has been addressed to
the Addressee only in connection with these matters. In this regard, we note that we have not advised the Addressee on the contents of the Transaction Documents and we have not assisted the Addressee in any way in relation to the negotiation of the
Transaction Documents or the transactions contemplated thereby. We exceptionally accept addressing this legal opinion to the Addressee solely in relation to the matters expressly opined on herein, but, other than in relation to the matters expressly
opined on herein, the giving of this legal opinion is not to be taken as implying that we owe the Addressee any duty of care in relation to the Transaction Documents, the transactions contemplated by the Transaction Documents or their commercial or
financial implications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in this legal opinion, capitalized terms used but not defined shall have the meaning given in Schedule
1 hereto, which shall form an integral part of this legal opinion. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Scope of the legal opinion </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This legal opinion is strictly confined to the specific matters of Luxembourg law and has been prepared without
considering the implications of any laws of any jurisdictions other than Luxembourg and, accordingly, we express no opinion with regard to any systems of law other than the laws of Luxembourg. In particular, as Luxembourg qualified lawyers, we are
not qualified nor in a position to assess the meaning and consequences of the terms of the Transaction Documents under the laws of the State of New York, United States of America and/or any other foreign applicable law and we have made no
investigation into such laws as a basis of the opinions expressed hereafter and do not express or imply any opinion thereon, including but not limited to in relation to any implied terms, statutory provisions referred to therein or any other
consequences arising from the entry into or performance under these Transaction Documents under such laws. Accordingly, our review of the Transaction Documents has been limited to the terms of such documents as they appear on the face thereof
without reference to the laws of the State of New York, United States of America and/or any other foreign applicable law (other than Luxembourg law). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This legal opinion is strictly limited to the matters stated herein and shall not be read as extending by
implication to any matters not specifically referred to. Where an assumption is stated to be made in this legal opinion, we have not made any investigation with respect to the matters that are the subject of such assumption. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have, for the purpose of this legal opinion, solely examined the documents (drafts, originals, copies,
translations or facsimile or electronic copies) that are listed in Schedule 1 hereto and referred to as the Examined Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have not examined and express no opinion herein with respect to any matter which may result from any
contractual obligations binding the Company and which may result from any contract, agreement, deed, undertaking or document or any matter in connection therewith of a contractual or legal nature, which is simply referred to in or annexed to the
Examined Documents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have not referred to or relied upon any documentation other than the Examined Documents and, other than
having examined the Examined Documents, we have not made any inquiries or investigations other than those stated in this legal opinion and such other inquiries and investigations as we have deemed necessary to provide the opinions set forth herein.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The declarations made in this legal opinion are stated and are only valid as at the date hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other than inquiries and investigations stated in this legal opinion as we have deemed relevant and necessary
to provide the opinions set forth herein, we are not responsible for (i)&nbsp;investigating and verifying the accuracy of the statements of fact, intention and representations and warranties contained in the Examined Documents, (ii)&nbsp;verifying
that no material facts or contractual provisions have been omitted and (iii)&nbsp;verifying whether the parties thereto (which for the avoidance of doubt, includes the Company) or any of them have complied, or will comply with them and with the
terms and conditions of any obligations binding upon them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We shall have no duty to inform the Addressee of any changes in Luxembourg law, in the legal status of the
Company and/or the General Partner, or any other circumstance, occurring after the date of this legal opinion and which may affect the matters addressed herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We express no opinion on any applicable licensing or similar requirements of the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We express no opinion in particular on public international law or on the rules of, or promulgated under, any
treaty or by any treaty organisation or European law (save for rules implemented into Luxembourg law or directly applicable in Luxembourg), on tax (except to the extent expressly opined in this legal opinion), transfer pricing, regulatory,
competition, accounting or administrative law, or as to the consequences thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this legal opinion, unless otherwise specified, the terms &#147;law&#148;, &#147;laws&#148;,
&#147;legislation&#148; and &#147;regulation&#148;, &#147;Luxembourg law&#148; and all other similar terms refer to all laws and regulations that are applicable as at the date hereof in Luxembourg, and deriving from laws enacted by the Luxembourg
legislator and/or judgements and orders of Luxembourg courts as long as published. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not give any opinion in particular (i)&nbsp;with respect to the compliance of the Company with Luxembourg
accounting and tax laws (except to the extent expressly opined in this legal opinion) and (ii)&nbsp;with respect to the validity and enforceability of the Transaction Documents. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>III.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Statements of legal opinion </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the Examined Documents and subject to the assumptions and qualifications set out below and to any matters not disclosed to us, we are of the
opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is a corporate partnership limited by shares (&#147;<I>soci&eacute;t&eacute; en commandite par
actions</I>&#148;) incorporated and existing under the laws of Luxembourg, for an unlimited duration. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Partner is a private limited liability company (&#147;<I>soci&eacute;t&eacute; &agrave;
responsabilit&eacute; limit&eacute;e&#148;</I>) incorporated and existing under the laws of Luxembourg, for an unlimited duration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on the Certificates of Non Inscription of a Judicial Decision and the Extracts, the Company and
the General Partner have not been declared bankrupt or <FONT STYLE="white-space:nowrap">wound-up</FONT> (in the meaning of voluntary or judicial or administrative dissolution and/or liquidation) or applied for the benefit of a judicial
reorganization proceeding (&#147;<I>proc&eacute;dure de r&eacute;organisation judiciaire</I>&#148;) and debt <FONT STYLE="white-space:nowrap">write-off</FONT> (&#147;<I>effacement de dettes</I>&#148;) or moratorium of payments (&#147;<I>sursis de
paiement</I>&#148;) and no registration of any judicial decision in relation to the appointment of an interim receiver (&#147;<I>administrateur provisoire</I>&#148;) or receiver (&#147;<I>s&eacute;questre</I>&#148;) of the Company or the General
Partner, or in relation to any bankruptcy proceedings, arrangement with creditors, or other similar proceedings from jurisdictions other than Luxembourg under the Regulation (EU) 2015/848 of the European Parliament and of the Council of 20&nbsp;May
2015 on insolvency proceedings has been made with the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg</I>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has the corporate capacity (i)&nbsp;to execute the Transaction Documents and (ii)&nbsp;to perform
its relevant obligations under the Transaction Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has taken all necessary corporate actions to authorize (i)&nbsp;the execution of the Transaction
Documents and (ii)&nbsp;the performance of its obligations under the Transaction Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Transaction Documents have been duly executed by the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under Luxembourg law, no consent, approval or authorization by, no notice to or filing with, any public
authority in Luxembourg is necessary for (i)&nbsp;the execution or performance by the Company of the Transaction Documents or (ii)&nbsp;to ensure that the Transaction Documents are admissible in evidence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) The execution and (ii)&nbsp;the performance of the Transaction Documents by the Company do not violate
(a)&nbsp;its Articles of Association, (b)&nbsp;the Luxembourg law dated 10&nbsp;August 1915 concerning commercial companies, as amended on the date hereof, (c)&nbsp;the international mandatory Luxembourg law (&#147;<I>ordre</I><I> public
international / </I><I>lois</I><I> de police</I>&#148;) and (d)&nbsp;any other Luxembourg laws applicable to the Transaction Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The choices of law as the laws governing the contractual obligations created by and contained in the
Transaction Documents and submission to jurisdiction provisions contained in the Transaction Documents are valid and will be upheld and recognized by the Courts of Luxembourg. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A final and conclusive judgment obtained against the Company in any federal or state court in the United States
with respect to the Transaction Documents, will be enforced by a Luxembourg Court subject to the provisions of Articles 678 <I>et seq.</I> of the Luxembourg new code of civil procedure (&#147;<I>nouveau code de proc&eacute;dure civile&#148;</I>) and
provided that an action for exequatur is brought before the Luxembourg District Court (&#147;<I>Tribunal d&#146;Arrondissement de et &agrave; Luxembourg</I>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is not entitled to claim for itself or any of its assets, revenues or properties any right of
immunity from the jurisdiction of any court in Luxembourg or from any legal proceedings taken in Luxembourg under or in respect of the Transaction Documents (whether through service of notice, attachment prior to judgment, attachment in aid of
execution, execution or otherwise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The statements in the sections of the Preliminary Prospectus Supplement and the Final Prospectus Supplement
headed &#147;<I>Certain Tax Considerations - Luxembourg Tax Considerations</I>&#148; and &#147;<I>Risk Factors - Risks Related to the Notes - The terms and enforcement of the guarantee by Medtronic Luxco may be subject to limitations under
Luxembourg law</I>&#148; and the section of the Registration Statement headed &#147;<I>Service of Process and Enforcement of Liabilities - Luxembourg</I>&#148;, to the extent that they constitute a general summary of certain matters of Luxembourg
law, fairly summarise the matters described therein in all material aspects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No proceeding in Luxembourg is pending or threatened against the Company and the General Partner that seeks to
restrain, enjoin, prevent the consummation of or otherwise challenge the execution, delivery or performance of any of the Transaction Documents or the consummation of any of the transactions contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>IV.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assumptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering this legal opinion, we have, without verification or other enquiry, assumed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The genuineness of all signatures, the authenticity, completeness and accuracy of all the Examined Documents as
originals, and the conformity with original documents of all Examined Documents submitted to us as copies, electronic or facsimile copies hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the persons who were purported to sign the Examined Documents have effectively signed them.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The legal capacity of the individuals, and the authority of the individuals (other than those acting on behalf
of the General Partner acting as managing general partner of the Company) who have executed any of the Examined Documents (either on their behalf or as representative of another person or entity). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the obligations created under or pursuant to the Transaction Documents constitute legal, valid, binding
obligations of each of the parties enforceable against the respective parties thereto in accordance with their terms, under all applicable laws (except to the extent expressly opined therein under Luxembourg law). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That all the necessary corporate and other actions have been taken in order to allow each of the parties to the
Transaction Document (other than the Company regarding necessary corporate actions) to validly execute the Transaction Documents and to perform its respective obligations thereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That there is no contractual or other prohibition prohibiting the Company from entering into and performing its
obligations under the Transaction Documents; and that each of the parties to the Transaction Documents is not or will not be, by reason of the performance of the Transaction Documents, in breach of any of its obligations under any previous
contractual arrangements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That each of the parties to the Transaction Documents (other than the Company) is a validly existing entity
with the capacity and power and authority to enter into, execute, deliver and perform the Transaction Documents and all obligations thereunder, in compliance with all requisite corporate action and documents governing such entity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the manner of execution of the Transaction Documents is valid and effective under any law which may be
applicable according to the place of execution (other than Luxembourg law). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That all contractual obligations created under or pursuant to the Transaction Documents are executed and will
be performed in good faith by the parties thereto (which, for the avoidance of doubt, includes the Company) and without committing any fraud or cheating. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the choices of law to govern the Transaction Documents and the submission by the parties to the
Transaction Documents to the Courts referred to therein with regard to any disputes thereunder, is valid and binding under the laws of any applicable jurisdiction (other than Luxembourg) and that such choices of law and submissions to jurisdiction
would be recognised and given effect by the Courts of any applicable jurisdiction (other than Luxembourg). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That none of the Examined Documents has been amended, supplemented, replaced (including appointment of any
other agent for the same mission), renounced, terminated or varied, nor has been revoked as at the date hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That any consents, approvals, registrations, licenses or other actions by or with any governmental authority
required to be obtained or made by the parties in any such jurisdiction other than by the Company in Luxembourg in order to execute, deliver or perform such Examined Documents have been or will be obtained or made at the appropriate times.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That since 30&nbsp;May 2024, no petition has been filed with a Court for the opening of <FONT
STYLE="white-space:nowrap">winding-up</FONT> (in the meaning of dissolution and/or liquidation), bankruptcy, suspension of payments or similar proceedings against the Company and the General Partner; and that the Company and the General Partner have
not been granted a suspension of payments or declared bankrupt or been subject to any similar procedure (which includes, without however limitation, judicial reorganization proceeding (&#147;<I>proc</I><I>&eacute;</I><I>dure</I><I> de
</I><I>r</I><I>&eacute;</I><I>organisation</I><I> </I><I>judiciaire</I>&#148;), debt <FONT STYLE="white-space:nowrap">write-off</FONT> (&#147;<I>effacement de </I><I>dettes</I>&#148;) or moratorium of payments (&#147;<I>sursis</I><I> de
</I><I>paiement</I>&#148;)), that no interim administrator (&#147;<I>administrateur</I><I> </I><I>provisoire</I>&#148;) or receiver (&#147;<I>s</I><I>&eacute;</I><I>questre</I>&#148;) has been appointed with respect to the Company and the General
Partner; and that no decision in relation to any bankruptcy proceedings, arrangement with creditors, or other similar proceedings from jurisdictions other than Luxembourg under the Regulation (EU) 2015/848 of the European Parliament and of the
Council of 20&nbsp;May 2015 on insolvency proceedings has been made and/or filed with the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre</I><I> de Commerce et des </I><I>Soci</I><I>&eacute;</I><I>t</I><I>&eacute;</I><I>s</I><I>,
Luxembourg</I>&#148;) with respect to the Company and the General Partner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the information contained in Examined Documents is complete, correct and accurate at the date hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That no proceedings have been instituted or injunction granted against the Company, which might restrain it
from (i)&nbsp;entering into and executing the Transaction Documents and (ii)&nbsp;performing any of its obligations under the Transaction Documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the Company and the General Partner have their effective place of management and control in Luxembourg.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the centre of main interests of the Company and the General Partner within the meaning of Regulation (EU)
2015/848 of the European Parliament and of the Council of 20&nbsp;May 2015 on insolvency proceedings is located at the place of their registered office in Luxembourg and the Company and the General Partner have no establishment outside Luxembourg.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the transactions envisaged and provided for in the Transaction Documents are in the best corporate
interest of the Company, conducive to the attainment of the corporate objects of the Company and not disproportionate to its financial means and the benefits derived therefrom. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That each of the transactions entered into pursuant to, or in connection with, the Transaction Documents and
all payments and transfers made by, on behalf of, or in favour of, the Company are made at arm&#146;s length. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That the Company will remain, at any time, a Luxembourg tax resident for Luxembourg tax purposes and should not
be viewed as being a resident or as having a permanent establishment, to which the payments under the Transaction Documents are attributable or can be attributed, in any other jurisdiction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That there will be no offer or resale of securities to the public within the territory of the Grand Duchy of
Luxembourg in connection with the Transaction Documents. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>V.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Qualifications </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This legal opinion is subject to the following qualifications: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this legal opinion, some Luxembourg legal concepts are expressed in English terms and not in their original
French terms. Terms and expressions of law and of legal concepts as used in this legal opinion have the meaning attributed to them under the laws of Luxembourg and this legal opinion should be read and understood accordingly. The concepts concerned
may not be identical to the concepts described by the same English terms as they exist under the laws of other jurisdictions. This legal opinion may, therefore, only be relied upon under the express condition that any issue of interpretation or
liability arising hereunder will be governed by Luxembourg law and be brought before a Luxembourg Court. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Translation into French or German language from all or from part of the Examined Documents may be required by a
Luxembourg Court in any proceedings where the Examined Documents might be produced. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any enforcement of an obligation arising from the Transaction Documents against the Company or the General
Partner, would be subject to any applicable bankruptcy, insolvency and any other similar Luxembourg procedures relating to or affecting the enforcement or protection of creditors rights and remedies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payments made, as well as other transactions (listed in the pertinent Section of the Luxembourg Code of
Commerce) concluded or performed, during the <FONT STYLE="white-space:nowrap">so-called</FONT> suspect period (&#147;<I>p&eacute;riode suspecte</I>&#148;) which is fixed by the Luxembourg Court and dates back (not more than) 6 months as from the
date on which the Luxembourg Court formally adjudicates a person bankrupt, and, as for specific payments and transactions, during an additional period of ten days before the commencement of such period, are subject to cancellation by the Luxembourg
Court. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular but not exhaustively, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 445 of the Luxembourg Code of Commerce sets out that, during the suspect period and an additional
period of ten days preceding the suspect period fixed by the Court, specified transactions (e.g., the granting of a security interest for past debts; the payment of debts which have not fallen due, whether payment is made in cash or by way of
assignment, sale, <FONT STYLE="white-space:nowrap">set-off</FONT> or by any other means; the payment of debts which have fallen due by any other means than in cash or by bill of exchange; the sale of assets without consideration or for materially
inadequate consideration) must be set aside or declared null and void, as the case may be, if so requested by the insolvency receiver; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 446 of the Luxembourg Code of Commerce states that payments made for matured debts as well as other
transactions concluded for consideration during the suspect period are subject to cancellation by the Court upon proceedings instituted by the insolvency receiver if they were concluded with the knowledge by such parties having received such
payments or having concluded transactions with the bankrupt, of the bankrupt&#146;s cessation of payments; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of the suspect period, Article 448 of the Luxembourg Code of Commerce and article 1167 of the civil
code (&#147;<I>actio pauliana&#148;</I>) give the creditor the right to challenge any fraudulent payments and transactions made prior to the bankruptcy, without limitation of time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with Article 451 of the Luxembourg Code of Commerce interests accrued after the opening of
insolvency proceedings would not be recovered by unsecured creditors, whereas the beneficiary of a guarantee is considered as an unsecured creditor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain privileges, such as the privileges of the Luxembourg tax authorities or social security institutions
over certain specific assets, may take precedence over any security or privileges of other creditors of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We express no opinion as to the availability under Luxembourg law or before a Luxembourg Court of remedies
other than those culminating in an award of monetary compensation. It means that obligations will not necessarily be enforced in all circumstances in accordance with their terms and that they will give rise in any case to specific performance.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">certain types of remedies (such as specific performance or injunctive relief) may not be available to persons
seeking to enforce provisions of an agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforcement of an obligation may be invalidated on the grounds of fraud, lack of consent (mistake, duress,
misrepresentation), illegal consideration, uncertainty of the object, incapacity and &#147;<I>force majeure&#148;</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the opinion expressed in statement 9. of Section III above the Luxembourg Courts would not
apply a chosen foreign law if that choice was not made &#147;<I>bona fide&#148;</I> and if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the foreign law were not pleaded and proved; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if pleaded and proved, such foreign law would be contrary to the mandatory provisions of Luxembourg law or
manifestly incompatible with Luxembourg international public policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A contractual provision allowing the service of process against the Company to any other party appointed to
such effect could be overridden by Luxembourg statutory provisions allowing the valid service of process against the Company in accordance with applicable laws at its registered office. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The enforcement of a final judgement rendered by any federal or state court in the United States by a
Luxembourg Court shall require that recognition and enforcement proceedings be conducted before the Luxembourg Courts pursuant to the relevant applicable provisions of Luxembourg procedural law, in particular where any enforcement measure against
assets located in the territory of Luxembourg is sought. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As there is no system of reciprocal enforcement in Luxembourg
in relation to judgments made in any federal or state court in the United States a final judgment of any federal or state court in the United States, which would be referring to any action or proceedings relating to the Transaction Documents, will
be enforced in Luxembourg pursuant to the provisions of Articles 678 <I>et seq</I>. of the Luxembourg new code of civil procedure (&#147;<I>nouveau code de proc&eacute;dure civile&#148;</I>), provided that an action for exequatur is brought before
the Luxembourg District Court (&#147;<I>Tribunal d&#146;Arrondissement de et &agrave; Luxembourg&#148;</I>) and provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such judgment is enforceable in such federal or state court in the United States where the judgment was
rendered; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any federal or state court in the United States that rendered the judgment had jurisdiction according to
Luxembourg principles of conflict of jurisdiction and, in particular, that Luxembourg Courts had not exclusive jurisdiction over the case at hand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any federal or state court in the United States that rendered the judgment has complied with its national
jurisdiction rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment rendered by any federal or state court in the United States is not inconsistent, in respect of the
determination of the competent Court and of the applicable law, with the solution that a Luxembourg Court would have found in application of the laws determined pursuant to the Luxembourg principles of conflict of laws (although some first instance
decisions rendered in Luxembourg &#150; which have not been confirmed by the Court of Appeal &#150; tend to disapply this condition); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any such federal or state court in the United States complied with its national order of procedure and, in
particular, with the rights of the defendant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the enforcement of such judgment does not contravene the mandatory provisions of Luxembourg law and Luxembourg
international public policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The mandatory provisions of Luxembourg law and the Luxembourg international public policy order is not legally
confined but rather fluctuates with related Luxembourg case law and we do not provide any opinion in relation thereto. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any judgment awarded in the Courts of Luxembourg may be expressed in a currency other than the euro or the euro
equivalent at the time of judgment or payment. However, any obligation to pay a sum or money in any currency other than the euro will be enforceable in Luxembourg in terms of the euro only. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest may not accrue on interest that is due on capital, unless such interest has been due for at least one
year and subject to the conditions set forth in Article 1154 of the Luxembourg Civil Code. A Luxembourg Court might consider the rule under Article 1154 of the Luxembourg Civil code to be a point of international public policy that would set aside
the relevant foreign governing law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No opinion is expressed as to the validity and enforceability of provisions whereby interest on overdue amounts
or other payment obligations shall continue to accrue or subsist after judgement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provisions granting to a party the right to recover its enforcement and other legal costs and expenses may
not necessarily be given effect by a Luxembourg Court. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provisions of the jurisdiction clauses whereby the taking of proceedings in one or more jurisdictions shall
not preclude the taking of proceedings in any other jurisdiction, whether concurrently or not, might not be entirely enforceable in a Luxembourg Court. If proceedings were previously commenced between the same parties and on the same grounds as the
proceedings in Luxembourg, a plea of pendency might be opposed in the Luxembourg Court and proceedings either stayed pending the termination of the proceedings abroad or dismissed, as the case may be. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foreign jurisdiction clause, Luxembourg Courts would have in principle jurisdiction for any
conservatory or provisional action in connection with assets located in Luxembourg and such action would most likely be governed by Luxembourg law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A power of attorney or mandate (&#147;<I>mandate&#148;</I>), as well as any other agency provisions (including
but not limited to, powers of attorney and mandates expressed to be irrevocable) granted and all appointments of agents by the Company, explicitly or by implication, will terminate by law and without notice upon the occurrence of insolvency events
affecting the relevant Luxembourg principal and, under Luxembourg law, may be capable of being revoked by the Company despite they being expressed to be irrevocable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Certificates of Non Inscription of a Judicial Decision only reflect whether a judicial decision according
to which the Company and the General Partner are subject to judicial proceedings or administrative decision according to which the Company and the General Partner are subject to administrative dissolution without liquidation has been registered with
the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg&#148;</I>) on 30&nbsp;May 2024. It cannot be excluded that a judicial or administrative decision (for example a decision
opening an insolvency proceedings) against the Company and the General Partner has been taken but does not appear in the Certificates of Non Inscription of a Judicial Decision. The registration of a matter required to be registered under the law
dated 19&nbsp;December 2002 on the Luxembourg Trade and Companies&#146; Register and accounting of undertakings, as amended, must be requested by the relevant person at the latest one month after the occurrence of the event subject to registration;
as a consequence (i)&nbsp;a delay may exist between the moment a judicial or administrative decision has been rendered and is effective and the registration thereof in the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce
et des Soci&eacute;t&eacute;s, Luxembourg&#148;</I>), and (ii)&nbsp;it cannot be excluded that no registration has occurred in the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s,
Luxembourg&#148;</I>) within the period of one month if the request for registration has not been and is not made by the relevant person(s); as a consequence the Certificates of Non Inscription of a Judicial Decision are not conclusive as to the
opening and existence or not of judicial or administrative decisions or judicial or administrative proceedings and, as to whether or not a petition or request for any of the judicial or administrative proceedings has been presented or made. The same
shall apply <I>mutatis mutandi</I> for the Extract. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This opinion is subject to all limitations resulting from the application of Luxembourg public policy rules,
overriding statutes and mandatory laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registration of the Transaction Documents (and any documents in connection therewith) with the
<I>Administration de l&#146;Enregistrement, des Domaines et de la TVA</I> in Luxembourg may be required should the Transaction Documents (and any documents in connection therewith) be produced before an official Luxembourg authority
(<I>autorit&eacute; constitu&eacute;e</I>), attached as an annex to a deed (<I>annex&eacute;s &agrave; un acte</I>) that itself is subject to mandatory registration, or deposited in the minutes of a notary (<I>d&eacute;pos&eacute;s au rang des
minutes d&#146;un notaire</I>). In such cases, a nominal registration duty or an ad valorem duty may be payable, depending on the nature of the document to be registered or produced, or in the case of voluntary registration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, the opinion expressed in statement 12. of Section III above concerning the section
of the Registration Statement headed &#147;<I>Service of Process and Enforcement of Liabilities&#151;Luxembourg</I>&#148; is given as of the date of the Registration Statement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VI.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Benefit of opinion </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This legal opinion is delivered to the Addressee in such capacity attributed to them under the Transaction Documents and its successors and assigns and is only
for its use. It may not, without our prior written consent, be relied upon for any other purpose or be disclosed to or relied upon by any other person save that it may be disclosed without such consent to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person to whom disclosure is required to be made by applicable law or Court order or pursuant to the rules
or regulations of any supervisory or regulatory body or in connection with any judicial proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">those persons (such as the officers, employees, auditors and professional advisers) of the Addressee who, in
the ordinary course of business of the business of the Addressee, have access to their papers and records or are entitled by law to see them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any affiliate of the Addressee and the officers, employees, auditors and professional advisers of such
affiliate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as otherwise required by law, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the basis that (i)&nbsp;such disclosure is made solely to enable any such person to be informed that an opinion has been given and to be made aware of its
terms but not for the purposes of reliance and (ii)&nbsp;we do not assume any duty or liability to any person to whom such disclosure is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent
to the filing of this legal opinion with the United States Securities and Exchange Commission as an exhibit to be incorporated by reference into the Registration Statement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may refer to CM Law giving this legal opinion under the heading &#147;Legal Matters&#148; in the related preliminary prospectus supplement and the
final prospectus supplement included in the Registration Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>VII.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Applicable law and jurisdiction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated in paragraph II. 1, this legal opinion herein is exclusively based upon, governed by and shall be construed in accordance with the laws of Luxembourg
effective on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luxembourg Courts shall have exclusive jurisdiction to settle any dispute, proceeding, suit or action that may arise out of
or be in connection with this legal opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally left blank &#150; Signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For CM Law </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rapha&euml;l Collin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Rapha&euml;l Collin</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Avocat &agrave; la Cour</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Examined Documents </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A .pdf copy of the updated articles of association of the Company as at 29&nbsp;February 2024 (the
&#147;<B>Articles of Association</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A .pdf copy of the updated articles of association of the General Partner as at 22&nbsp;April 2024;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An extract issued by the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des
Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) pertaining to the Company dated 31&nbsp;May 2024 (the &#147;<B>Extract 1</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An extract issued by the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des
Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) pertaining to the General Partner dated 31&nbsp;May 2024 (the &#147;<B>Extract 2</B>&#148; and together with the Extract 1 the &#147;<B>Extracts</B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A certificate of <FONT STYLE="white-space:nowrap">non-inscription</FONT> of a judicial decision or of
administrative dissolution without liquidation issued by the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) pertaining to the Company dated 31&nbsp;May 2024 (the
&#147;<B>Certificate of Non Inscription of a Judicial Decision 1</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A certificate of <FONT STYLE="white-space:nowrap">non-inscription</FONT> of a judicial decision or of
administrative dissolution without liquidation issued by the Luxembourg Trade and Companies&#146; Register (&#147;<I>Registre de Commerce et des Soci&eacute;t&eacute;s, Luxembourg</I>&#148;) pertaining to the General Partner dated 31&nbsp;May 2024
(the &#147;<B>Certificate of Non Inscription of a Judicial Decision 2</B>&#148; and together with the Certificate of Non Inscription of a Judicial Decision 1 the &#147;<B>Certificates of Non Inscription of a Judicial Decision</B>&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. copy of the executed minutes of the meeting of the board of managers of the General Partner acting as
managing general partner of the Company held on 23&nbsp;May 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. copy of the written action of authorized officer of the Company dated 29&nbsp;May 2024;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. fully executed copy of the base prospectus dated 3&nbsp;March 2023, as supplemented by a preliminary
prospectus supplement to prospectus dated 3&nbsp;March 2023 and as supplemented by a final prospectus supplement to prospectus dated 3&nbsp;March 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. fully executed copy of the formalities certificate issued by the Company dated 3&nbsp;June 2024;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. fully executed copy of the New York law governed base indenture dated 10&nbsp;December 2014 among
Medtronic, Inc. and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association (the &#147;<B>Indenture Trustee</B>&#148;), as supplemented by the New York law governed second supplemental indenture dated
26&nbsp;January 2015, between Medtronic plc and the Indenture Trustee, the New York law governed third Supplemental indenture dated 26&nbsp;January 2015, between the Company and the Indenture Trustee, the New York law governed fourth supplemental
indenture dated as of 22&nbsp;February 2023, between Medtronic, Inc. and the Indenture Trustee (the &#147;<B>Indenture</B>&#148;); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. fully executed copy of the New York law governed fifth supplemental indenture to the Indenture dated
3&nbsp;June 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. fully executed copy of the New York law governed underwriting agreement between Medtronic, Inc., as
issuer, Medtronic plc and the Company as guarantors, and Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc, as representatives of the several underwriters listed in such agreement,
dated 29&nbsp;May 2024 (the &#147;<B>Underwriting Agreement</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A pdf. copy of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-270272)</FONT> as filed with the Securities and Exchange Commission on 3&nbsp;March 2023 (the &#147;<B>Registration Statement</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The documents listed in items 11. to 14. (both inclusive) shall be referred to as the &#147;<B>Transaction Documents</B>&#148;.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The documents listed in items 1. to 14. (both inclusive) shall be referred to as the &#147;<B>Examined Documents</B>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.4
<SEQUENCE>7
<FILENAME>d811133dex54.htm
<DESCRIPTION>EX-5.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.4 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g811133g0531083522983.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Medtronic, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">710
Medtronic Parkway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis MN 55432 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.medtronic.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;3, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medtronic, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">710 Medtronic Parkway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, MN 55432 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Medtronic, Inc Senior Notes</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This opinion is furnished
to you in connection with the offer and sale by Medtronic, Inc., a Minnesota corporation (the &#147;Company&#148;) of &#128;850,000,000 aggregate principal amount of its 3.650% Senior Notes due 2029 (the &#147;2029 Notes&#148;), &#128;850,000,000
aggregate principal amount of its 3.875% Senior Notes due 2036 (the &#147;2036 Notes&#148;), &#128;600,000,000 aggregate principal amount of its 4.150% Senior Notes due 2043 (the &#147;2043 Notes&#148;), and &#128;700,000,000 aggregate principal
amount of its 4.150% Senior Notes due 2053 (the &#147;2053 Notes&#148; and together with the 2029 Notes, the 2036 Notes and the 2043 Notes, the &#147;Notes&#148;), pursuant to the Underwriting Agreement dated May&nbsp;29, 2024 (the
&#147;Underwriting Agreement&#148;), among the Company, the Guarantors (as defined below), Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc, as representatives of the Underwriters
party to the Underwriting Agreement. The Notes will be fully and unconditionally guaranteed on an unsecured unsubordinated basis (the &#147;Guarantees&#148;) by Medtronic Public Limited Company, an entity incorporated under the laws of Ireland
(&#147;Medtronic plc&#148;) and Medtronic Global Holdings S.C.A., an entity organized under the laws of Luxembourg (&#147;Medtronic Luxco,&#148; and together with Medtronic plc, the &#147;Guarantors&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Notes will be issued pursuant to the Indenture dated as of December&nbsp;10, 2014 (the &#147;Base Indenture&#148;), between the Company
and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the &#147;Trustee&#148;), as supplemented by the Second Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic plc and
the Trustee (the &#147;Second Supplemental Indenture&#148;), the Third Supplemental Indenture, dated as of January&nbsp;26, 2015, between Medtronic Luxco and the Trustee (the &#147;Third Supplemental Indenture&#148;), the Fourth Supplemental
Indenture, dated as of February&nbsp;22, 2023, between the Company and the Trustee (the &#147;Fourth Supplemental Indenture&#148;) and the Fifth Supplemental Indenture dated as of June&nbsp;3, 2024 (together with the Base Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture and the Fourth Supplemental Indenture, the &#147;Indenture&#148;), among the Company, Medtronic plc, Medtronic Luxco, the Trustee and Elavon Financial Services DAC, as the paying agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company, Medtronic plc and Medtronic Luxco have filed with the Securities and Exchange Commission (the &#147;Commission&#148;) a
Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;(File&nbsp;No.&nbsp;333-270272)&nbsp;under</FONT></FONT> the Securities Act of 1933, as amended (the &#147;Act&#148;), on March&nbsp;3,
2023 (the &#147;Registration Statement&#148;) including the prospectus dated as of March&nbsp;3, 2023 (the &#147;Base Prospectus&#148;), as supplemented by a preliminary prospectus supplement dated as of May&nbsp;29, 2024 (the &#147;Preliminary
Prospectus Supplement&#148;) relating to the Notes, and a prospectus supplement dated as of May&nbsp;29, 2024 (the &#147;Prospectus Supplement&#148;) relating to the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I am the Legal Director &#150; Corporate&nbsp;&amp; Securities of the Company. As to various matters of fact material to this opinion, I have
relied upon certificates of public officials and upon the representations of the Company or its officers or directors, including those made in the Indenture and in documents or certificates executed in connection therewith. I have also examined the
Amended and Restated Articles of Incorporation and Amended and <FONT STYLE="white-space:nowrap">Restated&nbsp;By-laws&nbsp;of</FONT> the Company, each as amended to date, and originals or copies of such other corporate documents and records and
other certificates and instruments and have made such other investigation as I have deemed necessary in connection with the opinion hereafter set forth. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;3, 2024 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">My opinion is limited solely to the
present substantive law of the State of Minnesota (excluding its conflict of laws principles). I express no opinion as to the laws of any other state or jurisdiction. I express no opinion on any matter of county, municipal, or special political
subdivision law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this opinion, I have assumed, among other things, the genuineness of all signatures, the authenticity of
all documents submitted as originals, the conformity to original documents of all documents submitted as copies, and that the information in the certificates, representations, and statements referred to above remains true and complete as of the date
hereof. In examining documents, I have assumed that all parties executing the same, other than the Company, have all necessary power to enter into and perform all of their obligations thereunder and that such parties have duly executed and delivered
such documents. I have also assumed, as to each such party other than the Company, the due authorization by all requisite action of the execution, delivery and performance of such documents by such parties, in each case at the requisite time in
order for such action to be effective, and that such documents are legal, valid, binding on and enforceable against such parties in accordance with their respective terms. I have also assumed that each natural person executing any of the documents
and agreements involved in the matters covered by this opinion has the capacity and is legally competent to do so. I have assumed that each of the documents and agreements involved in any matter covered by this opinion letter accurately describes
the mutual understanding of the parties as to all matters contained therein and that no other agreements or understandings exist between the parties relating to the transactions contemplated by such document or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, and subject to the qualifications hereinafter set forth, it is my opinion as of this date that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Based exclusively upon a good standing certificate received from the Office of the Secretary of State of Minnesota, the Company is validly
existing as a corporation in good standing under the laws of Minnesota. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The Company has the corporate power and authority under
Minnesota law to enter into the Underwriting Agreement, the Indenture and the Notes and to perform its obligations thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Each of
the Underwriting Agreement, the Indenture and the Notes has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I hereby consent
to the filing of this opinion with the Commission as an exhibit to Medtronic plc&#146;s Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;to</FONT> be filed on the date hereof, which
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;will</FONT> be incorporated by reference into the Registration Statement in accordance with the requirements of Item 601(b)(5) of
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K&nbsp;under</FONT> the Securities Act and to the use of my name therein and in the related Prospectus and any prospectus supplement under the caption &#147;Legal Matters.&#148; In giving this
consent, I do not thereby admit that I am within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas L. Osteraas</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thomas L. Osteraas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Legal Director &#150; Corporate and Securities of Medtronic, Inc.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Medtronic, Inc. Opinion</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mdt-20240603.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.9 -->
<!-- Creation date: 6/2/2024 12:01:17 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:mdt="http://www.medtronic.com/20240603"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.medtronic.com/20240603"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240603_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240603_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdt-20240603_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mdt_SeniorNotes2019Due2025Member" name="SeniorNotes2019Due2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2020Due2025Member" name="SeniorNotes2020Due2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotesDue2025Member" name="SeniorNotesDue2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due2027Member" name="SeniorNotes2019Due2027Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2020Due2028Member" name="SeniorNotes2020Due2028Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotesDue2028Member" name="SeniorNotesDue2028Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due20311.625PercentMember" name="SeniorNotes2019Due20311.625PercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due20311.00PercentMember" name="SeniorNotes2019Due20311.00PercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotesDue2031Member" name="SeniorNotesDue2031Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2020Due2032Member" name="SeniorNotes2020Due2032Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotesDue2034Member" name="SeniorNotesDue2034Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due20392.250PercentMember" name="SeniorNotes2019Due20392.250PercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due20391.50PercentMember" name="SeniorNotes2019Due20391.50PercentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2020Due2040Member" name="SeniorNotes2020Due2040Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2019Due2049Member" name="SeniorNotes2019Due2049Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mdt_SeniorNotes2020Due2050Member" name="SeniorNotes2020Due2050Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mdt-20240603_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.9 -->
<!-- Creation date: 6/2/2024 12:01:18 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mdt-20240603.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2025Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2025Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2025Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2027Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2027Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2028Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2028Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.625PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.625PercentMember" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.00PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.00PercentMember" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2031Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2031Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2032Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2032Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2034Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2034Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20392.250PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20392.250PercentMember" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20391.50PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20391.50PercentMember" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2040Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2040Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2049Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2049Member" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2050Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2050Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntitiesTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2025Member" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2025Member" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2025Member" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2027Member" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2028Member" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2028Member" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20311.625PercentMember" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20311.00PercentMember" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2031Member" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2032Member" order="28" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2034Member" order="29" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20392.250PercentMember" order="30" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20391.50PercentMember" order="31" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2040Member" order="32" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2049Member" order="33" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2050Member" order="34" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.071" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.171" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CountryRegion" order="30.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.021" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="44.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="45.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mdt-20240603_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.9 -->
<!-- Creation date: 6/2/2024 12:01:16 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntitiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due2025Member" xlink:to="mdt_SeniorNotes2019Due2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">0.250% Senior Notes due 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">0.250% Senior Notes due 2025 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2020Due2025Member" xlink:to="mdt_SeniorNotes2020Due2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes 2020 Due 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">0.000% Senior Notes due 2025 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotesDue2025Member" xlink:to="mdt_SeniorNotesDue2025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">2.625% Senior Notes due 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.625% Senior Notes due 2025 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2027Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2027Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due2027Member" xlink:to="mdt_SeniorNotes2019Due2027Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.125% Senior Notes due 2027 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2027Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.125% Senior Notes due 2027 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2028Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2020Due2028Member" xlink:to="mdt_SeniorNotes2020Due2028Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">0.375% Senior Notes due 2028 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">0.375% Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2028Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotesDue2028Member" xlink:to="mdt_SeniorNotesDue2028Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes Due 2028 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">3.000% Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.625PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.625PercentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due20311.625PercentMember" xlink:to="mdt_SeniorNotes2019Due20311.625PercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20311.625PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.625% Senior Notes due 2031 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20311.625PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.625% Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.00PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.00PercentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due20311.00PercentMember" xlink:to="mdt_SeniorNotes2019Due20311.00PercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20311.00PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes 2019 Due 2031, 1.00 Percent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20311.00PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.000% Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2031Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2031Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotesDue2031Member" xlink:to="mdt_SeniorNotesDue2031Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">3.125% Senior Notes due 2031 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">3.125% Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2032Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2032Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2020Due2032Member" xlink:to="mdt_SeniorNotes2020Due2032Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2032Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">0.750% Senior Notes due 2032 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2032Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">0.750% Senior Notes due 2032 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2034Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2034Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotesDue2034Member" xlink:to="mdt_SeniorNotesDue2034Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2034Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">3.375% Senior Notes due 2034 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotesDue2034Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">3.375% Senior Notes due 2034 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20392.250PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20392.250PercentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due20392.250PercentMember" xlink:to="mdt_SeniorNotes2019Due20392.250PercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20392.250PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">2.250% Senior Notes due 2039 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20392.250PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2.250% Senior Notes due 2039 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20391.50PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20391.50PercentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due20391.50PercentMember" xlink:to="mdt_SeniorNotes2019Due20391.50PercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20391.50PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.500% Senior Notes due 2039 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due20391.50PercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.500% Senior Notes due 2039 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2040Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2040Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2020Due2040Member" xlink:to="mdt_SeniorNotes2020Due2040Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2040Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.375% Senior Notes due 2040 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2040Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.375% Senior Notes due 2040 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2049Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2049Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2019Due2049Member" xlink:to="mdt_SeniorNotes2019Due2049Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2049Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.750% Senior Notes due 2049 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2019Due2049Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.750% Senior Notes due 2049 [Member]</link:label>
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2050Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2050Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mdt_SeniorNotes2020Due2050Member" xlink:to="mdt_SeniorNotes2020Due2050Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2050Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">1.625% Senior Notes due 2050 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mdt_SeniorNotes2020Due2050Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1.625% Senior Notes due 2050 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CountryRegion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Country Region</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CountryRegion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Country Region</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mdt-20240603_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.2.9 -->
<!-- Creation date: 6/2/2024 12:01:16 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mdt-20240603.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable" xlink:type="locator" xlink:label="dei_EntitiesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitiesTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems" xlink:type="locator" xlink:label="dei_EntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_EntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2025Member" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2025Member" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2025Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2025Member" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2027Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2027Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2027Member" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2028Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2028Member" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2028Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2028Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2028Member" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.625PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.625PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20311.625PercentMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20311.00PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20311.00PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20311.00PercentMember" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2031Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2031Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2031Member" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2032Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2032Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2032Member" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotesDue2034Member" xlink:type="locator" xlink:label="mdt_SeniorNotesDue2034Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotesDue2034Member" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20392.250PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20392.250PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20392.250PercentMember" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due20391.50PercentMember" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due20391.50PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due20391.50PercentMember" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2040Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2040Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2040Member" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2019Due2049Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2019Due2049Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2019Due2049Member" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mdt-20240603.xsd#mdt_SeniorNotes2020Due2050Member" xlink:type="locator" xlink:label="mdt_SeniorNotes2020Due2050Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mdt_SeniorNotes2020Due2050Member" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.071" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.171" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CountryRegion" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_CityAreaCode" order="30.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.021" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g811133dsp58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g811133dsp58.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  0 'L# 2(  A$! Q$!_\0
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C:/1=&U;4F.D7-_!: 6WF-;7423("T3;6=5WKM< !Q0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g811133dsp58a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g811133dsp58a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  : FX# 2(  A$! Q$!_\0
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MFIO$O[)_PP\9W+3:M\//!>I2OJW]NL]SHUO*6U#:$-V24_UQ0!6D^\RC!)%
M'SC\=_VH?B;JOPU_:4EFTCP7;^&_A1HLRO:Q:AJ,&I7\DFAV6I!!>6TL9@V"
MXEC,L1W-\C*8]IW;WQ$_;0\?^"?C9XJT>TTWPA)X8\%^+/!^@SK,ET^H7UMK
MDMO;LRN'V1RP23AP2KB15*G:3NKZ U+]GWP+K-OXEBN_!WAFYB\9A5\0)+IL
M++K850JBZ!7$V%55&_/RJ!T&*KW7[,WP[OGO6F\#^%)GU&>SN;MGTN%FN9;3
M'V21R5RSPX'EL>4P-N,4 >1_!+]JSXA?&/\ :$31$\-:=:>%K74_$>GZS(;*
MY:;1?[-O$MK+==;_ ")7OD<SJJ#]VL;*=[!BN3?7/B*#_@JIXSL-$M8M7LI?
MA;HMY<6.H>(;JRM+>674]5A>:.)8ID\R2.WB1F"J<0IR:M_ _P#X)QV_PO\
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MO[/?@OP;=VE[X?\ "?A?1M3TJR2QTVX@TR-!8QQQM'"B*H7"(C,BA2,(S*"
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M.^ /@;X>>'-3TC0?"'AK1=,UN)8=1MK'38H([]%A6!1,%4>9B)53YL_* .E
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M'\*:?)I>_P"R&UTN& 6^^5YFVA5 '[R21_9I'88+$F&W_95^&=GID%E%\/\
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M<;EP<$C.#6KIG@?1=%\,OHMGI&EVNC2(\;V$-JB6S*^=ZF,#:0V3D8YR<]:
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MY;!^49VO(F<[7<88]W5?2M)M="TV&SL;:WL[2V01PP01B..)1T"J, #V%6*
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MT;*IE78' &0Q'<U]K0>#M(M="_LN/2M.CTSR7M_LBVR"#RG^\FS&W:>XQ@T
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DC!"9.T?P]L5MW6D6E\A6>UMYE9@Y#QA@6 P#R.N.,^E '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g811133dsp61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g811133dsp61.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  = +T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]ZO&/BFT\
M#^$]2UF^?R[/2[:2ZF;/1$4L?QXKY/\ V&OVLO$WC[XTWVC^+K^XN+?Q-;R7
MVCI,BJMNR.Y,<9 &5V[QWYAKL?\ @I3\1+C3/A;I?@W3,R:MXUODMEB4_,T*
M,I(Q_M2&)?H37S_\??B3X6^'OB'P!%X-EO'\0_"V3^S;V1K<I!=^2^YRKY^8
M&3SA[B4U]'EF!C4P[C*-W4O9]K=?F]#^>_$;C:M@,_IUJ-?DI8'D=2%[>UE5
MDE*%OM.%&\UO9M'Z%ZCJ$.DZ?/=7,BPV]M&TLLC=$1022?H :^=S_P %$;-;
M!->;P-XJ7P))=?95\1$)Y1.[;N\O.[;G/?VZ\5WOQK_:/\/> _V?8_%MQ:R:
MSINO0116=E$P#7YN$RL>?X1MW9/;!X)XKY8\:_#/4?A%=>&O!?C34];TKX+Z
MY?+J$8\M&FLI7 ?['<R#.T(V<D9!Y<#(.WFR[!4YINLNNGR^*UMY+2W0^B\0
MN,,?@ZE..354DHIR:46HRJ-*BZLI:1HRM/FE%\ZLGHGK]N^,M:,?PYU74;&;
ME=-FN;>9.<'RBRL/T->0_P#!/'XH^(/BW\#KO4_$FJ3ZM?IJLL"S2JBD((HB
M%^4 =6/;O7JOCE+>+X1ZPMIY?V5='F$/EG*;/);;M/IC&*\,_P""5?\ R;A?
M?]AN;_T3!7/2A'ZE4E;7FC^I[F98S$1XPR[#J;Y)4:[<4WRMIT[.VSM=V;VN
M?2]?+/Q#_:;\>?'+XPW_ (%^$BV=I#H[,FHZY<*&52IVL5)!"H&RH.UF8J<8
M S7U!J"R/83"$XF,;!#Z-CC]:^1_^"5%[;VL'CO3YRJ:TMY#),C_ .L* .A]
M^)-V?0M[U6 A"-*IB))2<;63VU>_R,>.,9BJV:Y=D%&M*C3Q+J.<X.TVJ<5+
MDC+[+DWJUK9:'=?#KX"_&SP[XUTVZU?XK0:AI"S![^W%F'>1!R43>F!D\9XP
M"2.:^@+BYCLK=Y9I$BBB4N[NVU44<DDGH*\R_:Y_:(?]FGX4G7+?3AJ=[<W
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6X:PV&LE*4>>5OYI^];SY4U%>21__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g811133g0531083522983.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g811133g0531083522983.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 'P# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g811133g0601030541937.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g811133g0601030541937.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, $P# 2(  A$! Q$!_\0
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M#^84].IYZ $@U"]U+_D&0K';GI=W*G#>Z)P6'N2!Z9J.YLK&V3S=8U6:3/\
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MT<K^8?-B8D' '&"/2N/$U%2Q4:D]K'H8*C+$8&=*GOS+]#VNBO*?^%B^(?\
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5>&TMX[>WC6.*,;511P!4M%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140089619764368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  03,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Medtronic plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-36820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1183488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">20 On Hatch, Lower Hatch Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Dublin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">438 1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001613103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Ordinary shares, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member', window );">0.250% Senior Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.250% Senior Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member', window );">0.000% Senior Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.000% Senior Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2025Member', window );">2.625% Senior Notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.625% Senior Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/25B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member', window );">1.125% Senior Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.125% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member', window );">0.375% Senior Notes due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.375% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2028Member', window );">3.000% Senior Notes due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.000% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/28A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember', window );">1.625% Senior Notes due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.625% Senior Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember', window );">1.000% Senior Notes due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.000% Senior Notes due 2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2031Member', window );">3.125% Senior Notes due 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.125% Senior Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/31B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member', window );">0.750% Senior Notes due 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.750% Senior Notes due 2032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2034Member', window );">3.375% Senior Notes due 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">3.375% Senior Notes due 2034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember', window );">2.250% Senior Notes due 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.250% Senior Notes due 2039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember', window );">1.500% Senior Notes due 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.500% Senior Notes due 2039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/39B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member', window );">1.375% Senior Notes due 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.375% Senior Notes due 2040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/40A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member', window );">1.750% Senior Notes due 2049 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.750% Senior Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member', window );">1.625% Senior Notes due 2050 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.625% Senior Notes due 2050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDT/50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.625PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20311.00PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotesDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20392.250PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due20391.50PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2019Due2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mdt_SeniorNotes2020Due2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ' VPU@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !P-L-83RQ^2>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O;35(:'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1!JSE?@D)11I& "%F$A,MD:+71$17T\XXU>\.$S=C/,:, .'7I*4)45,#E-
M#*>Q:^$*F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A')HYEW>HX.WI\65>M[ ^
MD?(:\Z]D!9T"KMEE\FOSL-EMF:QY?5OP5<&;7<7%727J^_?)]8??5=CUQN[M
M/S:^",H6?MV%_ )02P,$%     @ <#;#6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*.'@7=TZ<GSK)W;-JUQ(]D$H7K-,%T*O#WT\.JCNOA,1&.+$QJ.#XF/?,PD
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ' VPU@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ <#;#6$\L?DGO    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ <#;#6)E<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !P-L-8
M8EY495<(  !M10  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ <#;#6)^@&_"Q @  X@P   T
M     ( !FQ   'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !P-L-8EXJ[',
M   3 @  "P              @ %W$P  7W)E;',O+G)E;'-02P$"% ,4
M" !P-L-8'#AEZC\!   \ @  #P              @ %@%   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ <#;#6"0>FZ*M    ^ $  !H
M ( !S!4  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M<#;#6&60>9(9 0  SP,  !,              ( !L18  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  ^Q<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>18</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d811133d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d811133d8k.htm">d811133d8k.htm</File>
    <File>mdt-20240603.xsd</File>
    <File>mdt-20240603_def.xml</File>
    <File>mdt-20240603_lab.xml</File>
    <File>mdt-20240603_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="71">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d811133d8k.htm": {
   "nsprefix": "mdt",
   "nsuri": "http://www.medtronic.com/20240603",
   "dts": {
    "inline": {
     "local": [
      "d811133d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mdt-20240603.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "mdt-20240603_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mdt-20240603_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdt-20240603_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 16,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 18,
   "entityCount": 1,
   "segmentCount": 17,
   "elementCount": 45,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 71
   },
   "report": {
    "R1": {
     "role": "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-06-03_to_2024-06-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d811133d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-06-03_to_2024-06-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d811133d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "terseLabel": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "terseLabel": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "mdt_SeniorNotes2019Due2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due2025Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.250% Senior Notes due 2025 [Member]",
        "terseLabel": "0.250% Senior Notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due2027Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.125% Senior Notes due 2027 [Member]",
        "terseLabel": "1.125% Senior Notes due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20311.00PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due20311.00PercentMember",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes 2019 Due 2031, 1.00 Percent [Member]",
        "terseLabel": "1.000% Senior Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20311.625PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due20311.625PercentMember",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.625% Senior Notes due 2031 [Member]",
        "terseLabel": "1.625% Senior Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20391.50PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due20391.50PercentMember",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.500% Senior Notes due 2039 [Member]",
        "terseLabel": "1.500% Senior Notes due 2039 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due20392.250PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due20392.250PercentMember",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.250% Senior Notes due 2039 [Member]",
        "terseLabel": "2.250% Senior Notes due 2039 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2019Due2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2019Due2049Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.750% Senior Notes due 2049 [Member]",
        "terseLabel": "1.750% Senior Notes due 2049 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2020Due2025Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes 2020 Due 2025 [Member]",
        "terseLabel": "0.000% Senior Notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2020Due2028Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.375% Senior Notes due 2028 [Member]",
        "terseLabel": "0.375% Senior Notes due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2020Due2032Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.750% Senior Notes due 2032 [Member]",
        "terseLabel": "0.750% Senior Notes due 2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2020Due2040Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.375% Senior Notes due 2040 [Member]",
        "terseLabel": "1.375% Senior Notes due 2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotes2020Due2050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotes2020Due2050Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.625% Senior Notes due 2050 [Member]",
        "terseLabel": "1.625% Senior Notes due 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotesDue2025Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.625% Senior Notes due 2025 [Member]",
        "terseLabel": "2.625% Senior Notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotesDue2028Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Due 2028 [Member]",
        "terseLabel": "3.000% Senior Notes due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotesDue2031Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.125% Senior Notes due 2031 [Member]",
        "terseLabel": "3.125% Senior Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdt_SeniorNotesDue2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medtronic.com/20240603",
     "localname": "SeniorNotesDue2034Member",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.375% Senior Notes due 2034 [Member]",
        "terseLabel": "3.375% Senior Notes due 2034 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.medtronic.com//20240603/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001193125-24-152334-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-152334-xbrl.zip
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M(> =1@:V(?^M^D[^-W^R33$\:!GH(>1%"9IS'T^]?0XO3-4\?&@U)#[LB%>
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MT)_V7FD0:A=6YD'JG!#E3Y63KH7VL40,P7JP X]/9U[*(!6IR''<YMV=&6-
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ME[42@<Z[@%>SYDGR33'C-UB2)Q&T2.%L9S*@?*9) (W+OH>,YGTGHR%#Q7*
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MZN:47ZFCY#V[?AH._D"G?K@UV-ZF'5-01+^C"C6E< U+:;#7<=B8G*1&K:!
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M75Z>ZZ+FW+A'VY6OJ!7KS/8$/;-,'=%UTEL2-KMB)LD ?-R^U]1!CC,MW30
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M]W=" WICT@!Q.IQ:1J_U_>>-%<IX:5*QCT$*L+Q*B2*[JH:>$) /1[N@CX_
M =]*Q['4ZB:*L<X!/EY\Y=RB9&G*#A#_S*K/%"PB43,"3H_Z!.NEZ'V0?BW=
M4W=FS#7.)I8X'GQ]AOWD%S)_1-*+B,VR$LXNS3Z)UK"CO<6+\)JB)]HQG V[
M)B[Z7\Z)OL)\19[=YV.]2\4H23J=>>]^.3P*BPB79V2C0M2?Z+,J?,]:+U-N
MK%0+% -S*A9I*@A<H)E+A7K/7)9RF,#9CT_66+)7Z]F0&[""#= ,V$"CB*Q"
M@2^_HSGBRZI1';(A(!:KFJ/X62SV1^/=XNE\1*J>@UDFSCO<;]=R4U^,PO>(
M%N573JE]*VK1J8(S'@$_&683_>JGMZ?A5X_GR#F!\\ '.$?)?.T?P Q'Q;2I
M& GBJFZ-^UY.\=Z K;3H FO>EQ &^E@IO]PCM%+M$79DD"X4$9EE7+<-IU%F
M5)/4#M_@-!0MA  DK%O$31[6IF_ ;$NX#0EOS%HN/:^^J?-8? 44K<03=4KW
M_TUF:'2>_WF>,:[U/\Y)-A%W$7OBT^<2,2[6G$!5/&#32L=^!1>SKCY'[],"
M^(C*(=#E*37[NE]]/3\'RZ#OJXTPWQ$#P,NBZ+QE4::"A\Z2P=M\JC>PNZ1<
M-&]#+&X'9.M)6+\3O",WP5;!'G,=&ASV.ZJIW'NX^_@1G/%\ "=\ B(YCMX2
MX_\'W%<^DM,%" SI\;.DQ-@U#C,PJFU=F3(7]!Z@UU6>Q6S&(%5!4;HT]:&=
M\.",(W;KIOE(JFNQ8BD-,XNHF5AR =*4:Z)(@KJL"$VKTX2E./JC %D;74@U
M%W*7/#4EHJQ ,<.K*9O,M9+2YM#.8:1@B.2+R&PNHWREC]WZVR@^ D=/()+R
MM(R"IBA>Q ?%V/XC8N+)H)16.<QFB>(ZAY Y?-IA3]G*/1:TY3L@V5AAGATW
M/YYAXRR$4B,G+RJJ-8*G5XBG6XO51QUC9-]E1ME8'6+-$#?C@6"0A]8ZP.Q%
MBYXT4)>]&G-$*]C:EK],7IND$G3X4MV@_6 O*AX,'O?6\=$VEION[S_9^_'I
M8WQJ?Y]??PNW>SK N_3TZ6/K#MC<,# M+X&)?\:]]A_57.LMD0,(V^EK2LG_
M-175A]P(2+0=GU':F/(L.#0GUR449-MA+5/W5H^*M!*%LH>F\*6N><#*,](;
MIV!JV[;"("W3"LB-5SCN$J9P1A=96<][9AYM_0X<;E0FE\EDF]PO^[M[/UUI
MY\I@P]I3V+X/3_Y@H!7.GW)8!-@*P!P7IA'@<8!>W^-40\ZWM& *KJ:S>)SB
M2%=*=<>*I-+JLG93VT>]W7W+--?L?75S]Y>8>%8N]!QWNVF"1?.[XZ-7J"U*
M^016?^CK1JN4.BM2-S-T*,,D3CAH(=A)SN%K77K2JT*_<E24")(+U@FWZ*J,
MH^_)57+.&HX[?^6N4(D6.T.<$><X%NV#!096$(A\G@:A!+(.]71(T(W(:AZE
MV-* S$+,&BVFA83Q4S*KW<=&G=%NV_D0GGLPD(-@;0?^,.0-Q'/"C(!OV 5V
M\-T%=JN,;CA41A?X#3Y0.K> ][5KM6^_TPQERY-6<"Y==RFCW/9H6<T$;7V7
M ?VG7&ITS.-$?.BYT8@WT$8H;0\,=J_@]H23.II.$D(<A9568SS<@\=D--(3
M/^5PH>UOL2Q-NHTH04>%<<!X<\,V:?#V0ZRY+;AKALFQZ9[4(J$\+]6_3^GT
M^WUGPV3.Y8BL#<7F7&TKY<#:(/.LLHMFE3?/9O-0BYJ5XAWI.JV[U412[O1^
MFF#_L;1Z\.[+)"4)[<)\7+6@XIZ3,@KGH=1B?5'[6I<H;+_C_:^X<:*/J,\8
M@4V'"=C?DMC.;79(Q9&VO"ZU+5#;:1-;\R=5?7=W?X7(1F$XGYRIA]-@8Y P
MIQ&-.M\>QSE\?*EHV+X<IJ#1.U@)HCGQ+.2I*CK8W>=>Z4]W']M'/>YDYD"=
M[_0JC[E=-7*C>=7+V0229\T"B(BJ^%.02!B/%Z3FLK> +6K4KUVFD\D#SE:K
MZ/+BL=$GF(Q\Y:[I*-\W\^8;C*O,@6A)D/"RJ,'.>W!4^OT6]W&YS[C[[Y'@
M,OANXSZ&'^:TW,C!;YS[O.-\961T$-C)%P)TRD8:DI)TK<2T%5*'BD&7"0;:
M,N<Z2"?%Y;:Z8&UO&_FP)&,0' BB3W.</JD1LH;O=Y:'%3%+$C+N]NC.S_7N
M36<1E8U8AHQ7 9AP1;\Z]Y13"(K2M?60R@3XRVBNT(+\M.81C 5>D$'Z.HL8
MJ(4EOIC#7\Z3R=A;;AX#J&%>,YY%;#H6XA>DK:$*"+17:NIN#XH6IF)6ZG=/
MOE#^AN]=*#4E/?>N'[^1':A=R(9":71E(]7?'-Z?@8WV92SXO.*U7103S(@J
M%YVP4]U#PB?,?L!4?Y1)7/,3L99="+2W.SN3CNO1@Y%J9N>+"C<<T]3J&G@?
M^:N TM"W^.5OP U!3WJ^56TCN6V3KT[A51BGT)4C,Q7IURT6N>](8Y<5^]H?
MVD(1& D0,J9JA^@*2*T2*(D2PMH'XVG*?]TJQK$D4'$F>!SM[NP_C+;^3$M0
M\\F%6U_"G#!/;5YNH^8_-,$E"2MK#JJTM38@BM&4G0Z>^?M5>A,@!457]UW[
MBC,Z#?%_?C%/R)/L'&)#!\$X2,V7OF&+^>%WB_EVFP-F:C^AZ_.\F! Y@01@
M_G](@"?L*A0RTC;L'>%>HSVAYZ?%LIG9MIRPGILJ)XU#."X7\0V#MEW\*@E[
M!@8V?@!F>-6N@+[3GN368H'*#+A$-I_&'%9@D&V&0\64,KKXE?LQ\B J;DLM
MME\GRIA_0 (XW44PH6N3A2'^\7 *NL4PZ9&+\1*IJ!)0T]\,2CD+2YM?"#R=
MH4$U;?XC/_-W\XRS7%P(;Y!:-G[IZ2\6[0'1:R_H?T<IIF^R,U4U!Z=:L,YQ
MM9WJF*"KPO$!/66TW5T8Z3DN)+$37]"T%V;2%I+835F9?=],\+/%G(T$3AP7
MW(AB@ JNEM"'68PVO7K) />A8O[QAW*:D^ET#H2Z"$TYL>6-?Z;E$6O\5K3A
M;B.?*8[N X+-D-$8@("TK6;CV" MU'=+)[!'<FM75;2E[=:U9Z?B/16EU#[%
MHN(0DP(FP;J+AQ<VOZ+JGU&EEN=]UK>SW=$\NO,&WTMS2^YN>;088&H7Y[H\
MQT9<"3)-J;UK.EMOLPH*4;-,#OZM(4+8Q'D+EX7NH'E--C\7JU#947U9$- 7
MW.S1):$)5L6XOM3<<ZP&&"2$L-R5P7/R,3KE;VE\-L@D'!?BI."$2@%4$J'8
M'_NR2'Y]+@/-T%1.Z-J(R[^OE3&:V.P?EVP?=S%.._'!_ P-GK*DB"$8VIR<
M^+$L_L"J3?@K836BCR0:%-,!0KN@@B9[S+Q4PD%8?=F$1[_66C@@II'=1D2,
M8U8@58=:$^822K54*79QL=@$Q6)7?7H&6A+G@P1A-LT<%=>DVR,L_.&LG602
MD*@N!#63LY+R0R2P1A6L>LZ8LS\"=I)HU8%K'BRGX4G1$:YM5B0%J+C*2>S^
M"XN ))6("_\KS.Y"&H_#&?N >:K?YAN #$-H?QL3<Y!BJ1BU2;+ X&TEJL7?
MZHA&-X[=-K7-"P=A/L]-CS#QO4O=$R6B3M%1FU4N6=3OD9;"7MR4S,@\YL07
MZHR=1^;(ET9%73<?K?C0TFN5-0[>.>Y'*PEDWM7AQV-?K1=$@;7Q %7_FA9E
MMI>+=8-ZL+1K;6*S^-O2=H.N24"9W)^P3IR!N#K>('6@22ZQ$$LWTMRT&#E'
M^GT(Z FWX'Q?9A?)</$U)7'4(8B#$^1(PVIVJVD=L5/"W=4(B[3B)3GM77>E
MXN1$@13@%(@@8X-8THRW*F2/7>:#C;NH@DY],H75:F*U9#M9JJ\UC_@W!B-P
MA1K1^Z)TI8XXWF%8_>BR0YX^5M[YV\G[PT.G.,@.-W*9?I7RRX9B%J2;26^O
M5^\_N"RQXT^8+//XQ\=/GF[W5V711S71>7/CG;_I(<Q!;N(T?17:*ZBCLC )
M"]*U&_T4B#I0E.))@6PE0TSIR,&S?;,NKT??75XWV,X7R((L,!]#3:W#_"Z;
M*.SX"O7ENQ[FA'K-KH?!XJ+1P=V+_-5;!4T:BS=]A<JDE87+D C;596&Y5ZU
MP!(SW@DYDW<5EOUU]S6Z^K9>>(73I;"%*AJ.T?<%,4J73*^_X1.+1RY/!\UD
M5EEZM"DH[7FMS)!$STE/!I_5J_HEI&XN:40J*HAB0%GD9E/L?Z6@A$MK9X\*
MAZTW-VC7M(2DT6*V=T=MDL1[68.*L&85'BM^IHJ1YAVH=*K-S;E5EE??NE<
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M+4M:!&WSD]SW6W>N><R=DV@_LD($AM,+@D7B:Q7IU]%H=MPWBW[NL 9K"9=
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MQ*9.Q.L6#"%(FH=D,;"^)S^0^.M7+?K+!F]928AZ= 1$X L>Z50"L'S@1EH
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M"Z%%H&$G:&]6-_4PX% 8DL$VCE)!7=O6VM^D87WPW;#^"C4*/4K1JK!S"YZ
M<0A !7"*4*1E[J(FQ>N //54$<16!PM=ATY+BKV*A)J0HJ/U"\#U%"F[&_V
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MSN7K7U_\==89];9@01"<A@#&N:%:9V8F!JD2BX?Y#/JAX66J-<=#.D?ZO<#
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M[_C0QW)O*=:"6EDI"L:]E%9,2N"R0E"-IVK)2EQ++O][2QI[">QLSH%.16.
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M=<\J]>?-:D;UZE27F^]PW;-*^7E4;Z.2?[328K;FMXSJ[5WSVZOK'Z]NFL'
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M=Z[R0/0LUW-\6M=?CBZPA(6,D-Y!"Q_<B:;S3Y;]X&B@<VKU#^52X\M'?.Z
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MJ*S3?71M[>Z(Q?7*),Q'\;D:G/I_'F8GH30)M3')C4!RNEB?&'I8=?M _A'
M=*7RF\SD$_R2S#2D2/XMGO)'-5!:LX%R<W,:^)*H4?[RN<YZZ#PYG];)Z4+:
M-:CMOC>SUI^2YRFD[J3;.SZY^N.79IQ5X==A5\THUUZ-8\>^AKL^MN.^$-?H
M=@F%]()O9)WV$]O$W2DP$8N=8NMG8^R5@P&80S!Y4F9L$GA_,KX-N.>I>W/
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M%<8$$;PX_ N^/+DZ.SWX?U!+ P04    " !P-L-8XKKL:J:?   2Q , $
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M.1H FQ8)S=1@ L/4T( IF9Z%0(G,NXS@*#*YF39Z .,>WF ?RI1==+35./M
MF8(T6+09^^$@LW;C-0F7-V8W<#@Y:2NFN?2E[C0G*1HW9F1?4ZM 8=]Y'_E#
MK3BX +FQ'R5! F<XAK.7741P[HUG B0>GM-9G;*+$*"+T%AB2[U^^Q!F7&NW
M#1*]]]&[C0%Y)[WR[:#5;35[?N7VV3$*H%$ ^Q4-@T$,G!'^#/%(C.BWHS".
M+L(L'"F5H?8!_^WJ '^1%+0X=;68N"[_3K/T(D*1 $0@L>=%>3Z'30^]<99.
MO!F0@^:,_P4>MXB //CN$]@SX8!' QHD9.' 2"F=WA#&#A-D*'@4-V  ! '-
M!1($O@ZC1$V3_CT,XC@<L>RU)><\BV91F!<U[X#G"D_ LVD2XFLG8/=X>9C!
MSXEG:77\BS*E/]W&([@?7H)5H51D2?&A\6I+:%NON5/TIF$&PC=?*CN %G1,
M8)7PSR#Q(OUX;F^[L%[A#?AT/@.>C?)S^AX88<+O@'?3SN%+A:CPE]F13VL\
MC0X%7QL*%I=G$Y!6YJR@L#KF*DT.9IR%!"73Z-=EJS>KB3(,LUF 9V/53C-E
MZC6;---YAI)BYMV<Z=9((GO60J[<(_Y!EB_2K"1SU1D<A7F4,5U$R&@!JFF$
M%,#!QB""O03F8BB+Q"]2U_N1I)<)BBW\=FF<P+46Z"/ZA2,BEWKQQ1'>O*O7
MRD,L];&+0\!'Q1&(IDM]X.(@VZ5!< R_8!#B0V;5OOP-R^+1E8 T<_(+6J6\
M5-Z"\3R.6<#.$U3 $7LY\-D9:_K0."I&]Q=6\57]-"]9]EJVYO,!L FJ6> &
M<+;."U.G$RGJ.2<>Q6_TE')6FLBI-.\\G.'80)JRUBOJE(4&1O$GR]V0E<:%
MK"4"Q['D4!=%P?HMNG,@7!;^:PZGEVR08%:TE^EO)U N)IYMX:U>,+L6P%/U
M&KX/I C^(@<!@0XWN ^XI9/@1[AZ*/#>+H(XPHW.P>\F>8,*:PA^W(B8BTX+
MJ3_F)S-TJ [&Y3FX)MI8%=ZV38U@#I\D,[!KY0?+#%HF*L\*?Q>'9WA\,,3U
M'.BZE2L$@P^ TY'K4E K9P&??]<6=W?6"* %VVN[+97[Y2UYI>/S,"NCDZ]D
M%X47##.?!Q<@@0;H_X[02,<?@?F!@I"9YYJL'B;PR#!$WVH%CZNCRHO&P)C%
ML%>\BE5OPUE[/.DY*@0X FD&^\4&(2P8=/\4K(>\\?CBJW/\S<>KGVYK_QA#
MF_V#=L];%OT$;N]W6KU>JW^P!O]Y'Y0^;@ Z>,!%H)@D7"GL- 4!&.7P#'R+
MQBC0F/U!<*$#T(L8B8(=.,N G;6-!1YG.([(NJ(?L;LI/X67:5OL7W/85_P$
M7HJ\@ZRH'\5?8$0LS#1SBU ,\%5QG%[F'Q\[U-'L]MN[ARUO:]E6/<0%QEYK
MO]UI8YY SVMV]KQCY#'OI'O\1[M''Q[O>U];G587DPJ S]J[E%3P^!SE>#E;
M:+%_;LM%'[#5+/6*0?7VEP8:,RO./'+G+)K-R0PC7EK@/0$GR_&''X 3J-C&
M&\QG&"$%\9"D,V^2CJ+Q%8;H0N _%1.Y!%[W@O$8GZX<.T_'&#5%+\##P/.,
M_0/4QLSEE?X9Q3Y6O8^<V2O8CR3A&+<X?@734E9=]I+M]S=8I3^F#U?<]]>X
M[WMPF)-(AY@;'LD;V )P]*9I'N;7$OBL!H?!-(*/2<XS9>:Y%D?UVD:TR>^^
M/(] YN#UR0C?KBSM*/?*4R1-@H,+RX 2\B9AD)":#/(<K AY!6SRXF'H_B%:
M,8$2-VW@8^;'R)4K9[RIIXP&ZI(YS^Q)%U^]+$+\,-RQ$6S>;N^7ZL1W"Z8J
M'Z'Y1U.]V]2C3>\TB3$N2FP(OX7AK/,KC@(9-U?PUQ@HCZ8/1UZ:&1CG,<4_
M93?Y)_G"[_FFCC@>8QR3  P^. /7H=:RT,TC$0NHU8>Y7X(!F(O7+1:#1 S,
M9^G8!!&4^X^?TRV?==_$8Z$K'L%;0?Y&DRFXTTQ'=G%6^F*H-2[/TYAM7#QK
M(K91E43#.0XK6Z$C=294GL\'HXA]?9[2^IE2$9I%X4K! 0>0G]$BKT)FD+,X
M*0XB!N(PGH]$\DSC>8:66^Y=AG&LV#6'T9".RXRRAY$N2X-M%#RP%ERZ=\C"
M(2J6=7@+3HSOB4Z\'%E\(A.OB&8^A8DW1RKPZ34GZ3R9+5N "3W""HH7$&_T
M,IX#/_>W/XN2AE8R%_C:P02\X'4RU\X<I#B:.GN!E9Q$4\Y)78X"<&)8*<[.
MP7P)O%X ZX2/R8(!U8T_V-AR;&'0):AQ X]^EHC1.PB2'TB'2#P[<F_0E$>U
MMAO-*!J$D_R>9C]P]$/P@E =H3XW,1_X0BPPBJ#%P:4/'Z F4CI<8DT7:&2-
MV&(8QFG.IL#&:YFJGA<'3&'!+UKS+)V&:*3-@<X48>V&0?P"Z>=]S=(<=>1L
MQO:&U_H).YCG_"Q:)OE5/@LGOD<QEBNK%(&F/(V#(3\HMKI?KP&AX(7)X]OG
M)C%MY[A]*WGRMK'U>IV<NQN'09;/\ R5&-?ZCC+D8"6^MS!+*DC2Y&HBD8DU
M+B@=+9,>RR4[F7L7F^N=_V0"9VHO!&</E&9V=:O%X.7OQH!MUS6OQDW8?!+B
M' 58(7E/?\?YT*6SHBQY\)2&\PP]6<S!G&7I:#[$?"D.C,WH]C&?@=)7$2DM
M+%O@(J>3:,ANW5&:A+C[X$.C.+9O^%G0A@%(>GTM'TG"G!X-V6B>@#;@'"X,
MGX6C-0I(G-@0Y4F)<OH;DC'U6J_YLO,'S1I6D@4S%/R&5/S+'JF(-2YG?[?Y
M),7],F__B1W2:^:3/HFUZ.O')S;O-KH5((0PA8!L,JR:NKW"&JU55RW.WGX*
M6_$4??)BR<&3(+2=+7,WVVR]AN9)]VFJL&N6G3P)7JI*!'\2)[<?_%PZY^<
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ML=1B*B]6+"Q#?D'"2@3Z0-1L940@7$?6\\:83-UC(@;E/9F 9"$,,$]RM&R
M$7)&]W0PG@O)(>;B!!,D5':$9R='X.9B!SNRP%0HAPA$_E4E_#3K%C,3!N_,
MYP.P8_#6D[C4GM5\AD*%,:^+J2+E52+G&'D2L>DZ8YFE3H5R:GP')<E&3[+F
M[:LT"HTQZ1*U7BL.*R/RSUP[4>=$CCD=I'P1\.A0[2JC\,UCXY=U6WNMHQ."
M)"OE#ZX/G^R-)! >3T5K=[7CQ<=J(Y#J\.*E!GIHX:00="@&?U6<=W'6&FL_
M$[VEBTH<E/C>$;]6* N4M;>+#+G'P58,9)B9H[<Y5.AZ\O 994EA<.XV^8?W
M[@^CQ:\MGD6W"?I(T54NDILN<@5]9]U.*:E,=#PQW!)B%A(!\&#6H_?W>3IC
MW4(ZR;?0%'.2FA=!/#<LTPTG8+ZAR.OIJ&-E[H3CW[O!WT+*@4LU;T.'.#GJ
MD&;*([!#1WDY&2VT+2F+Q?94SEV0 Q$XM*NRPWA"%++3,6BP=1:P[R:X*U%.
MGK")1Q;?E'(")MU8B&'D!F Y_KJIK$4ZJ1F]; >-FBZ=DVD\S[VM;1F +X<K
M#6/[#+]^=9W?FS->_#T&(RH><*YU7E]K3DI&/#X^.Q*.)D77/#@KW[ ':72*
MN=M1%XF+JA [*FH=^?*K]O@Y-G&_>79-2X](RK>)22S6);-J/8<;C[F$M]=T
MQ0MB^Z1:]N*4\X;Y!I!A\:*$0-I6ZCG<*N]6.H4$PS*&AD,L<<0E#&T1M9*W
M'S4B/MS$M:)UKNUIF/_L7+HMDG3!  U&3BI-4P'EOR,2O4KE7M'HIB#O"B%P
M815P/X<V-K%!U[9XE@QU8I4XQ(O&K5=\&^F84N[MH\OR49SSRB4)!5YF307[
ML: ,/*>;:F]CSL"0 ;P7=&JH4U=,BC[8 ?DX&,Y2QHZW_-=-ZL@3C:\<I[82
MRU[=W2[D,'\9XU_'0J ^#B2VK2Y),B8X,P:[HNH$K8&_1_?"W])H =C\MOQ]
MS4Y.&IVVDJNL%$L%W(_R13!'P?(!+DY4 R7ZX%T56R]C#\6XG&*AN8)N\5S[
M6JPX_J&2R\%H1-A6\(HPR!BU2Q'03ED+LP(8+LSU>#R&)6<YC^7MHJ<^IH8%
M'H:*X #HS =.)+ H,\W<TV3=H9@HD!<',W6M/KM,G1!6@42&+IR%TO":7N66
M4+&*"!ZT3[.P4O3@G.:#?\JEDMWGRH)LYO0.<@0LE:&TB*J(0LV"F1NQ?A,L
M!X'-" AM'&;T5."-.;4/_S#!>]T:T(I<^R8 H4H7<&<1.-B^793E1[F]$BVV
M9"JK5T9,XT@_BM[3J[6 +S8GTX3U)<+HWNHS]*V5KL"1[_D4IZB.@%O-4K69
M<BEHSU!&!IX>H@@:%0.YXH4+8C&'O,VR3?#)M")@BD4F.%U<S(9U\TOXX<75
MK26<&&YJ?^W*40AB=2G"2,&"#;QGERZ(G28A?+=<P905Z4+#-01-]U>F>6$P
M2#4"4BPU,@#FC#NH1>RM@*GO$8NLX-T6"YQ]'>HNJP)UG6+2")U8D;C9*'HN
M@AC/PU44QM(.1/)P,)>-K.-IRHDRY9]LZ(P;<N[9P]WT37::"2PPFIAS\[ H
M/0X.YB+3QR++UQ2T:$)7$I@4@NZJBE,$HE/4Q=^2IS!L0I"./-F@7@.*84!3
M4,^PK4G1WMIT:6F-?J)?2X=A[2Y"%3L9"M1K1(+*NGG,B7BA3S_=+X@1(,52
MJI%-F,&;= G;F2%O3K;\@G 9TAKD*IMTRB90Y4&*WS2;#<WL]3V5"J=A5&Z9
MW>IME,-7*L_:C5\M])@W^4E.-,-+%U!07/"LD/*D-V>NW1?IMU),YN!,#RJ'
MT<G[TPQ5\) ]).1;G"HVJR-"YWQSJ%0_7J,4;C8LXFB"+:*2W2NCRKQ_#LT\
MU*DCR5 6X%4I2R79IQT+#K+"";,@&;NZ%\%>")(\,R<M7RB(? D3F8@QCG0>
MG9U34!B[4*675@G5DG?XEA\0N=>-Z0"["<$LPDMEN1.RPM+1Z!P"#Y]/P&8<
M>F:QL/ 8$R+PHG_9FF')E*:S=$J4W8WV[N*1?$6Y13]8,Q:9$4\E^;TBVMT+
MIS/*O7'+4SZMBGK_=1Y?Z4<00>+-NP7/F*:/31!HL5MA\DD)Q\71[XKG5!')
M6K2GWO-ZK8BD9C1FB5-TQ5:AI]\:%U*<8VDA6M1P4Z\Q8G1'9UDZG]9KDDIY
M%&0_0K"*#MFG!;YHG#2\HS0["Q*[9=$T'F(+]"S#](_#JT1EANOL*<KLBOYO
M?IX6OH G5<PERNRJ$%T6E]LU^^<@JT!,N,7[PE.H?<Y2PI B?VX8(L.QZ@N\
M09;^""D=<\1;ANE[4JB,N?NX4&S.\H-:._O*V+&,G '8YD"UP"J@RR)2\&2U
M%ZF\61'(Y$ZD*BV&??V*04HQ%Y7G4/';W#&^2JRW'IFU1&BOUHO$CN43AA<>
MB]P?41WH%F )OGU[BU\ONK\=2!_&(/^!M0$9U57>T)&P;]&X+<UUG(I_P8SX
M881XL8*<1=MY<+5 -P'[;VU]1$B!QJ0!(EK ]!F"18S<"C_,^%Z_F->R[-*\
MFF=TQRS--$LOA5PCV=0#V9?E;L1]9D&5Z&MT_C IN F8H6NNXU2U23%DA"%"
M;:=97Q;<EH7NC?@P]=HJ)V:IR*S:>%U DRPL-7(/J<X,<))%58%]H23&$%N3
M46,T"#E5*BDLCW#)Y>3J<4T-@+[8TSN1_B*\7$(KY%:)>E94#K)+V69DN'T#
MFN+%$Y)(<"LQ1TF:DUDP-SKNNZPV?1G^675,T+?;:)E+4',[BT^FT\I .:W%
MO=1XL^!20^X))%(KM9K%>[4HR\*+E'AYDV^&G;CV] 97PS.=G.^T,5^1X*"N
M@RMCO?A,N4^/58<S9E+"8/-XIJX\"=Q>D$@HN"]IO9&$Q^/@,K=[FV!R23:/
MJ8D7*B',\;+NYQT<0]]KHY3!6[[#^4\P\<';.C,7"/^TP#;Y\KUX,RK11 WP
MK=*?[900I\F)DH9VW)ONY**$,*Y.P!9)J2QVH@)!!CW*RKTM3@&,334'G_/%
M*R=+1]S,%N35),S.D(EI;L@Q0^[;AQ_@93$F)<0Q/TO]WQ4P@LENG6(%@FIC
M"T(XG)42:4NOWE3'B*Q@B0WEGG//FDE:5APA+%ML]YO3=,20ZXQ;Z:GP&$TI
MO90F>,%/Q]A<"J.ZJ5^J><S6$!HZ"Z_N(H*?PMA;%LYT=V!:9)DCO0J&+!:]
MR;72#&SG!#;>975>E,IA!\]^A%</"(9!9KZ*B+$YCHO&49_C4[?O7RXW.C,^
M7YY2,'(@Y]QH%P.)(24U.Y)B P$1LU$L">67YRP_^;9'+B%E9Q&O1(:.\DHX
M%?N86\?'H!\JZ6BQ2XYY9@E(UR'#HPQ"A$G+I5Z66CY5E6,9%1=D"N++7R%!
MN+X<AQ<1PBBA7,@=9ARN!2]8*@W8>IHI0T6>XX;MG.@()DV%DG#*A-U$%=81
M^*MZ35N2JMYFH<$E3=?I;],P'D1V(MGSP45*QH*84/-<*E(F(#"'+ +A/("L
MYC@R_!-K"9=5&Q5(YS0T]50_4R>#RCBZEO% LV64*;UAGXQU4S15D]2YA"[=
MY^-:SX E4&=E<:3BCI6I%/R+$E#!,H58O4J]3WKKK\D]]HLLE5>%"6 -+6Q%
M="CQ5@/C 6:-7-2F9#T>LS S53X^Y4+AUFQ(U*-0W( ^\TS=X1C'PE2;<NFR
MI1HH[L"E90IO=%/9/E6;AJYY/LRBP:+&IF@S5T5-9/1BILA&M+G1W/1,2HK*
M0[!34@KJ'),8'$?+.D*+S_#"PZ6&!=VGB@,K#EF]5GW*(I)]&SNEW)HE"[&V
MQC#1/:ZJ("67+VR!](AFZO#4:\[IH=QZQ0+!(+T06 ,KUF4P;Z=1(L(#';)I
M2!X-F45X 9V'<86@6D2AZL-,W#E,S\B*\W3BF3H8JF^\F]IZG=<4EHVJYG8J
MYEH:INAZB#;UC8KU%UM^F6,C%G9'0K,W( !ALI8(+9Q&;,:RRN!P5,LV*M.]
M)?-5L-D:@J%E@.7/[2\G9MU5?5_1_6_:!<5493DHZH^"Y\80L^D24#M&1:8[
M?%TC[-8DCS/)5174 HYZ*1BW2RM201'TT9P-1BJ8(XTNZ =*_DMI#)5DSRFS
M<H81#JQE9Q<"M!*[$EC0CKXTNE]Y+J&XS J\ X& H;.S4&Q2. VH#!(*AO'S
M;"S2D"3$:$KUFL:RI"E5.%#>QJ+&(6"FSDV3^)O9"%%N.IBB.RO$,Y3C:(]T
M-R4SEW>XXFQ:WI+Q':EN>^:FMUG31+B! HL4II17SLK8HXOWE6<N(#*F4)CA
M3E;RH1(==J5Z%05O*]5QRWUF;&TV67C*"AW'[/JRYLN;.+K8F4F(41"\>E'
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MZ[5]<LOS_WVV(>XM[ZG=P1J=3JO7\[X=M+JMXWT%(^(DCE-DA)HF7J>:6!+
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M[A$B;W>.^RT]A\=$:4/D\WJMU]H][;;[W[UV#V@AP2+](4*.MSL$.G[4:G9
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M8,*]XZX23?@--YE0WS!,7D\-U% I&$\N!Z7Y8NL_(GWDL>@)%DTA,WV58?5
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MZ)5[@''Q:VQC?V(XR%4IV.",.[>'DPCT#@@W(NJF 8]P3F.:%'A<(6VR)A+
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MHBEQ(7I$C.T&\#[[ 99M#<]E9<O& HPFD'&8$UJR A4V5CAL03Q4H+<4X]%
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M$6%+YHI)QI$#.R8X:_L%R-.3A(XT ICF@G2=YJB0PY_3,,E#5<X4$ Z>40U
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MM-: %T8HU&LY*-+1#5"D-5QF%)+!Q6<*RA7BL? ZI7>77"F][2GS0^HU-[Q
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M=_TR[%'*X_SO&9[^9 XGV Q_RDU,M6%N<D29?(0T5_@JK%I9](4?<Q[Q8%L
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M& FVY*[8J!V9L!>$Z'8?@#I]%=.41BAK)O3N),,%.?PV">,LU+2M@-A^=FD
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M#)%HP<<QP3<#P/ N\>58 DBDS<Y9FP.N)M5!9=] N1.]"&8B!]T-VC"0@K^
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MN+_A;VDI__E5@-@SC87$#-N]C64YF'>8=];%:>_\ F)Q:_=OR=XVT@UV3W]
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M<@;XQ)!+2RPG=[( FHTBYI\.@ ]J.#VAU$&4Z#*P>B;H:Q ^'H2O%P^$F(Z
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M!C@E((TH@=OJJUGY@C:F0P&JB(OX5J(WP>HB+L*E7U2\X%J#"D$M]:L!,:3
M7)LS8$"TO5:U4:(*LA]DIMA,K>P^*8@7,D#A1Y0LF5=(!<CE")/?X'^/<^*C
MT0C@GYE/,WP[)MKK3HF.F4=RI18,'@OV!0P%^(2>>/35:#2$NTA X]NAF!;K
MU^GS*+)%-8"VAL) "]%46@/OFA=='4>L"M1L.)LGA<>001U:(P^,)JL.O&!:
MH]?E"!WWQCIN:B2F(#RCN"LKA<K@QRU/KK 52*H.2ZF+:-9K$]UCH ZLZG]S
MT#?)'>3$8GL(S% J7Y>1.,AG) CW8^-#L!VZY<.&=^J@^D<?ET6-GG2BC=14
M6=#&O6,<5K46(%7A,:9/5VDPDKPG(XR1=._=>VJ:#>K#%8I"'10@CY&;&4@Y
MNL2RSHV>AXHJE@C%[*,5XF%P1&,8&19;$ICR@>HG5T3_;4P93>GJHN!.:*#!
MXG[6RFK!?2P'0Y@Y,"XJA]2NEMVI%"3#A;F%<Q-"O_<40_3FB<1'9R*UL>G(
MTYH-H\*21T[8BE+F$=*F-$V #L#:*!$(4*I5RX44*7PEDO^;2R  J)W EZ@%
M6S4>(^6,HP^:&6/0*7R7I[4H]_CCNJ"2G&\2PL]E4D=*E4<(@SGP)D6GBCZB
MSE+\K,Q.Q>^L5\R(1TH SI3A4C)K-@KX&JBV*%4D)N>9S$S>" 5_M8"'1@A;
M:M)J.8:) +T86'9SQY)3'J*JAEXRK-GJ%$+=.*\S/)Q8 W72*MZ4(R>%TFNF
M*WOLT0P\2/#L%9I_P',M:O[VO$ECZXN9/(OGB'@9,@%#5!/#=<J$L)?CH2G_
MB"*<%]\0>M;+&)A"EA-C,*U@"5[ 7XXBF\*X[4$>F6JJ5N847S!ZNXY)_@&X
M6T ZCKB[E4E4"8?\SHSJ1-6J[+-C: %U7:)=?$PTRZ1L$F%!"Z+BE(M1.S^>
M0 I<P)U_A,!T1]\CV:E44XS>5X3T8S56Y(8],>11O^95CX?3 D;O8\BHT1>T
M$=1;J(^J!'1>^!/4?31N:51(Q2@UDCS0'!1Z7,+C )72V!I^$[PNA\2=!)0-
MIXE0MIA$*[$25)36&::^#<B<[,E623$$+^F5P=:U(^/)@+J $?Q&VT.=K5+(
M@(>W@-S9$:'.*%/6-4 %5N<VY8K,.J0F%X&EQIR%0GNJ).G0A3W44V41Y!C!
M5.3[&CIZKQ.PR J[-^ZU)TR)[Y8M+8ZNZ):--<2_H&=8 0Z'U4">.C=6N<1:
MN!03D19CB@E/E->O46- 65'4F5=<VE2%A<Z;#4S[PHZL1H]_WAF0.>1F2'6(
M8AVB^'<.45RO0Q3K$,6?S(P7,N^HHDD@5R9'3F0$LR#B<F1R0$:C/$8V2C&!
MZ-EI607#!!12\J>Y-$,YCRGYA:C"@=:4_E\+=D^&I05,'W)BC%?2PK@)/$>X
M"W*R@IH!S#V"E*UG.$P\IY^5"LV]-W<2A8J$3.-7,4H-2D=D9;E/9ALG>12B
MY):G5/K"W<U!?OX G8P4ALL#E)@H9*L(3:P&#. 36")X%5-$K,F8'798<>W*
MYIOU5VNKJ]LNJQZK\NZ7*4UP\CID #)YK!>ER%J7Q7N"L[.@J4Q4X<A<]F-A
M@>K(=)I]J1W--1+AEW_E -M0!KZQV6)X[M$I7.2DQ/=D''J%'_Q[V]PE>?,/
M2DWB'P_3!<QH> 2)YP#)<& ^.5L/'W#48ZOVS-BD*1=@G9T/ZLC\2VXNP5.@
M3<;L@^W"9-^9J,;J-TP/'9E'U7<02U>CR(ZW@',Y #<S;4H4<N,S-S\WQ8_X
MW7Z\%9%9R5M*FP>T818"KRDU9@UW,OV3A-%A5*P%?U .?D#FMI 2&562PG?P
M'PQ6Z\^>MHMSPR7^ZO5@2BQG2N(UG^8^,+1%4!S+E*=+R7*' @Q-U7X@&_KI
MHR@9(Q&IAJS5?OKG]G6]640_?1&&W[?H)(2S(0\K[*IE12SOOK0'YG/7+K&G
MP\\"^ML+_-RE;MSHK@5GZ:&BRO,:*3\ *0OI6YV'%&OD,/YUPX6MW3W%V^[)
M%4'UTD#O^BO7&>J=W :]Z0Q3*8FQ(W\&HE2K8\\/KP7TM=X+K[Y7;!!+2FAY
M.[< 1$V&G@XG"^CJO!\GZ/0TM='QZD&=CZBR;!*+N46^:K@\'5P6TAAOX4+Z
M=4@\2.61=_,+R<M%F?09N"I#@)*>%NH6';N4LK$ EQQ,["4'5M6]:US%6PIZ
M1>Z7=8RS(%>8F#7QL[I$KJB*L8M"L:WQ49+C7<RY,)-.^83LJ=42>JP'>K W
M%-NM33Y')=F9W&;FG)@A>YDGE?'2R*"_2CX9Q1U@(YCRJZPE0[A+ON%M+#+D
MV=I<DA@-J:@+3:-=8<?)6%!JB<V2@0_.PC(V)KMF(T^GS(8MNS;:N'2,A(P$
M:+8%9O:J4V\X/W<'EH-?Q_[8%CU"&T7+S5M\R7!\QDA!5:'-GMC1VR&S/*4$
MZ91+6,8^R6CV%].=%//&D6 0T2V/S H8XXD'@GDM4)EKRN.S!^[NGF"*@XQG
M[(DYAUCHHK1MT?:4,]F=?R_W/Y=6WT..%U#"NRDS)TV")7#K;#CG.A**9\/K
M5>+: /;C0+.(%B[/DLN0,^&.5\M%*"^&"XE71L10 2D);2POEN!4@A*)U<1]
M0V9DH[IZ%>G&0XSUY2-83Q-4Z=T29,(J84 \A'Z0>)FF:L_,XY&WD+8QCRS!
MGW?(T4#$>*_PE*NZL&1X480H6>DDND56"4R9QY]5GF;P=[/A,EC)2JM$H@8\
MMO'&K2+I50\E,'/,@LD2)7G+BJTZ& ( 25 IB]F"7!*.8-"NC*+QQ)2^AC(?
M,(_[7**7HQ"LH"4X**&D_*XR";*<DITR"!V<:E0XJ;F,^2S>KS6N)S@6"VD(
MK!Z+*?[L#@7Y%_P30$X'3"DL/%ZVN(\?GUXS\<=C9@%E/UZ4$K$D*!3 D65J
M/@0\"FQ(3ZM %F925&]E+2N-W2E<4A9X[V. ^KVWXHV05"$CGQN1A"*!X?5D
M>&QY5D=*8;5:">A4$LW>UGVLAUB0 =XSEZMAG1382A@M"A8M4S("4V=;IM1!
M3QIK>8]KJ6WP>O$VF1NH6'2E2&$=45Y'E/^=(\HWZHCR.J+\)W//!?1Y\! D
M:E,%BVIB"9WY-1>0#081%NMP7/(AC ]#T5UY!H'YK@+:SR;N1JN[ ;@\<[U0
MW\@!9PW,A&5EPUS[7<&?N!DK#*U >)F,:9"L?%Y'J'!/O6(;M-9+F6D1]5%E
M^2L/I;VQB*+B,9#>BSDK\M7ZGG7@;DPQB)WBEL=9LS$GZ2QW'!XGIV20^59Q
M#'<#[<P9Q/&J$+H]WBZ%B2NE.=9W?CS3<5U GQ.Y PK7"PJ, )-1)9(O!(T;
M<X<1+E\-'=0B6T[Z_3)RD"(Y$63+U%4-H\?#: %S/WCL:R54U<K4L<(R<!G>
M2A2[ZE0FH]5D 5LUI+S\")\A_ P)!.*8C]QU-%B;#N_V /)7"6ZW-:0T6IR$
MR7E/E40US$4B4RQKX2.T,88R]HHI4/!J &/LT:^!55%CVMAG)T5+CEI6KJ?$
M*'UWRZL)? [I>QL^9$Q89M:X%,X*99?#6G51XXHU7>J4S<DK:3:\;)*7A[__
M5N:3M-?:FZ_65MMK["60>:ZSW]!M55DF-SH;]5QY-A6J[0*UR=@1R%OIPEF*
M O&V F=]F!]_F!<T&>6N9*+1ZTQ.#"-9:7)7&!&C]%E40Q40-LA:;&UV_]XG
M2;>S G>0"B0,4P.[!M03 &H!TT8X2)M45]#=ZNXD"FL7\_-)9L.EML\_A<-T
M 6^ \#B<32ZZ-T?3F$ZIACZ63@6=9127E9*!-><1F? I2SE*-%K\[4406 7)
M!'YHCTY9Y8C"9TRVL[-D\C)-H8P\P<0?&WO$F><-^T;8UO3L&U"[F'Y^7]S%
MS5>BC^8&]+2BZ=U6Q<<K7&V]5*)NE4MEOXIV)Q@W&Y6+*U+HSA9=_I**6%O9
M,TBT$=F\J#C*V#3-&D-BG:GY'!#]#P@(F/)\&GP6A8]^CZD2^+DK'7:88[P>
MP/QWY]\RF"EO+G$F)OI]LZ'A<5%4R6AO6L) N6(CP;%4DRY+^IK20V8(>%CJ
MFE]/BL8%],./9U[ID!@:F/$OCHG:"[N5B[H,O#((E>MFG2W4*^!;1JHV&[,B
M< W)#(8<&S0Y]$HD_7EWB,QV=K37Y@1'?U,P],V,(,(B:,=.W?A:W2UM+N6>
MS.#*WI(U58JB9>SAIN2%_444.7: -XFW9I95,W80/<0?X\6Z: K,QNC5S751
M>=Q=F^5,(")<89\$,Y<;N3J"1=RC#6?N5\,E"[O&]6&';B+ BZR'LB>+%T\P
MXEF]^*6]L;6K;<!NQJX$7KN!"_,>*Y(;(V2S<8\9<GOYHS-!.N=X9+*EBUA>
ML_LM.WNOX8<UZS:D<KM"!7;%;5+^/;$FDYTL+=Z]'A6L EN&X<)P2F&A*/K0
M; P%)_D7U^CU[BEA^LR<&WRTO>NBGNFNH$N5T.;G0-,O8;LE1C6HB??<NQ:(
M1C3[&W,YKKO-2L8K["1VB0CD,[  H-M'PH1$80L-#/"R'A1[,XD=((9*#+"Z
M),#$H6L\3+0HT"1U42:RV3!K4+D1ZW51'D" C&[*4^X;P:?]9GV=(&8N&&HQ
M:\$S^10XT;*:=UEEX+"S,AV[_4/./JPX_ZS-I1C5NV)PPQ&GQHAH+"U%4::R
MEB%ITEA!4;!)DE?#3&T8"H:[47 [M6]K#I?>K00O4F:\;RFC?T;N79/MIUB3
M/P'SVH2-T!7AS'AQGW$77NE7;/\%'Z6[I^PH2<)>$DX8\.Y[IKKZ%/W.[[,.
MBZG#8OX&83&;=5C, H?%/!MAFSY\;P_VKCO'A]W?@3JTJ5+//23]F09P,]>P
MXL8S4ZTD!E/KE5,:W ):X7!_?T>I<(RR'TBB^P,E2%ZMW06/OP1U,?<;JV87
M,ON@J#H?NLOMX.FZV:D/>2SH&KCI]%]3JU04RA?=/?W0-.D:-?]IMXDB:HIK
M;.?>&%N+W[7X_7<0O[>^0?P&*>BB^R<\/+XY.]W[?U!+ P04    " !P-L-8
M=[>@\!\X  !:C@$ $    &0X,3$Q,S-D97@U,RYH=&WM?6ESV\;2[G=6\3^@
M?.I-256T;,E+'-M1E;PDT2G'\;65Y)Y[ZWX8 D-R8A!@L$AF?OWM;1: ("59
M5@[-X'PX,2EP,!CT]/3R]-//?SK[^<WQ\Y]>G[PZ'@Z>GYV>O7E]_/I_WWUT
M\.#Y/?X$7]^3OT?/7_SRZC_1BQ]?_O+FE_??W_G]I].SUW>B#V?_>?/Z^SNI
MR?3=F3;36?7T;5[,57KG.!H.X/<O=5;IXOCYJ]/?[,47)JEF3Y\</#+9G4BE
M9IK! 'I2W:';O+.7S54Q-=G=*E\\O;^HGD7R>9Q753[GKR9Y5MTMS5_ZZ:'_
M/%%SDRZ?GIFY+J.W^B)ZG\\5W.GDS>F/;[^_4^ D[QP_?W'\^M/,C$T5P0-'
MS^^].'Y^[]UQ</]@\",8O#6=E=G<.?XF&Y>+9S@*//>ZQUC]G9U83"N%BT +
M=_KSC]&']R^_OS-]<GAX^.#!]/[C^X?W']Q_]/#PNP??'ORQF.(OS[Z_\^:7
M'W_AI?MB\X]0'DY>O'D=O7S]YLV'=R<O3]_^^/V=^W?H\[N35Z_LY]]/7YW]
M]/V=P_OW_^=.].*7]Z]>OZ?O90[\S5V0F3<G[SZ\?FK_L?%5M=]KYPK1%-\?
MRS]>V8D\.OP?>+?WSE[YO_PFO^9']5.V%S8'>/C$?@__]SZXE7VDA9KJN^-"
MJX]W35::1#]5Y[E)HNL]TG%K<O!:X 7\Z\GA=X^>A;-J35[>D7U3J]?1.+>W
MB7#;G.5/-^Z6Q\%]UM_WBMOE2TSX9YU419Z9./HQS<<JC7[*T\1DTS+Z</#R
MX.2@XVEN818/[X\B=:ZS6D<_YRC'>CF*GO_PR]LS>(56,\Y,I>^6"Q7KIUE^
M42AXF6_N'AT^!HV,5QY';^I/>C[.ZV+ZA=_!+3[\7C73P\$W_SI\^.TS6(B3
M)"ET66J-3X#?/GFV_W4\R(NEO+ -KTO?G2N3RNMJ"_??\ER'UWXN+U2CZ '?
M\=]UIJ.C^T</\=:A.H3_X,&P9CJ'3[[0;GFO#YY&EVW<2,45?(RJ69'7TUED
MJA+NG:DI?CG5F2[@-PM55/"O#8/]"$]R\(V:%K ]GPT'Q4%ZT&4/!(_Y^$L\
MY2NMBNB#*<K1AI/[R6>?W%_V! Z.]K8)T#810I/@6,[.LEJF.OH^6G=ZWFF?
MPF!-A$>:M0#83 3Y.!6M[4_ \(JUQV%KRT4W?8O/HHZI92!G20VBF6=.COP6
MLAMHS:'W143K=QW-0)BCL=99I!:+W,"!DT2JC%(]!=&/\SHK=1J9#/:.CGXL
M5)9$K^IXMHSR27#&1'M.:S</'E';.$!>)+"[JCQ:%/DYO-!HF=?1A:EF,+2Q
M-\P7)L/EP.]AA^ERH>,*?X2WUY]T7--JP<WQBS.83ZEX 5_E<3T'NZ^,]F#Z
MB9Z IY'@?3_$,YW4(%6'^U&=T1S@IZFZ*%O/, :M?34C  YH6)IBD1>JTE9Q
ME#.SB%(S-[B",%8Y4S!_MS*GQV4>FV^T@D?0SRK[CP@6/L[G\#82PV,-!_Q$
MY?-[IW;]1OB:4%FAYBKTU)1H%R3P !,3P\/DL:+W5D4;K(?/L!TB?-_!_>1U
MZ? 2> GP,O'"E_E\H3*C2YSUXV?1>_EAL ;\5:'A!>'E<UW ]'4%'TLP;KH6
M"+1>*%)N2>1=9O5\#/]Y#^_FPT$XK1?1X7>'!X='WT5H5D1./GF2RT X1[=Q
M/$1X.J"<+ ISCE)B)2,U:FQ24RWQM>-,AH/+1,2/"?L!!(,'<'^FD>TG_35)
M#8CZC<4FN@6IN?_@L"4U/XH4O&,I:$B/P1V<99KUD'O87_%.%X4AT3J9%EJC
M>CJ(-C@RY'_?6*F?K:I3^,*49<V*Z>7/T1MU<279O%1[;1;-X6"M;,*J.0V:
MD,#H3_"*<:TV*>G197+U FPE/+[4Q5*CQ735'?#X"0R-XJ\*H^^>)';.J?K&
MU//T6:)'\-*NLB..GJSNB$NG_:64Z!?>#</!X7=/#AX\_FX47<SR$LZG&MX9
M_!<$2D[D(C;P60YD.-HGX++)$<TO ?>''_,@.H63#L[_6J4X!BP]')-PS7F>
MGO.!C0.5NCB'-U1:8X$$-R\B&'BL9RJ=X/@LR%&LLBROX/MHIE,6XA1'C%"
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MDY'22@%'(.!>E1*T&#60]P35)]  ,T"#G-=2R+_:"XZYN!H)X>'  WKDN*+
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M*[W9SFHV+#I\U7&><FF3@3YFP@6KV^1RL675$FN2WA(R+2-:0;G$0<='SQ!
M7P%'80'2SR)ZD0A$=G5^:>(+.T(^IZ2#?H,2SM^":.LE7$H(QL$G_ 4Y4/HP
M<FY")W=KL5^]"0_&^M@IX'&US+5W<\<JEY[$6,:)K8F?D;=-\8*+UO7#?3^?
MM$V0 '?CD'OB)%"SB*-W^NB":Q5-C1L^[S;-+SO7D,#\>J]JUD>;S=W]=_7]
M=_MOS0V=U5I[='S;_K4L[KFGB\3&^V93VY.#ZR%4XXB+);E/01P40=XD"XIR
MB:+57;U>#YFBD.7]E-*Q<9Q(Q2%:D30N1%V! ELFH,/M,=^Y#<8Y* @?-4<
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MP11#'X/7UA[]@P[<U/\,Y+]02P,$%     @ <#;#6,VC#'LP!   YQD  !
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M1($L)GA>Q6-2V1UWA!JQT^TRF $\A74.KN6R#6Q=MS&D4V&!WREYY3/A1G.
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M!=&VDEP]HR,)@$2WF;R+^\I:R>^AO9I''-?QX-4@098=^')/?)<&[VE$PN'
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M:R!U(<?*^6,\JN$C6;K\,25^]-Y>U7N(2&ENJX]GD!BA\C'ZCV00Z2'1G#[
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M.UJQPC&@+C8EHKTP$@UX@:H9YI- P")A;E+-N:@@7]D*Y@J?[(&;+>_9W&,
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M'*H46L)8P10]-%('ZT.J2'BS,)"/ TD@B"-I@V[:1![XADY0T;\)PS4)] M
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M#V2;/W#+7K&#V2'VS\P."3OR/U!+ P04    " !P-L-8YC1FV8(&  "V40
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M,3,S9&5X,3$N:'1M4$L! A0#%     @ <#;#6.*Z[&JFGP  $L0# !
M         ( !@[D  &0X,3$Q,S-D97@T,2YH=&U02P$"% ,4    " !P-L-8
M(M\8_F\1  ! 00  $               @ %760$ 9#@Q,3$S,V1E>#4Q+FAT
M;5!+ 0(4 Q0    ( ' VPU@-85C+V2   "#=   0              "  ?1J
M 0!D.#$Q,3,S9&5X-3(N:'1M4$L! A0#%     @ <#;#6'>WH/ ?.   6HX!
M !               ( !^XL! &0X,3$Q,S-D97@U,RYH=&U02P$"% ,4
M" !P-L-8 _'?:B$.   -,@  $               @ %(Q $ 9#@Q,3$S,V1E
M>#4T+FAT;5!+ 0(4 Q0    ( ' VPUC-HPQ[, 0  .<9   0
M  "  9?2 0!M9'0M,C R-# V,#,N>'-D4$L! A0#%     @ <#;#6-2SJAG/
M!@  ,4L  !0              ( !]=8! &UD="TR,#(T,#8P,U]D968N>&UL
M4$L! A0#%     @ <#;#6# MOND0"@  S80  !0              ( !]MT!
M &UD="TR,#(T,#8P,U]L86(N>&UL4$L! A0#%     @ <#;#6.8T9MF"!@
MME$  !0              ( !..@! &UD="TR,#(T,#8P,U]P<F4N>&UL4$L%
3!@     +  L M (  .SN 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>d811133d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mdt="http://www.medtronic.com/20240603"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdt-20240603.xsd" xlink:type="simple"/>
    <context id="duration_2024-06-03_to_2024-06-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.625PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20311.00PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotesDue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20392.250PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due20391.50PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2019Due2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001613103</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mdt:SeniorNotes2020Due2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-06-03_to_2024-06-03"
      id="Hidden_dei_EntityCentralIndexKey_duration_2024-06-03_to_2024-06-03">0001613103</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2024-06-03_to_2024-06-03"
      id="Hidden_dei_AmendmentFlag_duration_2024-06-03_to_2024-06-03">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_0">2024-06-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_2">Medtronic plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-606">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-607">1-36820</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-608">98-1183488</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-609">20 On Hatch, Lower Hatch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-610">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_3">2</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-612">IE</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-613">353</dei:CountryRegion>
    <dei:CityAreaCode contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-614">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-06-03_to_2024-06-03" id="Fact_4">438 1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-616">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-617">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-618">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-619">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-620">Ordinary shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-621">MDT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"
      id="ixv-622">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member"
      id="ixv-623">0.250% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member"
      id="ixv-624">MDT/25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2025Member"
      id="ixv-625">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member"
      id="ixv-626">0.000% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member"
      id="ixv-627">MDT/25A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2025Member"
      id="ixv-628">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member"
      id="ixv-629">2.625% Senior Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member"
      id="ixv-630">MDT/25B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2025Member"
      id="ixv-631">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member"
      id="ixv-632">1.125% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member"
      id="ixv-633">MDT/27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2027Member"
      id="ixv-634">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member"
      id="ixv-635">0.375% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member"
      id="ixv-636">MDT/28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2028Member"
      id="ixv-637">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member"
      id="ixv-638">3.000% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member"
      id="ixv-639">MDT/28A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2028Member"
      id="ixv-640">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember"
      id="ixv-641">1.625% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember"
      id="ixv-642">MDT/31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.625PercentMember"
      id="ixv-643">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember"
      id="ixv-644">1.000% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember"
      id="ixv-645">MDT/31A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20311.00PercentMember"
      id="ixv-646">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member"
      id="ixv-647">3.125% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member"
      id="ixv-648">MDT/31B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2031Member"
      id="ixv-649">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member"
      id="ixv-650">0.750% Senior Notes due 2032</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member"
      id="ixv-651">MDT/32</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2032Member"
      id="ixv-652">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member"
      id="ixv-653">3.375% Senior Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member"
      id="ixv-654">MDT/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotesDue2034Member"
      id="ixv-655">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember"
      id="ixv-656">2.250% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember"
      id="ixv-657">MDT/39A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20392.250PercentMember"
      id="ixv-658">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember"
      id="ixv-659">1.500% Senior Notes due 2039</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember"
      id="ixv-660">MDT/39B</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due20391.50PercentMember"
      id="ixv-661">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member"
      id="ixv-662">1.375% Senior Notes due 2040</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member"
      id="ixv-663">MDT/40A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2040Member"
      id="ixv-664">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member"
      id="ixv-665">1.750% Senior Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member"
      id="ixv-666">MDT/49</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2019Due2049Member"
      id="ixv-667">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member"
      id="ixv-668">1.625% Senior Notes due 2050</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member"
      id="ixv-669">MDT/50</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-06-03_to_2024-06-03_us-gaap-StatementClassOfStockAxis_mdt-SeniorNotes2020Due2050Member"
      id="ixv-670">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-06-03_to_2024-06-03" id="ixv-671">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
